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Abstract 
 
Fasciola hepatica infections cause morbidity and mortality in sheep and have a 
significant economic impact on farmers. The commonly used diagnostic tests; faecal 
egg count (FEC), anti-Fasciola antibody ELISA (AbELISA) and the biochemical 
assays (measuring GLDH and GGT) all have limitations, particularly in detection of 
pre-patent infections in sheep. A coproantigen ELISA (cELISA) is reported to detect 
low burdens of infection from 4 weeks post-challenge (wpc) and to only detect 
current infection. A faecal PCR has been used for early detection of infection, but is 
limited by inhibitory factors in faecal samples. Loop-mediated isothermal 
amplification (LAMP) is more resistant to inhibitory factors and has the potential to 
be a pen-side assay. Triclabendazole (TCBZ) is the drug of choice to treat immature 
F. hepatica but there have been increasing reports of TCBZ treatment failure in the 
UK. Treatment outcome is determined using a FEC reduction test (FECRT). A 
cELISA reduction test (CRT) has recently been proposed. 
Within this thesis the cELISA, along with FEC, and where feasible the AbELISA 
and the use of GLDH and GGT concentrations, are evaluated in (1) an experimental 
challenge model in sheep, (2) individual naturally exposed sheep, in early infection, 
pre- and post-treatment situations, (3) groups of naturally exposed sheep, including 
composite samples, in pre- and post-treatment situations and evaluating the FECRT 
and CRT, lastly a LAMP assay is developed for the detection of F. hepatica, and 
evaluated against cELISA, FEC and PCR based detection. 
 Two groups of 6 sheep were challenged with F. hepatica metacercarial cysts. In 
both studies, AbELISA was first to detect infection (3-4 weeks post-challenge 
(wpc)), followed by cELISA (3-10 wpc) and then FEC (9-10 wpc). Minor 
fluctuations were seen in both FEC and cELISA levels over both studies and a 
transient increase in cELISA levels was seen in the first study at 3-8 wpc. All 
animals were dosed with TCBZ 2 weeks prior to slaughter. The highest FECR was 
37% and all sheep had live fluke present in their livers post-mortem.  
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27 lambs were sampled monthly between June and November with AbELISA, 
GLDH, GGT, FEC and cELISA tests performed. GLDH and GGT concentrations 
were above reference ranges from June. AbELISA detected infection in most animals 
by September and in all but one animal by November. FEC and cELISA both 
detected some very early positive results, most likely false-positive results, but the 
majority of animals became positive in November. Twelve lambs were followed to 
slaughter and all had low burdens of fluke (≤10).  
A cross-sectional study was conducted including 36 British farms, comprising 812 
and 528 sheep pre- and post-treatment, respectively. Low FEC and cELISA results 
were seen, with better agreement between the two tests pre- than post-treatment. 
Disagreements between the two tests were more frequently seen where the FEC 
detected infection but the cELISA did not. This was true both before and after 
treatment. 
80 animals from 2 Scottish farms were confirmed to be infected with liver fluke and 
given either a TCBZ or closantel treatment and followed for 56 days. A closantel 
treatment was given to animals that were still infected at 21 days post-treatment 
(dpt). The highest FECR and CR of the TCBZ-treated groups was 60.3% and 56.4%, 
respectively, and the lowest FECR and CR of the closantel-treated groups was 83.7% 
and 94.9%, respectively. A small proportion of closantel-treated animals maintained 
a low FEC following treatment. Both the FECRT and CRT indicated treatment 
outcome from 7 dpt. 
In a postal survey, 41 sample packs were sent to British farmers, of which 25 farmers 
participated. Samples from 44 and 36 groups were submitted pre- and post-treatment, 
respectively. Individual and composite faecal samples from each group were tested 
by FEC and cELISA. Group mean FECs were low and prevalence of infection on 
farms did not follow a normal distribution. The composite cELISA was more 
sensitive than the average cELISA, whilst the opposite was true for FEC. The 
composite cELISA was less sensitive than the composite FEC in low burden 
situations. A modified version of the composite CRT showed good agreement with 
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the composite FECRT and appears promising in situations where burden was 
sufficiently high. 
A faecal LAMP assay, specific to F. hepatica, was developed and evaluated using 
samples from one of the groups of 6 experimentally challenged animals described 
above. FEC, cELISA and PCR testing were also performed and compared to the 
LAMP results. LAMP first detected infection at 3 wpc, followed by cELISA (7 wpc), 
FEC (10 wpc) and PCR (13 and 14 wpc). 
The studies within this thesis (1) confirm that cELISA can detect experimental 
infection of sheep with F. hepatica later than AbELISA but earlier than FEC, and 
confirm the TCBZ resistant status of a British isolate (Moredun isolate), (2) 
demonstrate that in animals naturally exposed to F. hepatica, the cELISA does not 
have an advantage of earlier detection over FEC and is not as sensitive as FEC in 
established infections (3) show that the modified CRT and composite CRT appear to 
give a good indication of treatment outcome from 7 dpt, but is of limited use in 
flocks with a low burden of infection, and (4) demonstrate that a faecal LAMP can 
detect F. hepatica infection at 3 wpc. 
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1.1 Liver fluke biology 
 
The liver fluke, F. hepatica, has a complex life-cycle including free-living stages and 
an intermediate snail host (Figure 1.1). The adult parasites reside in the large bile 
ducts of the host, shedding eggs which are released into the gall bladder and travel 
along the intestines to be excreted in the host’s faeces. In the environment, once the 
eggs have been freed from faecal matter, a free-swimming miracidium hatches. The 
miracidia locate and penetrate a suitable snail intermediate host (Galba trunculata in 
the UK) and migrate to the digestive gland, where a transformation to the sporocyst 
stage occurs. Each sporocyst undergoes asexual reproduction, giving rise to many 
rediae; each redia then undergoes asexual reproduction resulting in the cercarial 
stage. This process of multiple rounds of asexual reproduction results in large 
numbers of cercariae (estimates range from the hundreds to thousands) being 
produced from just one miracidium. The free-swimming cercariae are released from 
the snail host and migrate to vegetation where they form resistant cysts (or 
metacercariae). These metacercariae are ingested by a mammalian host, excyst in the 
duodenum and migrate through the peritoneal cavity to the liver. Here they move 
through the liver as immature fluke, developing into adults in the bile ducts. 
 
Figure 1.1 F. hepatica life cycle. Image used with kind permission of Nicola Sargison 
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F. hepatica has a worldwide distribution, occurring on all continents except 
Antarctica (Mas-Coma, 2005). In the UK, F. hepatica was historically found in the 
wetter West of the country. More recently, cases of liver fluke infection have been 
reported in areas which were historically ‘fluke-free’ (Figure 1.2) (Mitchell, 2002). 
This change in distribution is likely due to, amongst other factors, changing climate, 
increasing animal movements and changes in land management practices (Kenyon et 
al., 2009).  
Figure 1.2 Reported Scottish F. hepatica cases in 1995, 1998 and 2000 (Mitchell, 2002) 
 
 
1.3  Clinical effects 
 
Fasciolosis, the disease caused by liver fluke infection, can present in three different 
forms depending on the extent of exposure.  
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1.3.1 Acute and sub-acute 
 
The immature stages of fluke, which burrow through the liver parenchyma, cause a 
significant amount of damage early on in the infection (Sánchez et al., 2001). If a 
large number of infective stages are ingested over a short period of time, the animal 
can suffer from acute fasciolosis, which very quickly presents with haemorrhagic 
anaemia, hypoalbuminaemia and sudden death. A sub-acute infection occurs when 
large numbers of parasites are ingested over a period of weeks and presents with 
symptoms such as acute haemorrhagic anaemia, hypoalbuminaemia and 
submandibular oedema (bottle jaw) 1-2 weeks prior to death (Mitchell, 2002). Cases 




The chronic form of the disease is caused by extended low level exposure. The 
immature forms do not cause such damage in this presentation, rather the number of 
adults accumulating and feeding in the liver cause symptoms such as anaemia, 
weight loss, eosinophilia and hypoalbuminaemia (Mitchell, 2002). Submandibular 
oedema can also be seen in some cases. These symptoms lead to lower weight gain, 
lower wool yields, reduced milk production, reduced fertility and reduced twinning 
rates in ewes (Hope Cawdery, 1984). Chronic fasciolosis cases appear in winter and 
early spring. 
1.4 Economic impact 
 
The Scottish sheep industry suffers significant losses due to the effects of fasciolosis, 
although there are few exact figures in the literature. An individual farm was 
reported to lose £19,200 (£8.73 per ewe) due to a single outbreak of liver fluke, 
which was compounded by treatment failure (Sargison and Scott, 2010). These losses 
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occur not only from the death of animals, reduced productivity and treatment costs, 
but also from a loss of income at slaughter where livers are condemned due to fluke 
infection or damage. It was estimated that 7% of livers are rejected (Froyd, 1975), 
although as the incidence of fluke has increased, it is likely that this figure has also. 
Indeed, anecdotal reports suggest that in bovines liver condemnation rates may be as 
high as 78% (Anon, 2011). Quality Meat Scotland (QMS) report that of 499,826 
cattle and 1,531,945 sheep seen at abattoirs in 2009, 26.85% and 10.05%, 




There are a variety of tests available for the diagnosis of F. hepatica in animals. 
These require a variety of samples, some more practical to obtain than others, and 
test for a range of direct and indirect indicators of infection. Farmers require 
diagnostic tests which are convenient, rapid, cost effective and allow them to make 
efficient use of the treatments available. For farmers, it is a question of the existence 
of a current or historic fluke infection, when to treat, which drugs to use and how to 
determine the effectiveness of said drug. 
1.5.1 Faecal egg count (FEC) 
 
The FEC is the traditional test for liver fluke which has been adapted over time. This 
involves the detection of eggs in faeces via either flotation or sedimentation (Dennis 
et al., 1954; McCaughey and Hatch, 1964), and provides a determination of  the 
number of eggs per gram (epg). This has remained a popular test for a variety of 
reasons, including the ease of sample collection, of the test itself and of egg 
identification.  
By its very nature, this test is only able to detect a fluke infection after patency (egg 
production). This means an infection cannot be diagnosed until 9-15 wpi (Valero et 
al., 2006), which may result in false negatives in early infections. Due to the biology 
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of fluke infections, eggs are released from the adult parasite and pass into the bile 
duct, where they are sequestered and released sporadically into the intestines and 
passed out with the faeces (Mezo et al., 2004). This pattern of excretion means that 
there is not a constant release rate of eggs and they are seldom evenly distributed in 
faecal matter, which potentially allows for false negatives in mature infections. In 
addition, sequestering of eggs in the bile duct allows for eggs to be seen in faeces up 
to 3 weeks post successful treatment (Chowaniec and Darski, 1970), making this a 
poor test for determining treatment outcome, due to the potential for false positives. 
It has been stated that epg has a poor correlation with adult fluke burden in cattle 
(Abdel-Rahman et al., 1998), but that a relationship is present in sheep, with an 
increasing adult burden leading to a lowered epg (Happich and Boray, 1969).  
1.5.2 Liver investigation 
 
Another frequently used method of diagnosis is the investigation of livers at 
slaughter. This is routinely performed at abattoirs to ensure the quality of the liver, 
but is also carried out at post-mortem to determine cause of death. It involves the 
slicing of the liver to look for the presence of parasites or view the pathology caused 
by an infection, previous or current. This has the potential to be used as a 
surveillance tool for prevalence studies (Froyd, 1975), however, it must be noted that 
livers may have been condemned due to reasons other than fluke infection. Although 
this information can be useful to the farmer to adapt future management practices 
through knowledge of current or historic infection, the damage has already been done 
to that year’s income in terms of loss of liver, low body weight, low wool yield or 
death of animals.  
1.5.3 Serum antibody ELISA (AbELISA) 
 
Various enzyme-linked immunosorbent assays (ELISAs) have been developed to 
detect anti-Fasciola antibodies in serum (Zimmerman et al., 1982). Whilst these can 
detect an infection very early on, 4-8 wpi (Valero et al., 2009; Zimmerman et al., 
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1982), the antibody titres persist at high levels following successful treatment (Ibarra 
et al., 1998; Sánchez et al., 2001). This serves to make the test useful as an indicator 
of past exposure but unreliable for indicating current infection status past the first 
year of life. In addition, the requirement of a blood sample is invasive which makes 
this a less practical test for farmers, especially sheep farmers, than those which 
require faecal samples. 
1.5.4 Serum antigen ELISA 
 
The detection of F, hepatica antigens, rather than anti-Fasciola antibodies, in serum 
by ELISA was first demonstrated in mice (Langley and Hillyer, 1989), and sheep 
(Rodríguez-Pérez and Hillyer, 1995). This allows for a direct detection of parasites, 
thus only indicating current infection. The test also benefits from allowing a very 
early detection of infection, 1-2 wpi (Duménigo et al., 2000; Rodríguez-Pérez and 
Hillyer, 1995). However, as the host develops an immune response, antibodies bind 
to epitopes of the antigen forming an immune complex, reducing the ability of the 
antibody in the ELISA to bind to the antigen (Rodríguez-Pérez and Hillyer, 1995). 
This lowered sensitivity limits the use of this test in the field. The length of time 
taken for the amount of free circulating antigen to drop below detectable levels varies 
in the literature, whilst it has been reported to be absent from 5 wpi, other reports 
state that it does not decline until 10 wpi (Langley and Hillyer, 1989; Rodríguez-
Pérez and Hillyer, 1995).  
1.5.5 Biochemistry and haematology 
 
Subacute and chronic liver fluke infection can be diagnosed indirectly through the 
elevation or suppression of various haematological and biochemical factors. Sheep 
infected with F. hepatica were shown to have raised white blood cell counts, 
eosinophils, segmented and band neutrophil counts, mean corpuscular volumes, 
gamma-glutamyl transferase (GGT), glucose concentrations and globulins 
(Matanović et al., 2007). In the same study, levels of red blood cell counts, 
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lymphocytes, haemoglobin, packed cell volumes, mean corpuscular haemoglobin 
concentrations, aspartate aminotransferase, blood urea nitrogen, creatinine and 
albumin were found to be lower in infected animals than the uninfected controls. 
Most commonly, GGT and glutamate dehydrogenase (GLDH) are measured as an 
indication of bile duct and liver damage, respectively, with GLDH giving very early 
detection of infection, 2-3 wpi (Mitchell, 2002). However, as these are indirect tests, 
there is the potential for false positives, and thus mis-diagnosis, due to other 
underlying clinical conditions. In addition, the requirement for a blood sample also 
renders the test invasive.  
1.5.6 Coproantigen ELISA (cELISA) 
 
As stated previously, faecal samples are the most practical test samples in terms of 
ease of collection. As such, the detection of parasite antigens in host faecal matter 
was investigated by a number of groups using various capture antibodies. 
Monoclonal antibodies, ES78,were used in a sandwich ELISA which was able to 
detect an infection of 5 adult fluke in cattle and showed no cross-reactivity with 
Dicrocoelium dendriticum (Duménigo et al., 1996), a related trematode with 
mammalian hosts. Moustafa et al. (1998) used purified polyclonal antibodies raised 
against Fasciola gigantica, a trematode closely related to F. hepatica, to detect 
infection in mice, rabbits and rats and found the sensitivity of the test to be host 
species-specific, achieving 83.3% sensitivity in mice. In cattle, Abdel-Rahman et al. 
(1998) found a monoclonal antibody ELISA to be 100% sensitive and 90% specific 
in infections of greater than 10 fluke at post-mortem, detecting infection at 6 wpi and 
showing no cross-reaction with Paramphistomum microbothroides, a trematode 
parasite of livestock. The same study also reported a correlation between parasite 
burden and ELISA titres. This finding was also reported when using the monoclonal 
antibody coproantigen ELISA (Duménigo et al., 2000). 
A commercial cELISA, (BIO K201, Bio-X Diagnostics), based upon the MM3 
monoclonal ELISA (Mezo et al., 2004), was developed to detect parasite antigens in 
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faeces. This ELISA involves the use of a monoclonal antibody to bind gut secretions 
released from the parasite during normal metabolic function (Figure 1.3). The 
coproantigen used has been shown to be specific to the gastrodermal cells of adult 
and immature fluke (Flanagan et al., 2011b). The target antigens of the MM3 
monoclonal antibody were shown to be several Fasciola cathepsins L1 and L2 as 
well as a Kunitz-type protein (Muiño et al., 2011)  Experimental infections in sheep 
have indicated that the test can detect antigen from 5 wpi (Flanagan et al., 2011b), 
considerably earlier than FEC and can detect antigen from a single adult parasite 
(Mezo et al., 2004). Whilst there is indication that coproantigen concentrations 
correlate with adult fluke burden in cattle (Brockwell et al., 2013; Charlier et al., 
2008; Mezo et al., 2004), this has not been seen in sheep (Valero et al., 2009). There 
have been reports of this test performing well in sheep (Flanagan et al., 2011a; 
2011b; Valero et al., 2009), cows (Brockwell et al., 2013; Mezo et al., 2004) and 
humans (Ubeira et al., 2009), although there is no information regarding its use in 
natural sheep infections.  
Figure 1.3 Cross-section of an adult F. hepatica gut branch stained with MM3 monoclonal 
antibody from the BIO K201 kit.  
 
 
Initial investigation into the effects of sample storage on the consistency of the 
coproantigen ELISA has shown good agreement between freshly prepared 
supernatants and those that had been frozen for 12 weeks (Flanagan et al., 2011b). 
The same study showed that the storage of faecal samples at room temperature (20°C 
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and 26˚C) for 4 days increased the OD in some samples but decreased the OD in 
other samples when compared to samples processed on arrival, but the overall result 
(positive or negative) remained the same. It is worth noting that only a small number 
of samples were compared.        
1.5.7 DNA-based methods 
 
DNA-based detection methods are not yet used for the routine diagnosis of F. 
hepatica. These methods are still under development and, in their current form, may 
be cost-prohibitive to farmers. Despite this, DNA-based detection methods have the 
potential to directly detect infection with high sensitivity and specificity. 
1.5.7.1 Polymerase chain reaction (PCR) 
 
PCR is a commonly used method of DNA amplification. In PCR a DNA sequence is 
exponentially amplified using thermal cycling, opposing primer pairs, Taq 
polymerase, a proprietary buffer and dNTPs. PCR has been used to successfully 
amplify DNA extracted from both F. hepatica adult parasites and infected snails (Ai 
et al., 2010a; Caron et al., 2011; Cucher et al., 2006; Kozak and Wedrychowicz, 
2010). DNA has also been successfully amplified using PCR when extracted from 
metacercarial cysts and from eggs of other helminth species (McNally et al., 2013; 
Sugiyama et al., 2002). It is possible to quantify the amount of DNA amplified using 
real-time PCR (Alasaad et al., 2011). 
There are limited reports of successful amplification of DNA extracted from the 
faecal samples of animals infected with F. hepatica. Martínez-Pérez et al. (2012) 
used primers targeted to the cytochrome C oxidase 1 gene (cox 1) to amplify DNA 
extracted from faecal samples using a standard and a nested PCR. The standard PCR 
amplified DNA from 3 wpi, whilst the nested PCR amplified DNA from 2 wpi. 
Robles-Pérez et al. (2013) were able to use the same primer set to amplify DNA 
extracted from faecal samples from 2 wpi. As yet, this assay has not been developed 
for real-time PCR applications. 
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Despite the potential for sensitive and specific faecal-based diagnosis using PCR, the 
assay is limited. Faecal samples are known to contain substances which are 
inhibitory to Taq polymerase and this may affect test sensitivity (Wilson, 1997). In 
addition, PCR requires the use of a thermocycler and a DNA detection method such 
as the use of agarose gel electrophoresis. There is also the potential for 
contamination of samples if the user is not careful, affecting specificity. Lastly, there 
is the lengthy process of DNA extraction prior to PCR, which can be costly and time-
consuming. These factors raise the cost of the assay and require laboratory conditions 
for the test to be run. This may put the test out of the price range of most farmers.  
1.5.7.2 Loop Mediated Isothermal Amplification (LAMP) 
 
Loop-mediated isothermal amplification (LAMP) is an alternative DNA 
amplification method. It uses 3 primer sets, a master mix containing a DNA 
polymerase, which has strand displacement activity, and operates under isothermal 
conditions to amplify extracted DNA (Notomi et al., 2000). The process of 
amplification is more complex than that used in PCR and is illustrated in Figure 1.4. 
The F3/B3 primer set gives specificity to the assay and forms a structure recognised 
by the FIP/BIP primer set (Figure 1.4 (a)). This primer set binds to the structure 
formed by F3/B3 primer set and allows for amplification (Figure 1.4 (b)). The 
FLP/BLP primer set then binds to the structures formed by the FIP/BIP primer set 
and allows for further amplification (Figure 1.4 (c)). 
Unlike PCR, LAMP is more resistant to the inhibitory substances found in faecal 
samples. It is also faster than PCR, with amplification possible in 45 minutes or less, 
only requires a single temperature for the reaction, and the results can be visualised 
by use of a fluorescent dye, a colour changing dye or by eye, so there is no 
requirement for sophisticated equipment (Notomi et al., 2000). These factors make 
LAMP attractive as a potential diagnostic test. 
LAMP has been used to successfully amplify DNA from F. hepatica adults and was 
shown to be more sensitive than PCR (Ai et al., 2010b). In this assay, amplification 
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was achieved in 55 minutes, using DNA extracted using sodium dodecyl 
sulphate/proteinase K treatment. It has also been reported that LAMP can be used to 
amplify DNA extracted from snails infected with other trematode species and eggs of 
nematode species (Chen et al., 2013; Hamburger et al., 2013; Melville et al., 2014). 
The method has yet to be used on metacercarial cyst or trematode egg samples. 
Successful amplification of DNA extracted from faecal samples has been shown in 
Clonorchis (trematode), Opisthorchis (trematode) and Strongyloides (gastrointestinal 
nematode) infections (Arimatsu et al., 2012; Cai et al., 2012; Watts et al., 2014). 
Recent developments in LAMP chemistry have allowed real-time LAMP 
applications on multiwell microtitre plates e.g. for DNA extracted from the eggs of 
the gastrointestinal nematode Haemonchus contortus (Melville et al., 2014).  
In its current form, LAMP is unlikely to become a routinely used diagnostic test. The 
reagents are expensive, not thermostable at ambient temperatures and the lengthy 
DNA extraction requiring laboratory conditions remains. DNA extraction may be 
possible using a freeze/thaw method similar to that used by Mukhopadhyay et al. 
(2012) for faecal samples infected with parvovirus. The company which supplies the 
LAMP reagents is currently developing a lyophilised version of the reagents, which 
would be more thermostable and has been shown to give results in 10 minutes when 
used in a real-time LAMP assay (I. McElarney, personal communication to P. Skuce, 
2014). Visualisation of results using a lateral flow device has been shown for 
parasite, bacterial and viral DNA samples (Kiatpathomchai et al., 2008; Njiru, 2011; 
Rigano et al., 2010). With these developments LAMP could become a sensitive and 
specific pen-side faecal based test.  
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Figure 1.4  Process of DNA amplification using LAMP using (a) F3/B3, (b) FIP/BIP and (c) 
FLP/BLP primer sets. Images courtesy of Eiken Chemical Company Ltd reproduced by kind 
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Flukicidal anthelmintics are licensed for use in the UK but vary in the life-cycle 
stages they affect. Farmers require drugs which have a short meat or milk withdrawal 
period, affect the widest range of life stages possible (to limit the effects of immature 
fluke) and have high efficacy values. The ability to target immature fluke is of 
particular importance to sheep farmers due to the devastating effects of acute and 
sub-acute fasciolosis in sheep. In order to reduce the number of times animals need 
to be treated, combinations of anthelmintics have been released onto the market. 
These can be both combinations of different flukicides and combinations of 
flukicides and anthelmintics against nematode worms. Concern has been raised 
regarding the use of combinations targeting both nematodes and fluke as the ideal 
timings of treatments against these helminths would typically be different 
(Fairweather and Boray, 1999). Although there are 5 chemical families from which 
all flukicides are derived; halogenated phenols, salicylanilides, benzimidazoles, 
sulphonamides and phenoxyalkanes, only the two most commonly used families are 
described below.  
1.6.1.1 Benzimidazoles 
 
The benzimidazoles include triclabendazole (TCBZ), albendazole and netobimin. Of 
these, TCBZ affects the widest range of life stages; targeting very young immature 
fluke just 1 wpi in sheep and >2 weeks in cattle (Boray et al., 1983), whilst 
albendazole and netobimin are only effective against adult parasites (Bishop, 2005).  
1.6.1.2 Salicylanilides  
 
Closantel, nitroxynil and oxyclozanide are the available salicylanilides. Both 
closantel and nitroxynil are able to target young fluke (Sargison and Scott, 2010), 
effective in sheep at 6-8 wpi and 8 wpi, respectively (Fairweather and Boray, 1999). 
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Closantel acts later in cattle infections, >12 wpi, making it unable to target pre-patent 
fluke (Fairweather and Boray, 1999). 
1.6.2 Treatment outcome 
1.6.2.1 Controlled efficacy test (CET) 
 
Due to the lack of a standardised FEC reduction test (FECRT) for trematode 
infections, the only World Association for the Advancement of Veterinary 
Parasitology (WAAVP) approved way to determine treatment outcome is by use of a 
controlled efficacy trial (CET), also known as dose and slaughter (Coles et al., 2006). 
The method of CET for fluke is described by Coles et al. (2000) and Coles and 
Stafford (2001). Briefly, two groups of 6 to 8 animals were dosed with 200 F. 
hepatica metacercariae, a treatment group and a control group. The treatment group 
was given a fasciolicidal treatment at 12 wpi, whilst the control group remained 
untreated. All animals were killed at 2 weeks post-treatment (wpt) and livers 
examined for fluke. The formula below is used to calculate the efficacy of the 
treatment used in the treatment group, where FBC is the arithmetic mean fluke 
burden of the control group and FBT is the arithmetic mean fluke burden of the 
treatment group. However, performing a CET on a working farm is highly 
impractical. 
Efficacy (%) =  (FBC –FBT)    x 100 
            FBC  
 
1.6.2.2 Faecal egg count reduction testing (FECRT) 
 
A FECRT has been developed to determine treatment outcome. This does not require 
an absence of eggs but rather a 95% or greater reduction in the number of eggs being 
seen between the treatment date and 14 days post-treatment (dpt) (Coles et al., 2006). 
This allows for a small number of sequestered eggs to be seen without affecting the 
Fasciola hepatica infection in sheep: Current and novel diagnostic tests 
Chapter 1: Introduction  16 
interpretation of treatment outcome. Although this is a widely used test, it is based 
upon the criteria developed for nematode infections and there has been no 
standardisation of this test for trematode infections (Coles et al., 2006). 
1.6.2.3 Coproantigen reduction testing (CRT) 
 
A coproantigen reduction test (CRT) has been proposed (Flanagan et al., 2011a) as 
an alternative to the current FECRT. As with the FECRT, faecal samples are taken at 
the point of treatment and 14 dpt but all animals must be negative at 14 dpt for the 
treatment to be deemed successful. This has been reported in one study to date in 
which sheep were experimentally infected with either TCBZ resistant (TCBZ-R) or 
TCBZ susceptible strains of fluke and the animals in each group were either treated 
with TCBZ or left untreated as a control. Fluke were cleared according to the 
coproantigen ELISA by 14 dpt in all groups bar one of the TCBZ-R strains treated 
with TCBZ (Flanagan et al., 2011a). However, it is possible that the time taken for 
antigen from live parasites to be cleared varies between populations of sheep and 
fluke and, as such, further studies are required to validate this CRT and the time 
points used. 
1.6.3 Drug resistance 
 
Due to the range of fluke stages treated by TCBZ, it has been a popular drug for 
many years, generating a significant selection pressure on the parasite population. As 
such, there have been a number of reports of treatment failure and suspected or 
confirmed TCBZ resistance in sheep and cattle. These reports have been worldwide, 
including Australia (Brockwell et al., 2014; Overend and Bowen, 1995), Scotland 
(Mitchell et al., 1998; SAC, 1998), Ireland (Lane, 1998; Mooney et al., 2009), Wales 
(Thomas, 2000), The Netherlands (Gaasenbeek et al., 2001; Moll et al., 2000), Spain 
(Álvarez-Sánchez et al., 2006), South America (Olaechea et al., 2011) and Peru 
(Ortiz et al., 2013).  
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The currently used indicator of drug resistance is a FECRT. However, a <95% 
reduction only indicates a reduction of eggs in the faeces viewed post-treatment, 
compared to the number of eggs in the faeces viewed pre-treatment. This may be due 
to the release of eggs which had been sequestered in the gall bladder, or due to live 
parasites remaining and continuing to shed eggs. At best the FECRT can be used to 
indicate if a treatment has failed or succeeded at killing adult parasites. A distinction 
must be made between failure of a drug and resistance of a parasite population to a 
drug. Treatment failure can occur for a variety of reasons including under-dosing, 
which may be due to faulty dosing equipment, underestimation of animal weight or 
reduced bioavailability of the drug (potentially due to reduced metabolism caused by 
parasite damage in the liver). Other explanations for treatment failure include 
inadequate diagnostics or poor drug formulation (Fairweather, 2011a). Most 
commonly, if TCBZ treatment appears to fail, animals will be treated with an 
alternative flukicide such as closantel and, if that treatment is successful, TCBZ 
‘resistance’ (TCBZ-R) is declared. There is currently debate in the veterinary 
research community as to the usefulness of these declarations (Fairweather, 2011b; 
Sargison and Scott, 2011). Whilst it is important to be aware of the existence of 
TCBZ resistant fluke and alternative treatments, more harm can be caused by 
incorrect reporting and the subsequent needless abandonment of a very effective 
flukicide.  
Due to the difficulties surrounding the determination of true drug resistance, it is 
difficult to determine the true extent of TCBZ-R. However, strains of fluke believed 
to be resistant to TCBZ have been isolated in Australia, Ireland, The Netherlands and 
Spain, although the resistant status of the Spanish isolate has been called into 
question when used in experimental infections (Álvarez-Sánchez et al., 2006; Coles 
et al., 2000; Flanagan et al., 2011a; Moll et al., 2000; Walker et al., 2004). The Irish 
isolate (Sligo) has been shown to be resistant both in vivo and in vitro. The 
mechanism of resistance is not fully understood  and was previously believed to be 
associated with β-tubulin (Brennan et al., 2007), although further investigation found 
no difference in the and α- and β-tubulin isotypes between TCBZ-susceptible and 
TCBZ-R isolates (Ryan et al., 2008). Other studies, reviewed by Fairweather (2011c) 
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indicate that there may be a number of different mechanisms contributing to the 
development of TCBZ-R. These include an increase in the metabolism of TCBZ to 
TCBZ.SO and TCBZ.SO2 as well as a reduced uptake of TCBZ and TCBZ.SO, this 
may indicate the involvement of P-glycoprotein-linked drug efflux pumps (Alvarez 
et al., 2005; Mottier et al., 2006; Robinson et al., 2004). Due to the observation that 
the Australian isolate (Oberon) does not appear to suffer any fitness costs, it is 
unlikely that a reversion to susceptibility will be seen and indeed this has been 
illustrated in The Netherlands (Borgsteede et al., 2005; Brennan et al., 2007). Of 
particular concern is the reduced efficacy (69.3%) of closantel seen in the Oberon 
strain (Fairweather, 2011a).  
Closantel, whilst being a suitable alternative to TCBZ when used correctly (Coles et 
al., 2000), has also had resistance reported in Australia (Boray et al., 1990), 
indicating that mismanagement of this drug, or over-use in the treatment of H. 
contortus could lead to closantel-resistant strains of parasite developing as has been 
seen for TCBZ-R parasites. 
1.7 Control 
 
Traditionally, the management of fluke included activities such as regular treatment 
of stock with flukicides in the autumn and at lambing, drainage of boggy pasture and 
use of molluscicides (Hope Cawdery, 1984). With growing concern regarding 
damage to the environment and knock-on effects on ecosystems, the use of drainage 
and chemical molluscicides is no longer an option. Coupled with increasing 
treatment failure, farmers have had to adapt their management strategies. 
Fluke management now includes avoidance rather than elimination of snails, the 
invertebrate host (Sargison and Scott, 2010). It is recommended that boggy areas, 
which may contain the snail, and thus infective metacercariae, should be fenced off 
to avoid animal grazing. However, this is not always a practical solution as on many 
farms a large proportion of the pasture would need to be fenced off in order to 
achieve this. 
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Reliance on anthelmintics is still a crucial aspect of successful control programmes 
(Sargison and Scott, 2010). As such, it is also recommended that farmers monitor the 
efficacy of their treatments by use of a FECRT to ensure that parasites have been 
cleared from their animals. Regarding the treatment of sheep, there has been a drive 
to encourage farmers to treat according to individual weight or to the heaviest animal 
in the flock rather than the average weight or an estimation of individual weight 
(Fairweather and Boray, 1999). Indeed this is one of the take home messages of the 
Sustainable Control of Parasites of Sheep (SCOPS) group’s best practice advice to 
farmers and practitioners. This is to reduce the potential for under-dosing, a 
recognised major risk factor in the development of anthelmintic resistance.   
If farmers are to follow these guidelines, they require diagnostic tests that are 
practical and rapidly produce reliable results that can indicate treatment outcome. If 
there was a greater understanding of infected snail distribution on pasture, and how 
animals interact with these areas, it may enable farmers to manage their pastures 
more effectively, which would greatly benefit those farms with particularly boggy, 
low-lying fields. 
1.8 Intermediate snail host 
 
Galba trunculata, the intermediate host of F. hepatica in the UK, is a mud snail of 
the family Lymnaeidae and the only known snail host of fluke in Scotland. G. 
trunculata can inhabit small pools of slow moving water with slightly acidic soils, 
often co-habited by plants of the Juncus genus commonly known as rushes (Mitchell, 
2002; Rondelaud et al., 2011).  
As these snails are hermaphroditic, the introduction of a few infected snails can 
quickly create new foci of infection. In addition, it is has been shown that only a 
small percentage of snails, 4-11%, need be infected in order to create stable fluke 
transmission (Abdel-Rahman et al., 1999; Caron et al., 2011; Mage et al., 2002; 
Manga-Gonzalez et al., 1991; Mekroud et al., 2004; Schweizer et al., 2007).  This 
has an impact on control strategies that would target snails. It is not sufficient to 
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remove a large number of snails as only a small number of snails are required for the 
infection to become re-established.  
Whilst it is possible to detect infected snails on pasture, this is no longer widely 
performed in the UK. It does, however, still play a role in control programmes in The 
Netherlands. There are a variety of tools to detect infected snails including 
dissection, polymerase chain reaction (PCR), real time PCR (RT-PCR) and multiplex 
PCR (Caron et al., 2011; Kozak and Wedrychowicz, 2010; Schweizer et al., 2007). 
These have the potential to be used to gain a better understanding of the distribution 
of infected snails on pasture and potentially indicate pasture burden to farmers, 
allowing them to better manage their pastures and treatment plans. 
1.9 Other trematodes in Scottish Sheep 
1.9.1 Rumen fluke 
 
There are many different species of rumen fluke, 3 of which are of relevance in the 
UK; Paramphistomum cervi, P. leydeni and Calicophoron daubneyi. Historically, it 
was believed that P. cervi was the sole rumen fluke of livestock in the UK (Willmott, 
1950). At the time, identification was based on morphology and the actual 
identification was of P. scotiae and P. hiberniae, both of which have since been 
recognised as P. cervi (Kamburov 1976, cited in Eduardo (1982)). Rumen fluke have 
undergone several reclassifications over the years, typically based on morphology 
(Eduardo, 1982). Recent molecular genetic studies, using sequencing of the ITS-2 
region of ribosomal DNA, have identified only C. daubneyi to be present in UK 
livestock, with P. leydeni being found in Irish deer (Gordon et al., 2013; O’Toole et 
al., 2014)(unpublished data). All three rumen fluke species use a snail as the 
intermediate host. The species of snail varies between parasite species and location, 
with C. daubneyi being found to utilise G. truncatula as an intermediate host in 
France (Abrous et al., 1999). 
The pathogenicity of rumen fluke is a controversial topic (Sanabria and Romero, 
2008). This is despite the mechanism of pathogenicity of large infections of 
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immature fluke being demonstrated by Horak (1971). It was found that immature 
rumen fluke in the small intestine cause severe enteritis, resulting in malnutrition, 
dehydration and death (Horak, 1971). Horak (1971) also summarises several cases 
where rumen fluke were thought to be the cause of clinical signs in animals. More 
recently, several possible and confirmed clinical cases of paramphistomosis were 
reported in sheep and cattle in the UK (Foster et al., 2008; Mason et al., 2012; Millar, 
2012). The rarity of clinical cases of paramphistomosis may be due to the large 
number of immature fluke required (Horak, 1971). It is also possible that many cases 
of enteritis go undiagnosed or are mis-diagnosed due to veterinarians not considering 
rumen fluke as a cause. The number of reported cases may increase with greater 
awareness and better diagnosis (Foster et al., 2008). Paramphistomosis is treated with 
oxyclozanide, which is licensed in the UK for the treatment of Fasciola spp. in sheep 
and cattle, but not for the treatment of rumen fluke.   
The presence of rumen fluke in the UK has implications for the diagnosis of F. 
hepatica. Co-infections of both fluke species have been seen and, as the eggs are 
morphologically similar, this could lead to incorrect egg counts being recorded. A 
rumen fluke infection may be wrongly diagnosed as a F. hepatica infection, or a 
mixed infection could be reported as having a higher FEC if rumen fluke eggs are not 
identified. As most treatments for F. hepatica do not target rumen fluke, it is likely 
that, in a mixed infection liver fluke may be successfully treated but incorrectly 
identified rumen fluke eggs could give the impression that treatment was not 
effective. 
1.9.2 Lancet fluke 
 
The lancet fluke, Dicrocoelium dendriticum, is another liver fluke which is rarely 
seen in the UK. This liver fluke has a complicated life-cycle involving two 
intermediate hosts (an ant and a snail). It has only been reported in a few locations in 
the UK and is endemic on the Island of Coll in the Outer Hebrides (Anon, 2012; 
Cranwell et al., 2010; Sargison et al., 2012; Tarry, 1969). Large infections of these 
small liver fluke can cause disease, with clinical signs including photosensitivity, as 
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well as leading to the condemnation of livers (Sargison et al., 2012). D. dendriticum 
infections are treated with albendazole, although this is not wholly effective 
(Sargison et al., 2012). 
D. dendriticum infections do not have as many implications for liver fluke diagnosis 
as rumen fluke infections do. This is due to the rarity and small geographic area over 
which infections are seen in, the fact the eggs are morphologically distinct and that 
there is no cross-reaction with the cELISA (Gordon et al., 2013). There is, however, 
a potential for cross-reaction in DNA-based diagnosis, due to genetic similarities 
between these trematode parasites.  
1.10 Thesis aims 
 
This thesis aims to evaluate currently available and novel diagnostic tests for F. 
hepatica. To achieve this the cELISA, along with FEC, and where feasible the 
AbELISA and the use of GLDH and GGT concentrations, are evaluated in (1) an 
experimental challenge model (Chapter 3), (2) individual naturally exposed sheep, in 
early infection, pre- and post-treatment situations (Chapter 4), (3) groups of naturally 
exposed sheep, including composite samples, in pre- and post-treatment situations 
and evaluating the FECRT and CRT (Chapter 5), and lastly a LAMP assay is 
developed for the detection of F. hepatica, and evaluated against cELISA, FEC and 
PCR based detection (Chapter 6). 
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Chapter 2: Materials and Methods 
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2.1 Sample collection 
2.1.1 Faeces 
 
Faecal samples from live animals were either collected from paddock/pen floors or 
per rectum. When possible, faecal samples were collected from the field in screw top 
pots. If samples were received in bags or gloves, they were transferred to screw top 
pots for storage. For rectal faecal sampling, animals were restrained and faeces 
removed from the rectum using gloved fingers, index finger ± middle finger. Fresh 
gloves were used for each animal. In the case of deceased animals, the rectum was 
cut away from the carcass and squeezed to recover faeces. On arrival at the 
laboratory faeces were stored at 4˚C. Samples were prepared for coproantigen 
ELISA (cELISA) testing within 7 days and faecal egg counts (FEC) were performed 
within 23 days. 
2.1.2 Blood 
 
Blood sampling was carried out either by a qualified veterinarian or a personal 









, UK) were used. Samples were either stored at room 
temperature overnight to allow the clotting of the blood or centrifuged at 1,275 g for 
10 minutes to obtain the serum. If storage was required for archive purposes, serum 
samples were frozen in 1.5 ml microcentrifuge tubes at -20˚C. Frozen samples were 
not needed for any studies within this thesis. 
2.1.3 Livers 
 
Livers were collected at slaughter or post-mortem, each liver was double-bagged in 
polythene bags to ensure that no fluke were lost. The animal identifier was written on 
both bags and, where possible, the ear tag was included in the bag with the liver. On 
arrival at the laboratory, livers were stored at 4˚C if they were to be processed on the 
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same day (<24 hours). If processing was to be delayed, livers were frozen at -20˚C 
for no more than 7 months. 
2.2 Faecal testing 
2.2.1 Faecal egg counting (FEC) 
2.2.1.1 SAC method 
 
FEC was performed by Scottish Agricultural College Consulting: Veterinary 
Services (SAC C VS) Dumfries, using a sedimentation method. Briefly, 3 g of faecal 
samples were weighed and washed through 710 µm, 150 µm and 38 µm sieves in 
sequence, with the faecal material collecting on the 38 µm sieve. The contents of the 
38 µm sieve were washed into a 250 ml beaker which was then filled to the 200 ml 
mark with water. The contents of the beaker were allowed to sediment in water for 4 
minutes. The supernatant was then poured off and the sediment re-suspended in 
water to the 200 ml mark and allowed to sediment again. This was repeated as 
necessary until the supernatant was clear. The final sediment was transferred to a 
petri dish, stained with 1 or 2 drops of 0.1 - 0.5% (w/v) methylene blue, viewed 
under a light microscope at x8 magnification and any fluke eggs observed counted. 
2.2.1.2 Moredun method 
 
The Moredun FEC method consisted of a modified version of the method outlined by 
McCaughey and Hatch (1964). Briefly, 3 g of each sample was homogenised in 42 
ml of cold tap water and poured through a strainer into a 250 ml beaker. The filtrate 
was then poured through a 150 µm sieve into a 250 ml conical measure. The beaker 
was half-filled with water and the contents poured through the sieve again to wash 
any remaining eggs through to the conical measure. The conical measure was 
allowed to sit at a slight angle, ~20˚, for precisely 3 minutes at which point the 
supernatant was siphoned off using a vacuum line. One drop of 1% (w/v) methylene 
blue was added to the sediment, which was examined on a marked petri dish (7 cm 
diameter) at x16 magnification using a light microscope. Each sample dish was 
counted twice and an average taken, this was divided by 3 to calculate the number of 
Fasciola hepatica infection in sheep: Current and novel diagnostic tests 
Chapter 2: Materials and methods  26 
eggs per gram (epg). An animal was considered positive when at least 1 egg was 
detected. When less than 3 g of faeces were available the final result was divided by 
the amount of faeces tested to calculate the epg. Samples with less than 1 g available 
were considered to be insufficient for an accurate FEC to be performed and were 
thus excluded. FECs were performed by Danielle Gordon-Gibbs, Margaret Oliver, 
Lynsey Melville and Gillian Mitchell.  
2.2.2 Faecal egg count reduction (FECR) 
 
Faecal egg count reduction testing (FECRT) was used to determine treatment 
outcome. The reduction in the FEC, from 0 days post-treatment (dpt) to a subsequent 
post-treatment sampling point, was calculated using the formula below (Coles et al., 
1992). This was originally developed for nematodes, where FEC0 is the group 
arithmetic mean FEC at 0 dpt and FECt is the group arithmetic mean FEC at the post-
treatment sampling. In this thesis, group sizes of a minimum of 9 animals for 
naturally exposed animals, and 6 animals for experimentally challenged animals, 
were used to calculate FECR. 
FECR =  (FEC0 - FECt)    x 100 
    FEC0 
 
 
2.2.3 BIO K201 Fasciola Coproantigen ELISA (cELISA) 
 
The BIO K201 Fasciola Coproantigen ELISA (cELISA) (Bio-X Diagnostics, 
Belgium) was performed according to manufacturer’s guidelines, with the following 
modifications. All samples were homogenised prior to weighing out the 0.5 g (±0.03 
g) required for the cELISA and all subsamples were suspended in buffer and 
vortexed for 10 seconds prior to centrifugation. A full protocol with modifications is 
listed in Appendix 1. Samples were prepared to supernatant stage and supernatants 
were stored in 1.5 ml microcentrifuge tubes at -20°C until testing. Optical densities 
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were read at 450 nm on an ELx808 IU Absorbance Microplate Reader (BioTek
®
 
Instruments Inc, USA). 
For each plate run, the positive control had to be equal to or greater than a minimum 
optical density (OD), which was batch specific and ranged from 0.805 to 1.236, in 
order for the plate to be considered valid. Initially, the manufacturers stated that a 
test sample with an OD of ≥0.15 was to be considered positive by the BIO K201 kit 
criteria. Subsequently, the kit criteria outlined that a result should be interpreted as a 
percentage of the OD of the kit’s positive control. A sample was considered positive 
if this percentage was greater than a set value which was batch specific (ranging 
from 6.07% to 7.49%). The formulae used to calculate the OD and PD are shown 
below.  
   OD = well 1 value – well 2 value 
PD =        sample OD             x 100 
Positive control OD 
 
The composition of the kit was also altered twice during this study. In the first 
instance, a concentrated chromogen tetramethylbenzidine solution (TMB) was 
provided with the kit which had to be diluted with a provided substrate solution. 
When the results interpretation changed, the TMB was provided in a ready to use 
form. The third change in kit was the addition of a yellow colouring to the dilution 
buffer. The cELISA was performed by Danielle Gordon-Gibbs, Margaret Oliver, 
Lynsey Melville, Lisa Imrie and Gillian Mitchell. 
2.2.4 Coproantigen reduction (CR) 
 
A novel coproantigen reduction test (CRT) to determine treatment outcome was used 
in studies within this thesis, which differed to that proposed by Flanagan et al. 
(2011b). Instead the FECRT formula described in Section 2.2.2 was applied to pre- 
and post-treatment cELISA OD/PD values and a CR calculated. A CR of ≥95% was 
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deemed to indicate successful treatment. An additional criterion was added in 
Chapter 5, which automatically deemed treatment successful if the post-treatment 
cELISA PD indicated that no fluke infection was present. In this thesis, group sizes 
of a minimum of 9 animals for naturally exposed animals, and 6 animals for 
experimentally challenged animals, were used to calculate cELISA reduction (CR). 
2.3 Serum testing 
2.3.1 Biochemistry 
 
Serum testing for the determination of glutamate dehydrogenase (GLDH) and 
gamma-glutamyl transferase (GGT) concentrations was conducted by SAC C VS 
(Dumfries). GLDH was measured using a commercial biochemical assay kit (Randox 
Ltd) which measures the decrease in absorbance at 340 nm in the following reaction 
which is catalysed by GLDH: a-oxoglutarate + NADH + NH4+ → glutamate + 
NAD+ + H2O. GGT was measured using another commercial biochemical assay 
(Instrumentation Laboratory UK Ltd) which measures the rate of increase in 
absorbance at 405 nm in the following reaction which is catalysed by GGT: L-γ-
glutamyl-3-carboxy-4-nitroanilide + glycylglycine ↔ L-γ-glutamylglycylglycine + 
5-amino-2-nitrobenzoate. Both assays were viewed on an IL600 random access 
analyser using standard methods.SAC C VS reference ranges for normal liver and 
bile duct function used in this thesis were 2-10 IU/L and 27-31 IU/L, respectively. 
2.3.2 Pourquier fasciolosis antibody ELISA (AbELISA) 
 
The Pourquier bovine fasciolosis serum and milk verification ELISA, P05120-5 
(IDEXX Laboratories, USA) was performed by SAC C VS (Dumfries) or Biobest 
Laboratories Ltd (UK) for samples in this thesis. The AbELISA was performed and 
interpreted according to the manufacturer’s guidelines, which state that a sample is 
positive if the S/P % of the sample is >30. The SP % is calculated by dividing the 
OD of the test sample by the OD of the positive control and multiplying this number 
by 100. Biobest Laboratories Ltd gave further interpretation of the results stating that 
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an S/P % of 31-79 indicated a light infestation, 80-149 indicated a moderate 
infestation and ≥150 indicated a heavy infestation. 
2.4 Dose and slaughter trial 
2.4.1 Metacercarial cyst maintenance 
 
Metacerarial cysts were received from Ridgeway Research, Gloucestershire (UK) on 
plastic sheeting. These sheets were transferred to 500 ml capacity plastic tubs with 
screw top lids, which were filled with ~400 ml distilled water. Two or three sheets 
were stored in each tub. The tubs were stored at 4ºC. The water was changed weekly; 
this was done by pouring out the existing water into a jug and replacing with fresh 
distilled water. The tubs were gently swirled to ensure that the sheets were not stuck 
to each other and the fresh water was able to circulate around each sheet. The waste 
water was disposed of following heat inactivation of any metacercarial cysts that 
may be present (heated to 70˚C for several hours and then allowed to cool prior to 
disposal). Cyst maintenance was performed by Danielle Gordon-Gibbs and Gillian 
Mitchell. 
2.4.2 Fluke challenge preparation 
 
Infectious doses of metacercarial cysts were prepared for a dose and slaughter trial 
and experimental infections. The cysts were examined under a light microscope to 
check for viability (Figure 2.1). Using a metal spatula, cysts were scraped into a 
small volume of 0.5% agar, which was stirred with a metal spatula to obtain an even 
distribution. 100 µl aliquots of this stock solution were then taken and again 
examined under a light microscope to determine the concentration of viable cysts. 
Additional 0.5% agar could then be added to the stock solution to obtain the desired 
concentration of viable cysts. Doses were taken up into 20 ml syringes, capped and 
stored at room temperature for oral administration the same day. 
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Figure 2.1 Viable (a) and non-viable (b) F. hepatica metacercarial cysts. 
2.4.3 Liver processing 
2.4.3.1 SAC method 
 
The gall bladder and main bile ducts of livers obtained from slaughter were opened 
with scissors and any fluke present removed. Livers were then cut into ~1 inch slices 
and pressure applied to remove fluke. Liver slices were soaked in water overnight 
and pressure applied to each slice the next day. Water from the overnight soaking 
was passed through a 355 µm sieve and the debris examined under a dissecting 
microscope for the presence of any whole or partial fluke. 
2.4.3.2 Moredun method 
 
Fluke were extracted from livers obtained at slaughter or at post-mortem following 
the method outlined by Clery et al., (1996), with an additional maceration of liver 
slices. The full protocol used is presented in Appendix 1. Livers were processed by 
Danielle Gordon-Gibbs, Margaret Oliver, Lynsey Melville, Lisa Imrie and Gillian 
Mitchell. In some cases, for reasons of practicality, livers were frozen at -20˚C on 
receipt for investigation at a later date, as examination was not always possible on 
the day of collection. Retrieved fluke were temporarily placed in water and examined 
under a light microscope to determine fluke age. Fluke length and width of shoulders 
were noted and also used to determine fluke age. For partial flukes recovered, the 
(a) (b) 
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numbers of anterior and posterior ends were counted and the larger figure added to 
the number of whole fluke seen in order to determine liver burden. After examination 
fluke were stored in 75-100% ethanol.  
2.4.4 Egg recovery 
 
In some instances, sequestered eggs from the gall bladder were required, either for 
molecular work or to propagate the isolate. In these cases, the gall bladder was 
clipped off and contents collected on the surface of a sieve. Contents were washed 
with distilled water, any adult fluke removed and eggs allowed to sediment in a 
universal tube. Eggs were then re-suspended in either distilled H2O and stored at 4˚C 
or ethanol and stored at room temperature depending on their intended use, hatching 
or DNA extraction, respectively. Eggs that were to be hatched were kept at 4˚C 
overnight and posted to the relevant organisation/research teams the next morning. 
The quantity of eggs could be estimated by re-suspending the solution and counting 
the eggs present in a 100 µl aliquot. This was performed by Danielle Gordon-Gibbs, 
Lynsey Melville and Gillian Mitchell. 
2.5 DNA Extraction 
 
DNA extractions were performed by Danielle Gordon-Gibbs and Gillian Mitchell. 




 Blood and Tissue Kit (Qiagen) was used to extract genomic DNA 
from trematode tissue, trematode eggs and ovine faeces (0.2 g ±0.03 g). The kit was 
used as per manufacturer’s instructions for animal tissues (spin-column protocol); 
with the exception that DNA was eluted into 100 µl of Buffer AE rather than 200 µl. 
The DNA extraction was performed in a UV sterilisation cabinet (Bigneat Ltd, UK). 
A full description of the protocol used is listed in Appendix 1. 
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 DNA Stool Mini Kit (Qiagen) was used at 95°C to extract DNA from 
0.2 g (±0.03 g) ovine faeces as described by the manufacturers for stool pathogen 
detection, with the exception that samples were vortexed with the InhibitEX Tablet 
for 2 minutes rather than 1 minute and DNA eluted into 100 µl Buffer AE rather than 
200 µl. The DNA extraction was performed in a UV sterilisation cabinet (Bigneat 
Ltd, UK). A full description of the protocol used is listed in Appendix 1.  




 Fast DNA Stool Mini Kit (Qiagen) was used at 95°C to extract DNA 
from 0.2 g (±0.03 g) ovine faeces as described by the manufacturers for stool 
pathogen detection, with the exception that DNA eluted into 100 µl Buffer ATE 
rather than 200 µl. The DNA extraction was performed in a UV sterilisation cabinet 
(Bigneat Ltd, UK). A full description of the protocol used is listed in Appendix 1.  
2.5.4 Freeze/thaw DNA extraction 
 
A freeze/thaw DNA extraction method based on that outlined by Mukhopadhyay et 
al. (2012) was used to extract DNA from ovine faeces. Briefly, 0.25 g (±0.03 g) of 
homogenised faeces were weighed out into a sterile 1.5 ml microcentrifuge tube and 
frozen at -20°C. Samples used for assay development were stored at -20˚C for no 
longer than 1 month prior to DNA extraction, whilst samples used for the evaluation 
of PCR and LAMP assays were stored for ~1 year prior to DNA extraction. 
Subsequently, these samples were diluted in 500 µl of nuclease-free (NF) H2O 
(Sigma) and vortexed until mixed. Samples were then kept at 96°C for 10 minutes 
before immediately being placed on ice for 5 minutes. Lastly, samples were 
centrifuged at 12,000 g for 10 minutes and the supernatant recovered. 50 µl of this 
supernatant was then diluted in 450 µl of NF H2O (Sigma). This diluted DNA could 
then be used in amplification techniques.  
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2.6 DNA amplification 
2.6.1 PCR and gel imaging 
 





 PCR System 2700 (Thermo Fisher Scientific, 
USA) or an Applied Biosystems
®
 2720 Thermal Cycler (Thermo Fisher Scientific, 
USA). In each instance, a mastermix for 25 µl reactions was created in a DNA-free 
UV sterilisation cabinet (Bigneat Ltd, UK), using the Platinum
®
 Taq DNA 
polymerase kit (Invitrogen, USA) and dNTPs (Invitrogen, USA), NF H2O (Sigma). 
All primers were ordered from Eurofins MWG Synthesis GmbH (Germany), made to 
a 100 pmol/µl concentration using NF H2O (Sigma) as described on the 
oligonucleotide synthesis report prior to being stored at -20ºC.  
Briefly, 1.2% agarose gels were prepared by adding ~400 ml of distilled water and 8 
ml of 50x TAE (Tris-acetate-EDTA) to 4.8 g of molecular grade agarose (Bioline, 
UK)  and heating in a 600W (category E) microwave until the mixture bubbled. It 
was then allowed to cool before 40 µl of GelRed
™
 Nucleic Acid Gel Stain (Biotium) 
was added. The mixture was then swirled and poured into a gel plate with an 
appropriate comb. Finally, the gel was allowed to cool until it had set, at which point 
the comb was removed and samples could be added.  
For each PCR product, 2 µl of PCR product was added to 5 µl Blue Juice
TM
 gel 
loading buffer (Invitrogen, USA). These samples were run on a 1.2% agarose gel 
stained with GelRed
™
 Nucleic Acid Gel Stain (Biotium) at 100 volts. Gels were 
viewed on an AlphaImager
™
 2200 (Alpha Innotech) gel documentation system. 
PCRs and gel imaging were performed by Danielle Gordon-Gibbs and Gillian 
Mitchell. 
2.6.2 Loop-mediated isothermal amplification (LAMP) 
 
Loop-mediated isothermal amplification (LAMP) was carried out using the MAST 
Isoplex
®
 DNA Amp kit (MAST Group Ltd., UK). Reaction mixes and primer mixes 
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were made in 1.5ml microcentrifuge tubes in a UV sterilisation cabinet (Bigneat Ltd, 
UK).  All tubes and reagents were kept on IsoFreeze
®
 MCT racks. Fresh NF H2O 
(Sigma) was used for each mastermix. The Loopamp
®
 fluorescent detection reagent 
(Eiken Chemical Co. Ltd, Japan) was added to the reaction mix to visualise 
amplification. DNA samples were added in a separate area, again on a cool plate. A 
kit positive, parasite positive and at least one negative control, NF H2O (Sigma) was 
included in each run. HPLC purified primers were ordered from Eurofins MWG 
Synthesis GmbH (Germany) and brought to 100 pmol/µl, as described in the 
oligonucleotide synthesis report, using NF H2O (Sigma). Amplification was carried 




 PCR System 2700 (Thermo Fisher 
Scientific, USA) or an Applied Biosystems
®
 2720 Thermal Cycler (Thermo Fisher 
Scientific, USA). Amplification was viewed directly within the reaction tubes on an 
AlphaImager
™
 2200 (Alpha Inotech) gel documentation system. Reaction tubes were 
disposed of by incineration without tube lids being opened. LAMP assays were 
carried out by Danielle Gordon-Gibbs. 
2.7 Statistical methods 
 
Statistical analysis was performed in RStudio (R Core Team, 2014) unless otherwise 
specified.  
The “lm()” function, from the “stats” package, was used to fit a linear model to two 
sets of data in order to compare tests (R Core Team, 2014). The model form was x ~ 
y. 
The “cor()” function, from the “stats” package was used to calculate the correlation 
between two data sets (R Core Team, 2014). As the data were not of a normal 
distribution, the “spearman” method was specified in order to calculate the 
Spearman’s rank correlation coefficient (rho).  
The “confusionMatrix()” function, from the “caret” package, was used to create cross 
tabulations of the results of two tests, one of which was deemed to be the ‘gold 
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standard’ or reference test (Kuhn, 2014). The format of the table produced by 
“confusionMatrix()” is shown in Table 2.1.  
Table 2.1 Format of "confusionMatrix()" function table 
 
Reference 
Event No event 
Predicted 
Event A B 
No event C D 
 
From this table, the sensitivity (Se), specificity (Sp), positive predictive value (PPV) 
and negative predictive value (NPV) of the non-reference test were calculated using 
the “confusionMatrix()”. The formulae used to calculate sensitivity, specificity, PPV 
and NPV and prevalence are listed below (Kuhn, 2014). 
Sensitivity =   A 
(A + C) 
 
Specificity =   D 
(B + D) 
 
Prevalence =   (A + C) 
(A + B + C + D) 
 
PPV =   A 
  (A + B) 
 
NPV =  D 
   (C + D) 
 
In addition, the Cohen’s unweighted Kappa for the two tests was also calculated 
using the “confusionMatrix()” function. Kappa values were categorised according to 
the degree of agreement beyond chance, ranging from none to almost perfect as 
described by McGinn et al. (2004) and summarised in Table 2.2. 
The “wilcox.exact()” function, from the “exactRankTests” package, was used to 
perform a modified Wilcoxon rank sum test, which is an unpaired non-parametric t-
test, that allows for ties (repeat values) in the data (Hothorn and Hornik, 2013). 
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Table 2.2 Kappa values and corresponding category of degree of agreement beyond chance as 
described by McGinn et al. (2004) 






0.8-1.0 Almost perfect 
 
The FECR was performed in using the “FECRT()” function from the “bayescount” 
package (Denwood, 2009). The WAAVP method for the calculation of FECR was 
used (Coles et al., 1992), as opposed to the Bayesian MCMC or bootstrap methods 
also offered by the “FECRT()” function. As this function requires integers, all FECs 
were rounded to the nearest integer. All FECs which were <0.5 epg but >0 epg were 
rounded to 1.0 epg.  
The CR was performed in Microsoft Excel, using the formula specified in Section 
2.2.2, due to the impracticalities of rounding ODs and PDs to the nearest integer.
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3.1 Abstract 
 
Although the faecal egg count (FEC) is commonly used to diagnose Fasciola 
hepatica infections, it cannot detect the pre-patent stages of liver fluke which cause 
acute and sub-acute fasciolosis. Whilst the anti-Fasciola antibody ELISA 
(AbELISA) can detect pre-patent fluke infection, it is not specific for current 
infection. A new test, the coproantigen ELISA (cELISA), has been reported to detect 
early infection, only detect current infection, and be able to detect the presence of 
even low numbers of fluke. Triclabendazole (TCBZ) is the drug of choice to treat F. 
hepatica, especially in sheep, as it is the only drug available which can target all 
stages of the parasite within the definitive host. There have been increasing reports of 
TCBZ treatment failure in the UK, although resistance has yet to be confirmed. The 
present study aimed to develop a challenge model in order to (1) evaluate the 
performance of AbELISA, FEC and cELISA in sheep which had been 
experimentally challenged with F. hepatica, (2) determine the TCBZ resistant 
(TCBZ-R) status of the F. hepatica isolate used and (3) profile the dynamics of this 
isolate using blood- and faecal-based diagnostics. Over the course of 2 years, 2 
groups of 6 sheep were challenged with metacercarial cysts derived from a F. 
hepatica isolate obtained from naturally infected sheep with a history of TCBZ 
treatment failure. In both studies, AbELISA was first to detect infection (3-4 weeks 
post-challenge (wpc)), followed by cELISA (3-10 wpc) and then FEC (9-10 wpc). 
Although minor fluctuations were seen in both the FEC and cELISA levels over both 
studies, a transient increase in the cELISA levels were seen in the first study at 3-8 
wpc. TCBZ treatments were given to all animals 2 weeks prior to slaughter. The 
highest FEC reduction seen was 37% and all sheep had live, visually undamaged 
fluke present in their livers at slaughter, confirming the presence of fluke resistant to 
TCBZ. Drug efficacy could not be calculated. This study confirms that cELISA can 
detect experimental infection of sheep with F. hepatica later than AbELISA but 
earlier than FEC. A transient increase in cELISA values during early infection was 
described for the first time. In addition, TCBZ-R was confirmed for the first time for 
a British isolate (Moredun isolate) by means of dose and slaughter trials.  
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3.2 Introduction 
 
Fasciolosis in the UK is caused by the liver fluke, Fasciola hepatica, and is 
responsible for significant economic losses to the UK sheep and cattle farming 
industry. Although faecal egg counting (FEC) is a useful diagnostic test for chronic 
fasciolosis, it is unable to detect the pre-patent acute and sub-acute forms of the 
disease (Valero et al., 2006). Detection of anti-Fasciola antibodies by means of the 
antibody ELISA (AbELISA) gives very early indication of infection, from 4 weeks 
post-infection (wpi), but it cannot differentiate between past and current infection 
(Sánchez et al., 2001; Zimmerman et al., 1982). Due to the severity of acute and sub-
acute fasciolosis, a specific diagnostic test for this condition is urgently needed.  
The BIO K201 cELISA is a relatively new diagnostic test, developed by Mezo et al. 
(2004) and commercialised by Bio-X Diagnostics (Belgium). The authors that 
developed this test reported that it could detect infection from 5 wpi, that it was 
specific for current liver fluke infection and that it could detect infection by a single 
fluke in lambs (Bio-X, 2010; Mezo et al., 2004). However, there have been few 
studies investigating the commercial test in sheep (Flanagan et al., 2011a; 2011b). 
Triclabendazole (TCBZ) is the fasciolicidal drug of choice for the treatment of F. 
hepatica, especially in sheep, due to its unique ability to kill all stages of liver fluke 
within the definitive host (Boray et al., 1983). Whilst other treatments are available, 
they have little or no efficacy  against immature fluke, younger than 6 weeks old, 
which can cause acute and sub-acute fasciolosis (Fairweather and Boray, 1999). As 
acute and sub-acute fasciolosis are caused by pre-patent fluke and often result in 
sudden death, they can be difficult to diagnose and, as such, TCBZ is often given 
prophylactically i.e. without a diagnosis (Boray, 1985). This reliance on a single 
drug, for so many years, has placed a strong selection pressure for TCBZ resistant 
(TCBZ-R) fluke. 
The potential for TCBZ-R was first demonstrated in Australia by Overend and 
Bowen (1995). Since then, TCBZ-R isolates have been identified in Australia, 
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Ireland, The Netherlands and Spain (Álvarez-Sánchez et al., 2006; Coles et al., 2000; 
Moll et al., 2000; Walker et al., 2004). There have also been numerous reports of 
TCBZ treatment failure in the UK (Anon, 1998; Lane, 1998; Mitchell et al., 1998; 
Thomas, 2000). It is important to note that cases of treatment failure do not 
automatically indicate resistance. Treatment failure can occur for a number of 
reasons, including poorly stored medications and under-dosing. Under-dosing can be 
caused by underestimating animal weights, poorly calibrated dosing equipment or the 
dose not being completely swallowed or absorbed.  
To confirm that an isolate of F.  hepatica is truly resistant to a drug, a dose and 
slaughter trial is required (Coles and Stafford, 2001). Whilst this may appear 
unnecessarily extreme, it has been shown that F. hepatica isolates, believed to be 
resistant based on FECRT results, have proven to be susceptible when evaluated in 
dose and slaughter trials (Fairweather, 2011a). This mis-classification of isolates 
gives a false impression of the extent and spread of resistance. It could also have 
implications for future research into the detection and management of resistant fluke 
populations. For resistance to be better understood at a genetic level, isolates of 
known resistance status are essential. 
This chapter aims to establish a F. hepatica challenge model in sheep in order to (1) 
evaluate the performance of AbELISA, FEC and cELISA, (2) to determine the 
TCBZ resistant status of a British F. hepatica isolate (Moredun isolate) and (3) to 
profile the dynamics of said isolate using blood- and faecal-based diagnostic tests. 
3.3 Materials and methods 
3.3.1 Isolation of Moredun isolate 
 
Two in-lamb Blackface x Blue Leicester ewes, henceforth referred to as donor ewes, 
were selected from a Scottish farm, which had a history of repeated TCBZ treatment 
failure. These donor ewes were identified as being infected with liver fluke according 
to FEC and cELISA testing. The donor ewes were weighed and faecal sampled prior 
to treatment with TCBZ, according to the manufacturer’s recommended dose rate, 1 
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ml per 5 kg bodyweight (Fasinex
®
, Novartis Animal Health). Sampling was repeated 
at 0, 1, 2, and 3 weeks post-treatment (wpt). Both ewes were FEC and cELISA 
positive at each sampling, with limited reduction in FEC from pre-treatment levels 
(no greater than 69% FECR). At 3 wpt, they were again weighed and dosed with 
TCBZ (Fasinex
®
, Novartis Animal Health), according to the manufacturer’s 
recommendations. The animals were sampled again 35 days later, at which point 
they were still FEC and cELISA positive. The ewes were considered to be 
sufficiently healthy, allowed to lamb and a third TCBZ (Fasinex
®
, Novartis Animal 
Health) treatment given once the lambs had been weaned. FEC and cELISA results 
from each sampling point can be seen in Figure 3.1. Treatment was often followed 
by a reduction in FEC but not cELISA results (Figure 3.1) and at no point did the 
FEC reduction (FECR) exceed 66% for either animal. Full details of the FECR can 
be seen in Appendix 2. 
The donor ewes were killed 7 days following the third treatment. At this point, 46 
adult fluke were recovered from ewe A1055 and 75 from ewe A1087, as described in 
Section 2.4.3.2. In addition, fluke eggs were recovered from the ewes’ gall bladders, 
as described in Section 2.4.4. These eggs were combined into one sample and posted 
to Ridgeway Research (Gloucestershire, UK) where they were hatched into miracidia 
and used to infect Galba truncatula snails. The metacercarial cysts that were shed by 
the infected snails were collected on cellophane sheets and sent back to Moredun 
Research Institute, UK (MRI). The metacercarial cysts were maintained at 4˚C in 
ultra pure water, with weekly water changes for 5 months in the case of challenge 
experiment 1, and 2 months in the case of challenge experiment 2, until the point of 
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3.3.2 Challenge animals 
 
In both challenge experiments, six 1 year-old mule wethers (cross-breed castrated 
male sheep) were used. These were raised worm-free and had not been grazed on 
pasture or knowingly exposed to gastro-intestinal parasites or liver fluke. The liver 
fluke-free (and unexposed) status of the animals was confirmed by FEC, cELISA and 
AbELISA testing prior to starting the study. In the second challenge experiment, the 
animals were the control group for a vaccine trial (unpublished). As such, they were 
injected with QuilA adjuvant at -6, -3, 0 and 3 wpc (weeks post challenge). For both 
challenge experiments, sheep were housed and fed on hay and concentrates with 
water available ad lib for the 18 or 20 week duration of the studies. 
3.3.3 F. hepatica challenge 
 
All experimental procedures were carried out at MRI (UK) by either personal license 
holders or veterinarians. Ethical approval was obtained from the Institute’s 
Experiments and Ethical Review Committee, in accordance with the Animals 
(Scientific Procedures) Act 1986. Animals were health checked daily for the duration 
of the studies. 
The Moredun isolate was used for both challenge experiments. In the first challenge 
experiment, each animal was given an oral dose of approximately 160 viable F. 
hepatica metacercarial cysts suspended in 18 ml 0.5% agar, on the first sampling 
date. In the second challenge experiment, each animal was given an oral dose of 
approximately 90 viable F. hepatica metacercarial cysts suspended in 9 ml 0.5% 
agar, 6 weeks into the vaccine trial. In both cases, doses were administered via 20 ml 
syringe. Full details of dose preparation can be seen in Section 2.4.2. 
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3.3.4 Sampling and testing 
 
Blood and faecal samples were collected weekly for the duration of the studies as 
described in Section 2.1 (Figure 3.2). Serum samples were sent to Biobest 
Laboratories Ltd. (UK) for AbELISA testing, as outlined in Section 2.3.2. The FEC 
and cELISA were performed at MRI (UK), as described in Sections 2.2.1.2 and 
2.2.3. Samples were considered cELISA positive if the percentage difference (PD) 
was ≥6.07 or ≥7.49 for the first and second challenges, respectively.  
 
Figure 3.2 Set up of weekly sample collection from challenged animals 
The reduction in FEC (FECR) was calculated as described in Section 2.2.2, using a 
reduction of ≥95% as the criterion for successful treatment. A treatment was 
considered successful according to the cELISA if the cELISA result was negative 
post-treatment, as proposed by Flanagan et al. (2011b). 
3.3.5 Post-mortem 
 
In both challenge studies, animals were killed by captive bolt gun stunning followed 
by exsanguination. Livers were removed and the gall bladder clipped off prior to 
investigation for fluke and collection of fluke eggs from the gall bladder, as 
described in Sections 2.4.3.2 and 2.4.4 (Figure 3.3). As for the initial isolation, the 
eggs from all 6 animals were combined into one sample and posted to Ridgeway 
Research (Gloucestershire, UK) to maintain the isolate. 
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Figure 3.3 Sample collection set-up for challenge animals’ post-mortem 
3.3.6 Statistical analysis 
 
All statistical analyses were performed in RStudio (R Core Team, 2014). The “lm()” 
function was used to fit a linear model to compare faecal- and serum-based tests to 
liver burdens at slaughter (R Core Team, 2014), whilst the 
“cor(x,y,method=“spearman”)” function was used to calculate the Spearman’s rank 
correlation coefficient (rho) (R Core Team, 2014). Because of the low sample size in 
each experiment, statistical significance was set at P = 0.10. FECRs were calculated 
as described in Section 2.2.2. 
3.4 Results 
3.4.1 Challenge experiment 1 
 
Individual AbELISA, FEC, cELISA, and fluke burden results can be seen in 
Appendix 2. 
3.4.1.1 Challenge experiment 1: AbELISA 
 
Antibody titres remained negative at both the group and individual level until 3 wpc, 
at which point 4 of the 6 animals were antibody positive. By 4 wpc, all animals were 
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antibody positive and remained so until the end of the study. A summary of the 
individual antibody titres throughout the study can be seen in Figure 3.6. At both 5 
and 6 wpc, two animals had antibody titres which were distinctly separate from the 
rest of the group’s. In both cases, it was A1079 which had a lower antibody titre and 
A1076 which had a higher antibody titre than the rest of the group. An increase in 
antibody titre was seen at 9 wpc, followed by a decrease at 13 wpc and another 
increase at 14 wpc.  
3.4.1.2 Challenge experiment 1: FEC 
 
A positive FEC was first seen at 9 wpc, with 3 animals having a positive egg count 
and a group mean FEC of 0.5 epg. At 10 wpc, all but one animal had a positive FEC 
with a group mean of 4.1 epg. By 11 wpc all animals had a positive FEC, with a 
mean of 17.3 epg, and remained positive until the end of the study. A summary of the 
FEC results can be seen in Figure 3.4. From 9 wpc, A1074 consistently had the 
highest FEC, being distinctly separate from the rest of the group. Within each 
individual animal, fluctuations in FEC were observed (Figure 3.6). FECRs at 2 wpt 
ranged from -430 to 30%. The lowest FECR (-430%) came from animal A1076, 
which had a FEC of 5 epg pre-treatment but a FEC of 26.5 epg post-treatment, 
indicating a rise of 430% in FEC epg rather than a reduction. 
 
Figure 3.4 Individual FEC (epg) ranges of challenge experiment 1 wethers 
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3.4.1.3 Challenge experiment 1: cELISA 
 
At 3 wpc, all animals except A1076 were positive for liver fluke infection according 
to cELISA, with the mean group PD being 9.82%. There was a transient increase in 
cELISA level between 3 and 5 wpc where animals tested positive for infection. This 
was followed by a transient decrease between 4 and 7 wpc where animals tested 
negative for infection. At 8 wpc all animals were cELISA positive with a mean PD 
of 36.68% (Figure 3.6). All animals remained positive until the end of the study. A 
summary of cELISA results between 3 and 8 wpc is shown in Table 3.1. No animal 
maintained a positive cELISA result through 3 to 8 wpc. After becoming positive at 
3 or 4 wpc, each animal was negative at least once, usually at 6 wpc, before 
becoming positive again by 8 wpc. The peak value of the early rise in PD was 
17.48%, whilst the peak value of the second rise in PD was 117.62%. There was 
some natural fluctuation in cELISA readout at an individual animal level once the 
PD has begun to plateau.  
Table 3.1 cELISA results (PD) for challenge experiment 1 between 3 and 8 wpc. Positive results 
are shown in bold. The positive cut-off was ≥6.07% 
 
Animal 
A1074 A1075 A1076 A1077 A1078 A1079 
3 wpc 15.09 9.5 -5.89 18.59 15.44 6.18 
4 wpc 17.48 10.14 10.55 13.23 1.46 12.47 
5 wpc 8.57 7.4 8.92 17.13 -6.06 5.36 
6 wpc 2.1 3.09 5.59 1.68 1.95 6.42 
7 wpc 16.86 7.77 5.74 25.75 7.62 19.6 
8 wpc 47.08 26.92 20.11 23.62 42.15 60.18 
 
3.4.1.4 Challenge experiment 1: fluke burden in the liver 
 
Fluke burdens of challenge experiment 1 animals ranged from 22 to 80 adult fluke, 
with a median of 42. The recovery rate for the fluke ranged from 14 to 50% (mean = 
28%). A strong correlation was seen between fluke burden at post-mortem and both 
FEC (rho = 0.77, P = 0.072) and antibody titre (rho = -0.58, P = 0.228). There was 
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little correlation between fluke burden and cELISA PD at post-mortem (rho = 0.09, P 
= 0.872). The AbELISA, FEC, cELISA and liver burden results can be seen in 
Figure 3.7. All livers had some damage visible externally, with migratory tracts and 
lesions evident (Figure 3.5). Liver damage appeared to be mostly confined to the left 
lobe. 
  
Figure 3.5 Appearance of livers from animals A1076 (22 fluke recovered) and A1078 (28 fluke 





                
  
A1076 A1078 
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Figure 3.6 AbELISA (titre), FEC (epg), and cELISA (PD) results of challenge experiment 1 and 
2 at each sampling point. * indicates a TCBZ treatment was given. 
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  Challenge experiment 1      Challenge experiment 2 
 
Figure 3.7 AbELISA (titre), FEC (epg), cELISA (PD) and fluke burden results at the point of 
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3.4.2 Challenge experiment 2 
 
Individual AbELISA, FEC, cELISA, and fluke burden results can be seen in 
Appendix 2. 
3.4.2.1 Challenge experiment 2: AbELISA 
 
As in challenge experiment 1, antibody titres remained negative at both the group 
and individual level until 3 wpc, at which point 4 of the 6 animals were antibody 
positive (mean = 36.5, median = 35.5), and by 4 wpc, all animals were antibody 
positive and remained so until the end of the study, as can be seen in Figure 3.6. At 9 
wpc, A1337 had an antibody titre which was distinctly lower than the rest of the 
group. 
3.4.2.2 Challenge experiment 2: FEC 
 
A positive FEC was first seen at 10 wpc, with all 6 animals having a positive egg 
count and a group mean FEC of 2.8 epg. All animals remained FEC positive until the 
end of the study. A summary of the FEC results can be seen in Figure 3.6. FECRs at 
2 wpt ranged from -186 to 37%.  
3.4.2.3 Challenge experiment 2: cELISA 
 
At the individual level, the first positive cELISA result was seen at 7 wpc, i.e. around 
the same time as the persistent increase in cELISA in experiment 1, with 1 animal 
testing positive. The number of animals positive by cELISA increased until 10 wpc, 
at which point all animals were cELISA positive, with a mean PD of 40.6%. The 
group mean cELISA result was first positive at 8 wpc (mean PD = 10.9%, median 
PD = 3.85%). Once cELISA positive, all animals except A1337 remained positive 
until the end of the study. A1337 tested positive for liver fluke by cELISA at 14 and 
16 wpc, but negative at 15 wpc. The 15 wpc sample was re-tested and remained 
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negative. At 17 wpc, A1330 had a cELISA PD which was distinctly lower than the 
rest of the group, whilst A1339 had a cELISA PD which was distinctly higher than 
the rest of the group at 18 wpc. The cELISA PD of all animals at all sampling points 
can be seen in Figure 3.6. 
3.4.2.4 Challenge experiment 2: fluke burden in the liver 
 
Fluke burdens ranged from 22 to 44 adult fluke, with a mean of 35.7 and a median of 
38.5. The recovery rate for the fluke ranged from 24 to 49% (mean = 40%). A strong 
positive correlation was seen between cELISA PD at post-mortem and liver burden 
(rho = 0.94, P = 0.005). There was little to no correlation between fluke burden and 
either FEC or antibody titre (rho = 0.37, P = 0.468 and rho = -0.09, P = 0.872, 
respectively). The AbELISA, FEC, cELISA and liver burden results can be seen in 
Figure 3.7. In contrast to challenge experiment 1 damage was not evident on the 
surface of every liver. Where liver damage was seen it was confined to the left lobe. 
 
Figure 3.8 Appearance of livers from animals A1333 (41 fluke recovered) and A1342 (29 fluke 
recovered) at post-mortem 
3.5 Discussion 
 
This chapter aimed to establish a F. hepatica challenge model in sheep to (1) 
evaluate the performance of AbELISA, FEC and cELISA, (2) to determine the 
A1333 A1342 
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TCBZ resistant status of a British F. hepatica isolate and (3) to profile the dynamics 
of this isolate using blood- and faecal-based diagnostic tests. 
3.5.1 Test performance 
 
In terms of the kinetics of the infection, as described by AbELISA and FEC, the tests 
performed as expected with antibodies being first detected between 3 and 4 wpc, and 
eggs being first detected between 9 and 10 wpc (Valero et al., 2006; Zimmerman et 
al., 1982). However, the cELISA performed differently, with early detection at 3 wpc 
in challenge experiment 1 and late detection at 7 wpc in challenge experiment 2 
(Flanagan et al., 2011a; 2011b; Mezo et al., 2004). The lower metacercarial 
challenge (n = 90 as opposed to n = 160) may be responsible for the later detection in 
challenge experiment 2 compared to challenge experiment 1 although the average 
number of adult fluke recovered from animals was remarkably similar across 
experiments (38.5 and 42 for experiment 2 and 1, respectively). 
In the initial isolation and both challenge experiments, there were minor fluctuations 
in FEC and cELISA OD/PD. This has been reported in the literature in regards to 
FEC (Valero et al., 2011) and cELISA (Brockwell et al., 2013). At no point in 
challenge experiment 1 did the FEC stabilise or plateau, although the AbELISA and 
cELISA stabilised at ~7 and 10 wpc, respectively. In challenge experiment 2 
AbELISA, FEC and cELISA stabilised at ~6, 12 and 12 weeks, respectively. 
A transient increase was seen in the 3 to 8 wpc cELISA results of challenge 
experiment 1 animals. The earliest reported detection of liver fluke infection by 
cELISA was at 5 wpc (Flanagan et al., 2011b). There were no reports of a transient 
increase in cELISA results. All animals in our challenge experiment were affected 
and animals maintained an early positive cELISA for 1 to 3 weeks, reducing the 
likelihood that these fluctuations are due to false positive results. Animals also 
maintained the second negative cELISA period for 1 to 3 weeks, again reducing the 
likelihood that these are false negative results. The cELISA samples for 3 to 8 wpc 
were all tested across 3 cELISA plates over 2 days.  
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It is possible that this early coproantigen signal originates from antigens released 
from the parasites prior to entry of the liver, as metacercariae or excysted fluke 
which failed to migrate to the peritoneal cavity. The second negative cELISA period 
would then indicate the time at which the parasites are within the liver and antigens 
are channelled through the biliary system, stored in the gall bladder and then 
released. This subsequent release of coproantigens would then explain the start of the 
second period of positive cELISAs, which continued until the end of the study.  
This transient increase in cELISA values did not occur in either challenge 
experiment 2 animals, dosed with 90 F. hepatica metacercariae, or published reports, 
which use up to 250 metacercarial cysts (Flanagan et al., 2011a; 2011b; Mezo et al., 
2004). Thus, it is unlikely that the fluctuations in infection status are related to 
challenge dose or early fluke burden. In challenge experiment 2, a single animal had 
1 negative cELISA result at 15 wpc, which was preceded and followed by positive 
cELISA results. In the case of this animal and its faecal sample, it is highly likely 
that this is a false negative result, surrounded by true positive results. The false 
negative may be due to an error in the test, poor storage of the faecal sample prior to 
the formation of a supernatant, or user error, relating to the labelling or handling of 
samples. 
At the end of challenge experiment 1 (17 wpc), a correlation was seen between FEC  
(epg) and the number of fluke recovered from the liver and both FEC (epg) and 
AbELISA. Only the correlation between liver burden and FEC was statistically 
significant. However, this correlation was not seen at the end of challenge 
experiment 2 (18 wpc), with a correlation being seen between cELISA (PD) and the 
number of fluke recovered from the liver. This correlation was also statistically 
significant. The lack of consistency of the FEC and fluke burden relationship 
between challenge experiments may be due to the fluctuations in egg shedding often 
seen in liver fluke infections (Valero et al., 2011). The relationship between cELISA 
and fluke burden would be expected to be relatively stable, as there is no evidence 
that coproantigens are stored in the gall bladder. Although the challenge dose was 
significantly higher in challenge experiment 1, the resulting fluke burdens were 
similar between challenge experiments, making it unlikely that burden played a role 
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in the changing cELISA/fluke burden relationship at post-mortem. Despite the 
burdens being similar between the two experiments, the cELISA PDs were higher in 
experiment 1 than in experiment 2. If the cELISA plateaus at a certain point the PD 
may no longer be able to correlate with liver burden. This may be what has happened 
in experiment 1, as no PD was lower than ~80% whereas this is the upper end of the 
PDs seen in experiment 2. 
If the number of fluke recovered from the liver at post-mortem (18 wpc) and the 17 
wpc AbELISA, FEC and cELISA results from challenge experiment 2 are compared, 
a different relationship is seen. Now, as for challenge experiment 1, there is a 
correlation between FEC and fluke burden (rho = 0.77, P = 0.072) whilst no 
correlation is seen between either AbELISA or cELISA and liver burden. This is 
likely due to the apparent increase in FEC at 18 wpc in the challenge experiment 2. It 
is highly unlikely that the fluke burden in the liver had changed between 18 and 17 
wpc as there was no evidence of dead or decaying fluke in the liver on examination 
at slaughter. This highlights the natural fluctuations seen in FECs and the 
implications they may have when attempting to estimate liver burden or determine 
correlations. 
3.5.2 TCBZ-R status of the Moredun isolate 
 
Due to the lack of a control group, it was not possible to calculate the efficacy of 
TCBZ when used against the Moredun isolate. Despite this, it is clear that TCBZ is 
not sufficiently effective against the Moredun isolate to clear infection at 17/18 wpc. 
FECRs were never greater than 37% and large numbers of visually undamaged adult 
fluke were recovered post-mortem following treatment with TCBZ. Further studies, 
with the use of a control group and animals treated and slaughtered at different 
weeks post-challenge, would further characterise the dynamics of this isolate’s 
resistance to treatment with TCBZ. Despite the poor efficacy of TCBZ against adult 
fluke it may still be an effective treatment against immature fluke of the Moredun 
isolate. This was seen in the Oberon isolate where, despite TCBZ having 0% efficacy 
at 2 and 12 wpc, it had a limited efficacy at 4 wpc (Walker et al., 2004).  
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A preliminary sequence analysis of the region encoding part of the second nucleotide 
binding domain of Pgp, a candidate anthelmintic resistance gene, identified an 
increase in allele frequency, including an S1144R SNP (Wilkinson et al., 2012). 
DNA was extracted from fluke recovered in challenge experiment 2, but found not to 
contain the SNP proposed by Wilkinson et al. (2012) to identify TCBZ-R fluke 
(unpublished data). This indicates that in the Moredun isolate at least, this SNP is not 
involved in the ability to survive treatment with TCBZ. Other isolates will need to be 
investigated to determine if this SNP is involved with their susceptibility to TCBZ. 
3.5.3 Comparison with other experimental challenge models 
 
A F. hepatica isolate is a strain of F. hepatica which has been collected from a 
natural infection and propagated in the laboratory for study. There are several F. 
hepatica isolates available for research purposes, which are summarised by 
Fairweather (2011a). These have been shown to have different characteristics in 
terms of fecundity, status of resistance to various flukicides, time to first positive 
FEC and cELISA and in recovery rates from the livers of animals. The results in this 
chapter only relate to the Moredun isolate. As no other isolates were tested under the 
same conditions, any differences between the Moredun isolate and those previously 
reported may be due to the conditions of the challenge models and the protocols used 
for FEC, cELISA and recovery of fluke from livers. The Oberon isolate has been 
confirmed to be TCBZ-R whilst the Leon, Fairhurst and Cullompton isolates are 
susceptible to TCBZ (Álvarez-Sánchez et al., 2006; Flanagan et al., 2011a; McCoy, 
2005; Walker et al., 2004).  
The animals became FEC positive between 63 and 77 days post-challenge (dpc), 
whilst cELISA positives first occurred between 42 and 77 dpc, using the data from 
all 12 challenged animals. In the case of the cELISA results from challenge 
experiment 1, the first positive was taken to be the earliest positive following the 3-8 
wpc fluctuations. The only study to date which recorded the earliest FEC and 
cELISA detection of infection in known isolates was carried out by Flanagan et al. 
(2011a). In that study, animals were challenged with 200 metacercariae, a larger dose 
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than the 160 or 90 cysts given in the present study. If the results are compared using 
the earliest detection of eggs and coproantigens, the Moredun isolate had earlier 
detection by FEC than the Cullompton (77 dpc), Fairhurst (70 dpc) or Leon (75 dpc) 
isolates, but later detection by FEC than the Oberon isolate (59 dpc). The Moredun 
isolate also had earlier detection by cELISA than the Oberon (47 dpc), Cullompton 
(50 dpc), Fairhurst (53 dpc) and Leon (62 dpc) isolates (Flanagan et al., 2011a). 
The recovery rate of fluke from animals in the challenge studies varied, with a mean 
of 28% and 40% in challenge experiment 1 and 2, respectively. The low recovery 
rate seen in challenge experiment 1 is likely to be due to the age of the metacercariae 
when the infectious dose was prepared. Whilst each dose contained ~160 viable 
cysts, these cysts had been stored for 5 months, and may have been compromised by 
this extended storage.  On the other hand, for the second experiment, the cysts were 
only stored for 2 months. When compared to the findings of Flanagan et al. (2011a) 
in relation to untreated groups of sheep, the Moredun isolate had a higher recovery 
rate than the Fairhurst (6%), Oberon (11%) or Leon (22%) isolates but a lower 
recovery rate than the Cullompton isolate (51%). 
Due to the lack of a control group, it is not possible to know whether this recovery 
rate is a true indication of the number of fluke which survived to adulthood, or is 
reduced in the case of a partially effective treatment.  
3.6 Conclusion 
 
In conclusion, (1) the cELISA appears to be a more useful tool for earlier indication 
of liver fluke infection than the standard FEC, although there may be fluctuations in 
very early infections, (2) a TCBZ-R F. hepatica isolate, the Moredun isolate, has 
been identified in Great Britain, further studies will reveal the extent of resistance in 
this isolate, and lastly (3) the Moredun isolate appears to become patent and produce 
coproantigens earlier than TCBZ susceptible isolates but in contrast eggs are detected 
later and coproantigens are detected earlier in the Moredun isolate than in the TCBZ-
R Oberon isolate. 
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4.1 Abstract 
 
Pre-patent Fasciola hepatica infections cause acute and sub-acute fasciolosis. This 
disease has a significant economic impact on sheep farmers, and can result in the 
sudden death of sheep. The commonly used faecal egg count (FEC) is unable to 
detect the pre-patent form of liver fluke. The serum based anti-Fasciola antibody 
ELISA (AbELISA) and biochemical assays, which measure concentrations of GLDH 
and GGT, are capable of detecting pre-patent fluke but the AbELISA cannot 
differentiate between current and past infection and changes in GLDH and GGT 
healthy concentrations may not be specific to F. hepatica infection. A commercial 
coproantigen ELISA (cELISA) is reported to detect low burdens of infection, from 4 
weeks post-infection (wpi) and to only detect current infection, but this has yet to be 
evaluated in sheep naturally exposed to liver fluke. The studies presented in this 
chapter aim to evaluate the currently available diagnostic tests for liver fluke in terms 
of ability to detect initial and established infection in sheep naturally exposed to F. 
hepatica. Firstly, in a longitudinal evaluation of test performance, 27 April-born 
lambs were monitored from June to November 2010, with blood and faecal samples 
taken monthly for AbELISA, GLDH, GGT, FEC and cELISA testing. A subset of 12 
lambs was followed to slaughter and livers recovered. GLDH and GGT 
concentrations were found to be above reference ranges from the start of the study 
and unsuitable, on their own, for the diagnosis of liver fluke infection in these lambs. 
AbELISA detected infection in most animals by September and in all but one animal 
by November. FEC and cELISA both had some very early positive results which 
were most likely false-positive results, but the majority of animals became positive at 
the November sampling. The 12 lambs that were followed to slaughter all had low 
burdens of fluke (≤10) in their livers. Secondly, a cross-sectional study was 
conducted over 36 farms from Great Britain, comprising 812 sheep pre-treatment and 
528 sheep post-treatment. Faecal samples were collected and FEC and cELISA 
testing was performed. Low FEC and cELISA results were seen, with better 
agreement between the two tests pre-treatment than post-treatment. Disagreements 
between the two tests were more frequently seen where the FEC detected infection 
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but the cELISA did not. This was true both before treatment, where cELISA would 
be expected to be more sensitive than FEC due to its ability to detect immature fluke, 
and after treatment, where shedding of residual eggs from the gall bladder may 
occasionally yield false positive FEC results. In animals naturally exposed to F. 
hepatica, the cELISA does not have an advantage of earlier detection over FEC and 
is not as sensitive as FEC in established infections, which is in contrast to results 
from experimental challenge studies and limits the value of cELISA for detection 
and management of natural infections.  
4.2 Introduction 
 
There are four main tests routinely used to diagnose liver fluke in live sheep; the 
faecal egg count (FEC), serum based anti-Fasciola antibody ELISA (AbELISA) and 
enzyme assays, which measure glutamate dehydrogenase (GLDH) and gamma-
glutamyl transferase (GGT) concentrations. A coproantigen ELISA (cELISA) is 
commercially available but is not yet routinely used. The AbELISA and enzyme 
concentrations detect parasites indirectly, whereas the FEC and cELISA detect 
parasites directly. 
FEC is the most commonly used diagnostic test, although it cannot detect pre-patent 
infections (<9 weeks post infection (wpi)), so cannot detect acute or sub-acute 
fasciolosis (Valero et al., 2006). This is a major drawback, because acute fasciolosis 
can cause sudden death in sheep, prior to any clinical signs of infection. Blood-based 
diagnostics can be used to support a clinical diagnosis of pre-patent infection, but the 
collection of blood samples is invasive and requires the presence of a veterinarian, 
which may limit uptake by farmers, especially in the case of sheep. In addition, 
although the AbELISA can detect liver fluke infection from 4 wpi, an animal can 
remain positive for up to 9 months after an infection has been successfully treated. 
As such, AbELISA does not differentiate between current or past infection (Sánchez 
et al., 2001; Zimmerman et al., 1982). Serum concentrations of GLDH may be 
elevated from 2 wpi, but normal ranges vary depending on breed, sex and age (Phiri 
et al., 2007; Sandeman and Howell, 1981). In addition, raised enzyme levels are not 
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specific to liver fluke infection. The cELISA is reported to combine early detection 
(5 wpi) with high specificity for current liver fluke infection, but to date has only 
been evaluated for sheep in experimentally challenged animals (Bio-X, 2010; 
Flanagan et al., 2011b; Mezo et al., 2004). Challenge studies conducted at the 
Moredun Research Institute, UK (MRI) with the Moredun isolate confirmed that 
cELISA was an earlier indicator of infection then FEC (Chapter 3). The cELISA 
showed a high sensitivity and specificity when used in cattle naturally exposed to F. 
hepatica (Charlier et al., 2008). However, given the potential differences in how 
infections progress in sheep and cattle, as well as the differences in faecal 
composition between the two species, these results cannot be directly applied to 
sheep. The next logical step in test evaluation is to assess its performance in naturally 
exposed sheep. 
This chapter aims to evaluate the currently available diagnostic tests for liver fluke, 
in terms of ability to detect early and established infection in individual sheep 
naturally exposed to F. hepatica. The chapter addresses these aims in 3 ways, (1) 
longitudinal monitoring using invasive and non-invasive tests, (2) a cross-sectional 
analysis using non-invasive tests and (3) an investigation of the ability of FEC and 
cELISA to quantify liver fluke burden.  
4.3 Materials and methods 




In 2010, 27 Blackface x Blue Leicester April-born lambs were selected by the 
farmer, based upon his interest in their infection status, from a commercial flock in 
Dumfries and Galloway in SW Scotland. The flock had a history of liver fluke 
infection and all lambs were grazed on the same field. Between the August and 
September samplings, one lamb died from non-fluke related causes. 
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4.3.1.2 Sampling and testing 
 
Each lamb was blood- and rectally faecal sampled, for diagnostic purposes, at the 
end of the month, for 6 months, between June and November 2010 by a veterinarian 
from Scottish Agricultural College Consulting Veterinary Service (SAC C VS), 
Dumfries. Serum blood samples were assayed for GLDH and GGT concentrations 
and AbELISA titres at SAC C VS, Dumfries, whilst faecal samples were sent to SAC 
C VS, Edinburgh for sedimentation FEC (SAC method) and, subsequently, to MRI 
for cELISA. A cELISA result was determined to be positive if the net optical density 
(OD) titre was ≥0.15, according to the manufacturer’s recommendations (Bio-X 
Diagnostics, Belgium). Detailed descriptions of the procedures can be found in 
Sections 2.2.1.1, 2.2.3, 2.3.1 and 2.3.2.  
A convenience sample of 12 animals was followed to slaughter in November and 
January, where faecal samples and livers were obtained. These were lambs the 
farmer had elected to send direct to slaughter, rather than sell through markets. Once 
again, FECs were performed by SAC C VS, Edinburgh and cELISAs were 
performed at MRI. In addition, livers were examined for the presence of fluke as 
described in Section 2.4.3. The livers from the animals slaughtered in November 
were collected and examined by Heather Stevenson (SAC C VS) using the SAC 
method, and those in January by Danielle Gordon-Gibbs (MRI) using the Moredun 
method. 
4.3.2 Cross-sectional monitoring using non-invasive tests 
4.3.2.1 Sample collection 
 
Samples used for the analysis of FEC and cELISA in this chapter originated from a 
number of studies. These include the evaluation of the coproantigen reduction test 
(CRT) and the evaluation of coprological tests when composite samples are used, 
both of which are described in detail in Chapter 5, as well as studies which are not 
described within this thesis. 
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Faecal samples from sheep were either collected on-farm by the team (Danielle 
Gordon-Gibbs, Heather Stevenson, Royal (Dick) School of Veterinary Studies 
students, Professor Ruth Zadoks, Dr Philip Skuce, Professor Neil Sargison and 
Margaret Oliver) or collected by farmers and posted to the laboratory as part of a 
small postal survey. Sample collection spanned from December 2010 until March 
2014. The animals varied in age, breed and sex. The results from pre- and post-
treatment samples were analysed separately due to the fact that whilst in a patent 
infection both FEC and cELISA are expected to detect infection pre-treatment, 
following successful treatment low levels of egg shedding can lead to false positive 
FEC results but this does not affect cELISA results.  
812 samples were collected pre-treatment or as routine diagnostic samples (one 
sample per animal) from 36 different farms located across Great Britiain. Between 1 
and 146 samples were collected from each farm (mean = 23.9, median = 20). For 10 
of the samples, no details of origin were provided. Postal code location data were not 
available for 4 of the farms (Figure 4.1). In addition, 528 post-treatment samples, one 
per animal, were collected from 24 farms in the same manner, from the same 
animals, as described above. Between 7 and 72 samples were collected from each 
farm (mean = 22, median = 20). Timing of post-treatment sampling ranged from 7 to 
56 days post treatment (dpt), as can be seen in Figure 4.2.  
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Figure 4.1 Map of UK showing origin of samples used in cross-sectional evaluation of FEC and 
cELISA. Locations in red indicate both pre- and post-treatment samples were received, 
locations in blue indicate only pre-treatment samples were received. 
 
Figure 4.2  Distribution of post-treatment sample collection time points  
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4.3.2.2 Detection of liver fluke infection 
 
FEC and cELISA were carried out as described in Sections 2.2.1.2 and 2.2.3 at MRI. 
During the period of sampling, changes were made to the cELISA kit by the 
manufacturers, as described in Section 2.2.3. The outcome of the cELISA for each 
sample was, therefore, determined according to the batch of kit used. Pre-treatment, 
141 samples were analysed using the net optical density (OD), whilst post-treatment, 
139 samples were analysed in this way, i.e. positive if net OD ≥0.15. All remaining 
samples were considered cELISA positive if the percentage difference (PD) between 
the sample’s net OD and that of the positive control was higher than the cELISA kit 
specified. This positive cut-off was batch-specific and ranged from 6.07 to 9.32%. In 
a small number of instances, livers were also collected and examined as described in 
Section 2.4.3.2. 
4.3.3 Statistical analysis 
 
Statistical analysis was carried out in RStudio (R Core Team, 2014). The 
“confusionMatrix()” function of the ‘caret’ package was used to calculate cross-
tabulations of observed and predicted results by different tests (Kuhn, 2014). From 
the subsequent 2x2 tables, unweighted Kappa, sensitivity, specificity, positive 
predictive value (PPV), negative predictive value (NPV) and prevalence were 
calculated. To account for ties in the data, a modified version of the Wilcoxon rank-
sum test (“wilcox.exact()” function), was used to determine if there was a 
statistically significant difference in FEC (epg) and cELISA PD/OD between 
sampling points (Hothorn and Hornik, 2013). To determine if there was a correlation 
between the number of fluke recovered from the liver (liver burden) and FEC (epg), 
cELISA PD/OD or AbELISA titre, the Spearman’s rank correlation coefficient test 
(“cor(x,y,method=“spearman”)”) function was used, which is denoted by rho (R 
Core Team, 2014). Linear models (“lm()” function) were fitted to sets of data in 
Section 4.4.3 and the R
2 
of these models calculated (“summary(lm)”function) (R 
Core Team, 2014).  
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4.4 Results 
4.4.1 Longitudinal detection of liver fluke infection 
4.4.1.1 Diagnosis of infection using invasive assays 
 
Blood samples were collected from all lambs at each sample point. GLDH 
concentrations are shown in Figure 4.3. Between June and November, the GLDH 
concentrations ranged from 1 to 365 IU/L (mean range = 18 to 109.8 IU/L, median 
range = 16 to 77 IU/L). The mean and median GLDH concentrations were above the 
SAC C VS “normal” range (2-10 IU/L) at all sampling points. At an individual level, 
2 animals had GLDH concentrations within the “normal” range in June, 6 in July, 2 
in August, 2 in September and 0 in October and November (Appendix 3). There was 
no consistency in which lamb had the highest GLDH concentration at any given 
sampling. The proportion of animals which had GLDH concentrations outside of the 
“normal” ranges is shown in Figure 4.4. 
At the individual animal level, the GGT concentrations ranged from 10 to 363 IU/L 
(mean range = 49.33 to 103 IU/L, median range = 48 to 75 IU/L) between June and 
November. The mean and median GGT concentrations were above the SAC C VS 
“normal” range (27-31 IU/L) throughout the study (Figure 4.3). At the June and July 
samplings, one lamb had a GGT concentration which was distinctly higher than that 
of the rest of the group. No individual lamb consistently had the highest GGT 
concentration between August and November. The proportion of animals which had 
GGT concentrations outside of the “normal” ranges is shown in Figure 4.4. 
Individual AbELISA values ranged from -7 to 334 between June and November 
(Figure 4.3). At the individual level, the number of positive animals per month was 
4, 4, 3, 16, 24 and 25 for the months June to November. The infection status of three 
animals fluctuated between months, changing from positive to negative and back. At 
both the July and August samplings, one lamb had an antibody titre which was 
distinctly higher than the rest of the group. In November, all animals except one were 
positive; this animal did not have a positive test result throughout the study. The 
proportion of animals testing positive for liver fluke infection by AbELISA titre is 
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shown in Figure 4.4. The mean AbELISA values were first above the positive cut-off 
value at the September sampling and remained so until the end of the study (mean 
range = 14 to 198.7, median range = 2 to 214.5). 
4.4.1.2 Faecal tests 
 
Rectal faecal samples were collected from 27 animals in June, July and August, 26 in 
September, 24 in October and 23 in November, although the quantity of material 
available was occasionally insufficient to perform FEC and/or cELISA. The results 
of the FEC are shown in Figure 4.3. All animals were FEC negative in June. The first 
positive egg count was in July, with 3 animals having >0 epg (group mean = 0.07 
epg). One animal was positive in August (group mean = 0.02 epg), 0 animals in 
September, 2 in October (group mean = 0.03 epg) and 15 in November (group mean 
= 0.61 epg).   
The cELISA titres are shown in Figure 4.3. No animals were positive at the June 
sampling, 1 animal was positive in July, but, no animals were positive at the August 
and September samplings. For October and November, 3 and 15 animals were 
cELISA positive, respectively. The mean OD value was first above the positive 
threshold of 0.15 at the November sampling. The proportion of animals testing 
positive for liver fluke infection by cELISA is shown in Figure 4.4. 
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Figure 4.3 Box plots of GLDH and GGT concentrations, AbELISA titres FEC epg and cELISA 
OD of naturally exposed lambs at each sampling. --- indicates the “normal” ranges as defined by 
SAC C VS or positive cut-off value. In the GLDH and GGT plots * indicates a significant 
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4.4.1.3 Determination of infection date and proportionality 
 
The proportion of lambs testing positive by each test, at each sampling point, is 
shown in Figure 4.4. At the individual level, lambs would have first been infected 
between April and September (Figure 4.5). The first instance of a lamb testing 
positive by a test was taken to be a true positive; fluctuations in infection status were 
not taken into account.  FEC gave the earliest estimate of point of infection, with 
positive FECs in July indicating infection in late April, 9 weeks prior to the positive 
FEC. The group infection status would indicate the point of infection to be between 
June and September, with the biochemical assays indicating early infection in June, 
and the cELISA indicating infection in September. 
 
Figure 4.4 Bar chart showing the proportion of lambs positive for liver fluke infection by each 
diagnostic test (AbELISA, GLDH, GGT, FEC and cELISA) at each sampling month 
 
Figure 4.5 Bar chart showing the estimated point of infection of a proportion of lambs by each 
test, based upon the first instance of a positive result by the respective test.  
Fasciola hepatica infection in sheep: Current and novel diagnostic tests 
Chapter 4: Investigation of existing diagnostic tests in naturally exposed sheep: 
Studies at an individual animal level                                                                     70 
4.4.2 Cross-sectional study investigating cELISA and FEC 
performance in sheep 
4.4.2.1 Sample collection 
 
Sample collection was carried out from December 2010 until March 2014, with the 
majority of samples being collected in 2011. The distribution of pre- and post-
treatment sample collection can be seen in Figure 4.6.  
 
Figure 4.6 Time of collection of pre- (blue) and post-treatment (red) samples. 
4.4.2.2 Determination of infection status by cELISA 
 
Of the 280 samples tested prior to the change in cELISA kit parameters, only 3 
animals would have been given a different infection status by cELISA, depending on 
whether the OD or PD was used. All 3 instances were with pre-treatment samples, 
with ODs of 0.129, 0.183 and 0.213 resulting in PDs of 6.83%, 4.95% and 5.76%, 
respectively. Infection status of animals used in this analysis was calculated 
according to the batch of test used, but plots relate to PD values. 
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4.4.2.3 Agreement between FEC and cELISA 
4.4.2.3.1 Individual FEC vs. cELISA pre-treatment 
 
The FEC and cELISA results from individual pre-treatment samples can be seen in 
Figure 4.7, with full details given in Appendix 3. FECs ranged from 0 to 408.5 epg 
(mean = 12.5, median = 0), whilst cELISA PDs ranged from -11.8% to 142.3% 
(mean = 24.7%, median = 2.8%). Substantial agreement was seen between the 
individual FEC and individual cELISA pre-treatment (Kappa = 0.83) (Table 4.1). 
Disagreement between FEC and cELISA was seen in 68 samples (8.4% of samples 
tested), with 56 of these being FEC positive but cELISA negative and 12 being 
cELISA positive but FEC negative. The median FEC of the cELISA negative but 
FEC positive samples was 0.83 epg, in contrast it was significantly higher for the 
samples which were FEC and cELISA positive, at 11.83 epg (P < 0.0001). If FEC is 
used as a gold standard, the cELISA has a sensitivity of 85.9% and a specificity of 
97.1% (PPV = 96.6%, NPV = 87.8%, prevalence = 48.9%). 
Table 4.1 Agreement between FEC and cELISA in individual pre-treatment samples. The 
Kappa value is shown. 
 
4.4.2.3.2 Individual FEC vs. cELISA post-treatment 
 
The FEC and cELISA results from individual post-treatment samples are shown in 
Figure 4.7. FECs ranged from 0 to 344.8 epg (mean = 11.72, median = 0), whilst 
cELISA PDs ranged from -2.3% to 115.4% (mean = 13.8%, median = 0.9%). 
Substantial agreement was seen between individual FEC and individual cELISA 
post-treatment (Kappa = 0.67) (Table 4.2). Disagreement between FEC and cELISA 
was seen in 74 samples (14% of samples tested), with 66 of these being FEC positive 
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but cELISA negative and 8 being cELISA positive but FEC negative. The median 
FEC of the cELISA negative but FEC positive samples was 0.5 epg; in contrast it 
was significantly higher for the samples which were FEC and cELISA positive, at 25 
epg (P < 0.0001). If FEC is taken as the gold standard, the cELISA had a post-
treatment sensitivity of 63.9% and a specificity of 97.7% (PPV = 93.6%, NPV = 
83.6%, prevalence = 34.6%). 
Table 4.2 Agreement between FEC and cELISA in individual post-treatment samples. The 
Kappa value is shown. 
 
The majority of animals were sampled at 3 wpt (n = 262). The sensitivity of the 
cELISA, when using the FEC as a gold standard, ranged from 50 to 75% when 
animals were sampled 4 wpt or sooner. The specificity ranged from 90% to 100% 
when animals were sampled 4 wpt or sooner. At 5 wpt, the cELISA had a sensitivity 
of 0% and a specificity of 100%, when using FEC as a gold standard, as  no true 
positives or false negatives were detected by cELISA . The sensitivity of the 
cELISA, using the FEC as a gold standard, could not be calculated at 8 wpt due to no 
animals being positive by FEC, the specificity remained 100%.  
At all post-treatment sampling times, there were disagreements between the FEC and 
cELISA. Although disagreements were seen in both directions (cELISA positive but 
FEC negative and cELISA negative but FEC positive), overall the majority of 
disagreements were cELISA negative but FEC positive and in these instances the 
median FEC was low (Table 4.3). At 1, 5 and 8 wpt, there were no cELISA positive 
but FEC negative disagreements. The agreement between FEC and cELISA at each 
wpt, as well as the Kappa value and the sensitivity and specificity of the cELISA (if 
FEC is considered the gold standard) is shown in Table 4.4.  
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Table 4.3 Median FEC (epg) of cELISA negative and cELISA positive samples at each week 
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4.4.3 Ability of FEC and cELISA to quantify liver fluke burden 
4.4.3.1 Samples from the longitudinal study 
 
Twelve livers from lambs in this study were collected at slaughter (Figure 4.8), 6 in 
November (examined using the SAC method), and 6 in January (examined using the 
Moredun method) (see Sections 2.1.3, 2.4.3.1 and 2.4.3.2). Gall bladders were not 
recovered for these animals. One liver was negative for liver fluke at the November 
sampling, this animal was positive for liver fluke by AbELISA and cELISA and 
GLDH and GGT concentrations indicated liver and bile duct damage. Insufficient 
faeces were obtained from this animal for FECs to be performed at any sampling 
point. For the 11 positive animals, fluke burdens ranged from 2 to 12 adult parasites 
(mean = 5.17, median = 4.5). No immature fluke were seen. The FEC and cELISA 
results for these animals, at the time of slaughter, can be seen in Table 4.5. 
. 
 
Figure 4.8 Number of fluke recovered at slaughter from the livers of naturally exposed lambs * 
indicates the lamb was slaughtered in January rather than November. 
 
 
Fasciola hepatica infection in sheep: Current and novel diagnostic tests 
Chapter 4: Investigation of existing diagnostic tests for Fasciola hepatica in naturally 
exposed sheep: Studies at an individual animal level  77 
Table 4.5 Liver burden, FEC (epg) and cELISA (PD) results for the lambs slaughtered in 
November and January. * indicates livers were examined using the Moredun method. ND = no 
data available. 
 
4.4.3.2 Samples from all studies 
 
A total of 25 livers were collected from animals which had been grazed on pasture 
known to support the liver fluke lifecycle. The animals originated from 4 different 
Scottish farms, all of which are included in Section 4.4.2. Animals included 6 lambs, 
which are described in Section 4.3.1.1, and 19 sheep older than 1 year. The 
remaining 6 lambs from which livers were recovered from, described in Section 
4.3.1.1, were not included as the method of fluke extraction differed. Gall bladders 
were recovered from 6 animals from 3 different farms; the details for these animals 
can be seen in Table 4.6. Fluke were detected in 14 of the 25 livers examined. Liver 
burden ranged from 0 to 75 fluke, with a mean of 7.6 and a median of 2. Full details 
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Table 4.6 Summary of liver investigation, FEC (epg) and cELISA (PD) results for animals 
where gall bladders were recovered at slaughter. ND = no data 
 
 
4.4.3.2.1 FEC and cELISA 
 
The FECs ranged from 0 to 80.67 epg (mean = 12.1 epg, median = 1.7 epg), with 18 
animals having a positive FEC at slaughter. The cELISA PDs ranged from -1.1% to 
132.4% (mean = 30.9%, median = 5.2%), with 12 animals having a positive cELISA 
result at slaughter. 
4.4.3.2.2 Liver burden vs. FEC 
 
Substantial agreement was seen between liver examination and FEC in terms of 
determining fluke infection (Kappa = 0.84) (Table 4.7). Gall bladders were not 
recovered for the 4 animals which were negative for fluke in the liver but positive by 
FEC. Using liver examination as a gold standard, knowing that this may not be 
entirely accurate when gall bladders are missing, the FEC had 100% sensitivity and 
63.6% specificity (PPV = 77.8%, NPV = 100%, prevalence = 56%). Gall bladders 
were recovered for 6 animals and, in these the FEC had 100% sensitivity and 
specificity. There was a positive correlation between FEC (epg) and fluke burden 
(rho = 0.88 P < 0.0001) (Figure 4.9). This positive correlation was equally as strong 
in animals where the gall bladder had been recovered and those where it had not been 
recovered (rho = 0.83, P = 0.04 and rho = 0.82, P < 0.0001, respectively).  
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4.4.3.2.3 Liver burden vs. cELISA 
 
Substantial agreement was again seen between liver investigation and cELISA when 
determining the liver fluke infection status of an individual animal (Kappa = 0.68) 
(Table 4.7). One animal was negative for liver fluke infection by liver investigation 
but positive by cELISA. The gall bladder was not recovered for this animal and it 
had a positive egg count (13.3 epg). Two animals, which had a low number (2 and 3) 
of fluke recovered from the liver, were cELISA negative. Using liver examination as 
the gold standard, the cELISA had 78.6% sensitivity and 90.9% specificity. For the 6 
animals which had gall bladders recovered, the cELISA had 40% sensitivity and 
100% specificity. There was a positive correlation between cELISA (PD) and fluke 
burden (rho = 0.66, P = 0.0003) (Figure 4.9). The positive correlation was slightly 
weaker when looking only at animals where the gall bladder was recovered (rho = 
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4.5 Discussion 
 
This chapter aimed to evaluate the currently available diagnostic tests for liver fluke, 
in terms of their ability to detect both initial and established infection in individual 
sheep naturally exposed to F. hepatica. The chapter addressed these aims in 3 ways, 
(1) longitudinal monitoring using invasive and non-invasive tests, (2) cross-sectional 
analysis using non-invasive tests and (3) investigation into the ability of FEC and 
cELISA to quantify liver fluke burden.  
4.5.1 Longitudinal monitoring 
 
In the longitudinal monitoring of lambs, both GLDH and GGT were found to be 
unsuitable for the detection of F. hepatica infection when using the SAC C VS 
“normal” ranges to indicate hepatocellular damage. By SAC C VS criteria, the 
majority of animals were positive by both tests at the start of the study. This would 
indicate that animals were infected at least 6 weeks prior to the start of sampling, 
which would place infection in the month of May. This is very unlikely due to the 
animals only being one month old at this point and ingestion of infective cysts a rare 
occurrence. In addition, when using the SAC C VS “normal” ranges, 2 animals had 
elevated GGT concentrations before GLDH concentrations rose, which would 
suggest damage to the bile ducts prior to liver tissue damage. This would be counter-
intuitive, given the known migration pathway of immature fluke. In all of the 
published studies consulted, a positive cut-off was not used. Instead, an animal, or a 
group of animals, were considered positive if the GLDH or GGT concentration was 
significantly higher than either that of the control group or of the animal/group in 
question prior to infection. Indeed, in most studies, the control or pre-infection 
concentration of GLDH and GGT are not within the normal (uninfected) range set by 
SAC C VS, with control animals/groups having GLDH and GGT concentrations of 
18-20 and 70-100 IU/L, respectively (Ferre et al., 1996; Ferre et al., 1997; Raadsma 
et al., 2007). If this criterion of a significant increase from the control is used to 
determine test outcome, and the June sampling is considered to be the control, then 
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infection is likely to have occurred in September or October at the latest, according 
to GLDH and GGT concentrations, respectively. A further point to note is the 
fluctuating concentrations of GLDH and GGT in individual animals. This may be 
explained by the instability of GLDH in serum at room temperature and 4˚C 
(Anderson, 1977), but still suggests that GLDH and GGT are not sufficiently robust 
indicators of fluke infection to be used as routine diagnostic tests in the absence of 
other supporting evidence. 
Although the AbELISA indicated early exposure, with a few animals being positive 
at the first sampling, the majority were not antibody positive until September, 
indicating an August exposure. Fluctuations between a positive and negative 
infection status were seen in 3 animals. This is a concerning result if the test is used 
at the individual animal level. F. hepatica antibodies are known to persist at 
detectable levels in an animal for several months (Ibarra et al., 1998; Sánchez et al., 
2001). There is no biological reason for individual animals to have circulating anti-
Fasciola antibodies one month, but not the following month, other than in the case of 
anti-Fasciola maternal antibodies, which wane quickly after weaning. No 
information could be found on anti-Fasciola maternal antibodies in sheep. In calves, 
it has been shown that the length of time anti-Fasciola maternal antibodies are 
detectable in serum varies depending on the number of cysts the mother was exposed 
to prior to birth. In low-dose infections, anti-Fasciola  maternal antibodies were 
detectable for 7 weeks, extending to 12 weeks in high-dose infections (Mezo et al., 
2010). As such, it is possible that, in June, anti-Fasciola maternal antibodies were at 
a detectable level. This would explain animal A0255, but not the fluctuations seen in 
A0259 and A1556. Indeed, the difference between the positive and negatives that 
were detected in these fluctuating animals were large and, rather than a steady 
increase in antibody titres over the course of the study, fluctuations are seen in nearly 
all animals. Two animals which maintained a positive antibody titre throughout the 
study may have been exposed to fluke due to grazing from an early age. This would 
indicate infection in May at the latest, possibly earlier. One animal, A0268, did not 
develop a positive antibody titre throughout the study, nor did it develop a positive 
FEC or cELISA result and both GLDH and GGT concentrations did not differ 
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significantly from the June sampling. It is highly likely that this animal remained 
uninfected.  
Of the three animals which had early positive FECs, two maintained a positive 
antibody titre throughout the study. It is possible that these two animals were truly 
infected in the month following their birth. Unfortunately, the livers of these animals 
were not available for inspection at slaughter. On the other hand, it is possible that 
these may be false positive FECs which may arise for a variety of reasons. These 
include equipment contamination or a mislabelling of samples in the lab, or 
potentially the passage of undigested eggs (Hillyer, 1988). The fluctuations in the 
FEC of lambs during this study are reasonable, considering the low fluke burdens 
seen in the livers recovered and the nature in which eggs are stored in the gall 
bladder and sporadically shed (Valero et al., 2002).  
Although one animal had a positive cELISA OD in July, this was not maintained in 
the following sampling months until November. Two other animals had cELISA 
ODs which changed from positive to negative between sampling, although these 
were October and November samples. The coproantigens detected by the cELISA 
are a direct indicator of infection and should be detectable until the infection is 
cleared (Bio-X, 2010; Mezo et al., 2004). This suggests that the positive result in 
July was likely a false-positive and not indicative of a true infection. In this study 
animals became cELISA positive the same month as they became FEC positive, 
contrary to the earlier detection of infection previously reported (Flanagan et al., 
2011a; Valero et al., 2009).  
One explanation for the negative cELISAs, fluctuations and delayed detection of 
infection, would be the storage of the faeces. Following collection they were taken to 
SAC C VS, Edinburgh, where FECs were performed, and then posted to MRI for the 
cELISA to be performed on the remaining sample. This delay of up to 5 days in 
preparation for cELISA could have resulted in degradation of the coproantigens, 
resulting in false negative cELISAs. Whilst rigorous studies into the stability of 
coproantigens at room temperature and 4˚C have yet to be conducted, an initial 
investigation gave conflicting results regarding storage of faeces at room 
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temperature, ODs falling with longer storage in 3 samples stored at 26˚C, but 
fluctuating in 10 samples stored at 20˚C (Flanagan et al., 2011b). In the study by 
Flanagan et al. (2011b) all samples maintained a positive result, but as no OD values 
were reported it is not possible to know if these were samples with high or low ODs. 
In their discussion Flanagan et al. (2011b) point out that storage conditions will have 
the biggest impact on samples with low ODs, potentially resulting in a positive 
sample testing negative after a period of storage at room temperature.   
A second, equally plausible, explanation could be the low burden of fluke seen in 
this study, with a maximum of 10 fluke being recovered at slaughter. There are no 
reports in the literature of the cELISA being used in naturally infected sheep. In the 
majority of published studies involving experimental infections, the infective dose of 
metacercariae have been high, with high fluke burdens being seen at slaughter. The 
exception to this is the original description of the cELISA, in which lambs were 
infected with a small number of cysts and it was found that, in the very low 
infections (only 1 fluke recovered at slaughter), coproantigens were not detected 
until 7-8 wpi (Mezo et al., 2004). This highlights the importance of understanding 
the conditions under which a diagnostic test has been evaluated. It also shows that 
cELISA cannot be relied upon to detect infected animals with a low fluke burden.  
It was not possible to ensure that gall bladders were attached to the livers which were 
collected from abattoirs. One animal had no fluke present in the liver tissue and bile 
ducts, but had positive cELISA and AbELISA results. It is highly likely that fluke 
were lost when the gall bladder was removed. This may have also contributed to the 
low burdens reported in this study, although the numbers of fluke in the gall bladder 
itself was likely to be low. Gall bladders should be collected wherever possible when 
attempting to quantify a fluke burden as fluke can be found within them post-
mortem.  
In young animals, >7 weeks old, the AbELISA appears to be the most reliable 
diagnostic test for liver fluke, although from a veterinary perspective it is impractical 
to regularly blood sample animals, especially sheep. GLDH and GGT concentrations 
may be valuable in older animals, which have persistent anti-Fasciola antibodies, but 
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control values are needed. The cELISA has little benefit over the FEC, in terms of 
earlier detection, in animals with a low burden. 
4.5.2 Cross-sectional analysis 
 
In the cross-sectional sheep study, the majority of pre- and post-treatment samples 
were collected during the winter months of 2011 as part of a postal survey. During 
the sample collection period, the Bio-X cELISA kit was altered, including the criteria 
for determining a positive result. The new criteria would have changed the treatment 
outcome of only 3 samples, however, for analysis in this chapter, the batch criteria 
were used to determine treatment outcome. Agreement on treatment outcome 
between FEC and cELISA was good, both pre- and post-treatment, with slightly 
better agreement pre-treatment. Biologically, in an initial infection, with a sufficient 
challenge, the cELISA would be expected to become positive earlier than the FEC.  
Due to the animals in this study being naturally exposed to fluke, it is not possible to 
know when the point of infection was, nor the number of metacercariae ingested, as 
such it is expected that some animals would be positive by both FEC and cELISA 
and some positive by cELISA alone. Interestingly, the majority of disagreements pre-
treatment are FEC positive but cELISA negative. Unless a flukicide treatment had 
been recently administered, this disagreement is not readily explainable biologically. 
Whilst it cannot be ruled out for some animals in this study, the majority were part of 
a postal survey which involved a pre- and post-treatment sampling and this greater 
sensitivity of the FEC was seen in pre-treatment samples. Again, fluke burden may 
be playing a role, all samples that were cELISA negative but FEC positive had <10 
epg or <15 epg pre- and post-treatment, respectively (median = 0.83 and 0.5 epg, 
respectively). There was a significant difference both pre- and post-treatment 
between the median FEC of samples that tested positive by both FEC and cELISA 
and those that tested positive by FEC alone.  
The reported sensitivity of the cELISA, when using FEC as a gold standard, was 
lower than expected, at 85.1% and 64.6% pre- and post-treatment, respectively. It is 
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important to note that FEC is not truly a gold standard. As discussed earlier, a 
negative FEC can occur in low-level infection and low positive FECs do occur 
following successful treatment. As all animals were naturally exposed to fluke and 
very few could be followed to slaughter, the true infection status of the animals 
remains unknown. A more recent Australian study, which had the benefit of access to 
a large number of samples known to be uninfected and FEC positive samples, 
calculated the sensitivity of the cELISA to be 88% (Palmer et al., 2014). 
4.5.3 Quantifying fluke burden 
 
Difficulties were experienced when trying to collect livers to investigate the ability 
of FEC and cELISA to quantify liver fluke burden in naturally exposed sheep. 
Miscommunication in the abattoir, in addition to an already hectic environment, 
meant that gall bladders were removed from the liver by the staff. Gall bladders were 
also not always provided when collecting opportunistic paired liver and faecal 
samples from local farmers and veterinarians. As such, out of the 25 livers examined, 
only 6 had a gall bladder attached. This had implications for using liver examination 
as a gold standard, as it is possible that fluke were lost either within the gall bladder 
or from the main bile duct once the gall bladder was removed. FEC had a sensitivity 
of 100% and a specificity of 63.6%, the low specificity was due to the absence of 
fluke in 4 livers, all of which had no gall bladders attached. Where gall bladders were 
recovered, the FEC was 100% sensitive and specific. The cELISA had a sensitivity 
of 78.6% and a specificity of 90.9%, in this case the specificity was lowered by the 
absence of fluke in one liver, which again did not have a gall bladder attached.  
Of more interest though is the low sensitivity of the cELISA, this was due to the 
presence of fluke in 3 livers, but the absence of a positive cELISA result in the paired 
faeces. Two of these animals had low liver burdens (≤3), but did have a patent 
infection, albeit a low FEC (<2 epg). However, the cELISA has previously been 
reported to detect coproantigens from a single fluke during a patent infection in 
sheep (Mezo et al., 2004). The third animal in our study (A0500) had a moderate 
liver burden (24 fluke) and FEC (40.7 epg). It is possible that poor storage of this 
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sample, prior to receipt for the study, resulted in degradation of the coproantigens, 
although storage conditions are unlikely to have affected only one sample. 
The correlation between the cELISA PD and the fluke burden was surprisingly low. 
It would appear that once a fluke burden crosses a certain threshold, the cELISA PD 
does not increase, no matter how high the burden becomes. The maximum limit for 
the cELISA PD would appear to be between 100 and 120%. Unfortunately, PD 
values of ≥100% occurred in fluke burdens as low as 5. The FEC on the other hand 
had a much better positive correlation with liver burden.  
The low correlation seen between cELISA PD and fluke burden in sheep in this 
study was contrary to the good correlation seen between cELISA PD and fluke 
burden in cattle (Brockwell et al., 2013; Charlier et al., 2008). There are a number of 
potential reasons for this, including the effect of the calcification of bile ducts in 
cattle, the larger volume of faeces produced in cattle and the distribution of 
coproantigens within the faeces, the overall burden of cattle infections or the larger 
volume of faeces examined in the cELISA in cattle samples (2 g vs. 0.5 g). All of 
which may affect the relationship between cELISA PD and fluke burden. 
4.5.4 Conclusion 
 
In conclusion, (1) in young sheep, naturally exposed to F. hepatica, healthy GLDH 
and GGT concentrations may be higher than those suggested by SAC C VS, 
detection of infection by cELISA may be delayed in cases of low fluke burdens and 
care should be taken to avoid degradation of samples, (2) using FEC as a gold 
standard the cELISA has a sensitivity of 85.1% and 64.6% in pre- and post-treatment 
infections, lower than that seen in experimentally challenged animals (Chapter 3), 
with the majority of disagreements between FEC and cELISA being FEC positive 
but cELISA negative, (3) the collection of gall bladders is important when 
determining fluke burden, especially in low burdens, which was the case in the 
majority of animals seen in this study. FEC (epg) appears to correlate better with 
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liver burden than cELISA (PD) does, and also had a higher sensitivity (100%) and 
specificity (63.6%).
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5.1  Abstract 
 
The coproantigen ELISA (cELISA) is a promising diagnostic test, which has been 
reported to detect low burden pre-patent infections and only indicate current fluke 
infections; these are all potential advantages over the faecal egg count (FEC). The 
recently proposed cELISA reduction test (CRT) to determine treatment outcome was 
based on an experimental challenge infection of sheep, but has yet to be fully 
evaluated in animals naturally exposed to Fasciola hepatica. The first study 
presented in this chapter aimed to evaluate the CRT in natural infections on two 
Scottish farms with 80 animals in total included in the final analysis. Animals were 
followed for 56 days with either a triclabendazole (TCBZ) or closantel treatment at 
the start and a further closantel treatment given to any animal with a positive FEC or 
cELISA result at 21 days post-treatment (dpt). The second study aimed to evaluate a 
composite cELISA and composite CRT, with the intention of developing a simple 
and reliable test to determine treatment outcome which would be appealing to 
farmers. Both the technical performance of the test and farmer compliance with the 
test protocol were evaluated. Farmers were recruited through the farming press and 
knowledge exchange events, and participated voluntarily. In total, 41 sample packs 
were sent to farmers across Great Britain, of which 25 farmers subsequently 
participated. Farmers were asked to submit two groups of 10 faecal samples from 12 
animals before treatment and at 21 dpt, based upon a published protocol. Samples 
from 44 pre-treatment groups were submitted whilst 36 sets of samples from post-
treatment groups were submitted. Individual and composite faecal samples from each 
group were tested for evidence of liver fluke infection by FEC and cELISA, and 
mean values as obtained from individual samples (average value) were compared to 
values derived from composite samples (composite value). Average FECs were low 
but had higher sensitivity for detection of liver fluke infection in a group of sheep 
than composite FECs. By contrast, the composite cELISA was more sensitive than 
the average cELISA. The composite cELISA was less sensitive than the composite 
FEC in low burden situations. A modified version of the composite CRT showed 
good agreement with the composite FEC reduction test and appears promising in 
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situations where burden was sufficiently high. In conclusion, the CRT and composite 
CRT appear to give a good indication of treatment outcome, with the benefit of 
results from 7 dpt, but are of limited use in flocks with a low burden of infection. 
5.2  Introduction 
 
Sub-acute fasciolosis, caused by pre-patent Fasciola hepatica infection, causes 
significant economical losses to sheep farmers, with sudden death often being the 
first sign of a problem. Because this condition is caused by migrating immature fluke 
that do not lay eggs, it cannot be detected by faecal egg counting (FEC). In 
experimental challenge situations, the coproantigen ELISA (cELISA) is able to 
detect early stages of infection and, as such, is a promising alternative to FEC 
(Flanagan et al., 2011a; 2011b; Gordon et al., 2012a; Mezo et al., 2004). In 
individual naturally exposed animals, the cELISA was less sensitive than FEC 
(Chapter 4).  
Although the cELISA was less sensitive than FEC when used on samples from 
individual animals it still needs to be evaluated at the group level. This is because 
most treatment decisions and evaluation of treatments are done at the flock level. In 
addition, FEC is prone to false positives following successful treatment due to the 
release of sequestered eggs from the gall bladder (Valero et al., 2002). The cELISA 
has been reported to only detect current infection and so may be more useful than 
FEC in terms of determining treatment outcome (Bio-X, 2010).  
Although there is no World Association for the Advancement of Veterinary 
Parasitology (WAAVP) recommended test to determine fasciolicide treatment 
outcome in the live animal (Coles et al., 2006), the faecal egg count reduction test 
(FECRT), as described for nematodes, is commonly used for the evaluation of liver 
fluke treatments (Fairweather, 2011b; Gordon et al., 2012b). A cELISA reduction 
test (CRT), which was developed using samples from experimental challenge 
experiments, has been proposed as an alternative (Flanagan et al., 2011a; 2011b). 
The CRT has yet to be evaluated in naturally infected animals. In addition to being 
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able to give an early indication of treatment outcome in experimental challenge 
experiments, the cELISA has also been shown not to cross-react with rumen fluke, 
an emerging co-infection in UK, Irish and European livestock (Gordon et al., 2013; 
Kajugu et al., 2012).  
This specificity for F. hepatica infections is of increasing importance due to the 
emergence of endemic rumen fluke in the UK (Foster et al., 2008; Gordon et al., 
2013; Mason et al., 2012; Millar, 2012). Rumen fluke eggs are morphologically 
similar to those of F. hepatica, making diagnosis by FEC difficult if training has not 
been given (Rojo-Vázquez et al., 2012; Silvestre et al., 2000), even then, 
distinguishing the two fluke species’ eggs can be relatively subjective. As rumen 
fluke are not affected by many fasciolicidal drugs, it can also be difficult to 
determine treatment outcome when an animal is infected with both types of fluke 
(Rolfe and Boray, 1987, 1988). 
It is common practice in the UK to regularly treat sheep for liver fluke without 
evidence that animals are actually infected (Besier and Love, 2012). This is, in part, 
due to the severity of acute infections and the inability of FEC to detect this stage of 
infection, but it is also due to the high cost and inconvenience of diagnostic testing 
compared to routine treatment. Put simply, if diagnostic testing is more expensive 
and inconvenient than treatment, then most farmers will choose to treat without a 
diagnosis. Single animal testing can cost between £8 and £34 depending on the test 
and the company providing it (AHVLA, 2014; SRUC, 2014). The use of composite 
(pooled individual) samples has been proposed as a means to reduce the cost of 
routine diagnostic testing, thus making evidence-based decision making more 
appealing to farmers. A composite FEC protocol for detecting triclabendazole 
resistance (TCBZ-R) has been developed for use in sheep, utilising samples from 12 
animals, but this has not yet been evaluated with the cELISA or CRT (Daniel et al., 
2012). Initial investigation by Brockwell et al. (2013) showed that the cELISA 
performed well when used on composite samples from smaller groups of cattle (n = 
5).  
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A composite CRT has the potential to reliably give an early indication of treatment 
outcome in sheep, even in pre-patent infections, whilst also being cheaper than 
individual testing.  
 The present study has three main aims, therefore, (1) to evaluate the CRT in sheep 
naturally exposed to F. hepatica, as part  of a treatment trial; (2) to evaluate the use 
of a composite cELISA, in terms of (a) detecting F. hepatica infection status and (b) 
determining treatment outcome in British sheep flocks, in the form of a pilot study 
using group average as the gold standard; and (3) to provide a preliminary 
assessment of farmer compliance with the proposed composite sampling protocol for 
diagnosis and treatment evaluation. 
5.3  Materials and Methods 
5.3.1  CRT evaluation: farms and sampling 
5.3.1.1  Farms and animals 
 
Two working farms with a history of TCBZ treatment failure were selected for this 
study. Farm 9 was located in the south-east of Scotland, mainly kept mule (cross-
breed) sheep and kept the study ewes on pasture. Farm 22 was located in Dumfries 
and Galloway, mainly kept Blackface x Blue Leicester sheep and housed the study 
ewes. Only ewes were used in this study, all of which were presumed to be in-lamb. 
5.3.1.2  Sampling and treatments 
 
A pre-screening was conducted on each farm to determine the liver fluke infection 
status of the flock. Following this, animals were alternately allocated to either a 
TCBZ (Fasinex
®
, Novartis Animal Health) or a closantel (Flukiver
®
, Janssen Animal 
Health) treatment group. On Farm 9, ewes were considered to weigh approximately 
80 kg, as the farmer estimated that no animals exceeded this weight. Farm 22 ewes 
were weighed individually using a calibrated weigh crate. All animals were dosed 
according to dosage guidelines laid out by Novartis Animal Health and Janssen 
Animal Health for their respective products, with the modification that the dosage 
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was rounded up to the nearest ml and 1 ml added to allow for loss in the syringe 
during dosing. All dosing was performed orally using a 20 ml syringe to ensure 
accuracy. As the study took place on working farms, with in-lamb ewes, all animals 
in the TCBZ treatment group with evidence of liver fluke infection at 21 days post-
treatment (dpt) received a closantel treatment. This ensured that the welfare of the 
animals was not compromised. 
Rectal faecal samples were collected from ewes on both farms at each sampling 
point, as described in Section 2.1.1. Sample collection was carried out by Danielle 
Gordon-Gibbs, Professor Neil Sargison and Royal (Dick) School of Veterinary 
Studies students on Farm 9 and by Danielle Gordon-Gibbs, Dr Philip Skuce, 
Professor Ruth Zadoks, Heather Stevenson and Margaret Oliver on Farm 22, 
hereafter referred to as the sampling team. Samples were taken at 0, 7, 14 and 21 dpt 
to observe the kinetics of egg and coproantigen shedding post-treatment. Samples 
were also taken at 35 and 56 dpt in order to obtain 21 and 35 days post-closantel 
treatment samples from the TCBZ-treated group, and to determine if immature fluke 
survived the treatment in the closantel-treated group. The 35 dpt sampling could not 
be carried out on Farm 22. Samples were individually stored in 50 ml Falcon tubes at 
4°C until required for testing. 
5.3.2  Composite sampling evaluation: farms and sampling 
5.3.2.1  Farmer recruitment 
 
Farmers were recruited in a number of ways. The study was advertised in the farming 
press and at an annual Quality Meat Scotland (QMS) Press Day (2011). Interested 
farmers submitted their contact details and were sent a sampling pack at the start of 
the study. In addition, several veterinarians approached the team indicating that some 
clients might be interested in participating. In these instances, the veterinarian was 
sent 3 sampling packs at the start of the study to distribute to interested clients. 
Lastly, farmers who had heard about the study via ‘word of mouth’ approached the 
team requesting to participate, and were subsequently sent sampling packs.   
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5.3.2.2  Sampling packs and sampling 
 
Sample packs were sent to farmers prior to treatment and prior to the 3 weeks post-
treatment (wpt) sampling date. Each pack contained 2 bags of 10 sampling pots and 1 
spare pot; pots were marked with a ‘fill–to’ line. The pack also included latex gloves, 
a postage paid return envelope, a cover letter and a questionnaire. In addition, the 
pre-treatment sample pack contained a laminated sampling instruction sheet (Figure 
5.1). A simple sampling procedure was used, based on the method described by 
Daniel et al. (2012). Farmers were instructed to pen 12 animals and collect 10 
individual faecal samples from the pen floor. These sheep were to be treated with a 
flukicide of the farmer’s choice and marked accordingly. The same 12 sheep were to 
be penned 3 weeks later and a further 10 samples collected. Samples were sent by 
post and, upon receipt, stored at 4°C until testing. All documents included in the 
sampling packs may be viewed in Appendix 4. 
 
Figure 5.1 Contents of sampling packs sent to farmers for the collection and submission of 
faecal samples for FEC and cELISA testing. 
 
5.3.3  Detection of infection status 
 
The cELISA was performed as described in Section 2.2.3. Samples were 
homogenised using a metal spatula and 0.5 g (±0.03 g) prepared to supernatant stage 
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and supernatants stored in 1.5 ml microcentrifuge tubes at -20°C until cELISA 
testing, which was never longer than 6 weeks following collection. The remaining 
faecal sample was then stored at 4°C prior to FEC.  
For the samples used in the CRT evaluation, a sample was considered positive if the 
net optical density (OD) was ≥0.15, as outlined by the BIO K201 kit (Bio-X 
Diagnostics, Belgium) batch criteria used at the time.  
For the samples used in the composite sampling evaluation, a sample was considered 
cELISA positive, if its OD was at least 6.07%, 7.46% or 9.32% of the test control 
positive, hereafter referred to as the percentage difference (PD). The positive cut-off 
used was dependent on the batch of kit used, as outlined by the BIO K201 kit batch 
criteria used at the time (Table 5.1). A group was considered cELISA positive if the 
mean PD was equal to, or greater than, the cut-off used for the individual samples in 
that group.  
Table 5.1 Number and types of composite study samples tested at each cELISA cut-off value. 
 
In addition, a composite sample was formed for each group in the composite 
sampling evaluation. Following the homogenisation of individual faecal samples for 
cELISA sub-sampling, 1 g of faeces was taken from each of the 10 pots in the group. 
The resulting 10 g was then homogenised and sub-sampled for FEC and cELISA 
using the same procedure as for individual samples, i.e. 0.5 g (±0.03 g) of the 
composite sample was used for cELISA and 3 g of the composite sample was used 
for FEC. Samples were tested no later than 6 weeks after collection. 
In the evaluation of the CRT, the Farm 9 pre-screening samples were examined by 
the veterinarian (Professor Neil Sargison) for presence of liver fluke eggs but actual 
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counts were not performed. In all other instances, in both studies, FECs were 
performed as described in Section 2.2.1.2. Samples of less than 3 g were processed in 
the same manner, with the average number of eggs being divided by the number of 
grams of faeces available. Samples of <1 g were not included in either study. In the 
evaluation of composite sampling a group was determined to be positive for liver 
fluke if the mean FEC was >0 epg. 
5.3.4  Evaluation of treatment outcome 
 
The reduction in the FEC from the pre-treatment sampling to the post-treatment 
sampling was calculated using a standard nematode faecal egg count reduction 
(FECR) calculation, as described in Section 2.2.2 and proposed by (Coles et al., 
1992). The FECR was also calculated using the composite FEC before and after 
treatment rather than the arithmetic mean. A FECR of ≥95% was considered to 
indicate a successful treatment. 
The coproantigen reduction (CR) was calculated using the same formula used for 
FECR, as described in Section 2.2.4. For the CRT evaluation, the mean group OD 
pre- and post-treatment was used. In the case of the composite sampling evaluation, 
the mean group PD pre- and post-treatment was used. The CR was also calculated 
using the pre- and post-treatment composite PD. A CR of ≥95% was considered to 
indicate a successful treatment. 
For the CRT evaluation, the FECR and CR were calculated at 7, 14, 21, 35 and 56 
dpt, always using 0 dpt as the baseline. Post-treatment samples were requested at 21 
dpt for the composite sampling study. 
5.3.5  Statistical analysis 
 
All statistical analyses were performed using RStudio (R Core Team, 2014). Because 
the data did not follow a normal distribution and contained ties (data entries of the 
same numerical value), an unpaired non-parametric t-test (“wilcox.exact()” function) 
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was used to compare differences between treatment groups and farms (Hothorn and 
Hornik, 2013). FECRs were calculated using the ‘bayescount’ package (“fecrt(), 
WAAVP method” function) on FECs rounded to the nearest integer (Denwood, 
2009). FECs <0.5 but >0 were rounded up to 1.0 epg for the FECRT. CRs were 
calculated in Microsoft Excel, due to the impracticalities of rounding ODs and PDs 
to the nearest integer. 
The agreement between FEC and cELISA testing, as well as between composite and 
group average testing, were evaluated using Cohen’s unweighted Kappa test (1960) 
via the “confusionMatrix()” function (Kuhn, 2014). Kappa values were categorised 
according to the degree of agreement beyond chance, ranging from none to almost 
perfect (Section 2.7) (McGinn et al., 2004). 
Where appropriate, the performance of a test was evaluated using an alternative test 
as a ‘gold standard’ to determine true infection status of samples/animals. The 
“confusionMatrix()” function was used to calculate the proportion of true positives 
the test could detect (sensitivity) and the proportion of true negatives the test could 
detect (specificity) (Kuhn, 2014). In addition, the probability that positive results 
were truly positive (positive predictive value) and the probability that negative 
results were truly negative (negative predictive value) were also calculated using the 
“confusionMatrix()” function.  
5.4  Results 
5.4.1  Evaluation of the CRT 
5.4.1.1  Treatment trial 
 
In total, 394 and 407 faecal samples were collected from 86 and 70 ewes on Farm 9 
and Farm 22, respectively. Despite samples being collected by the sampling team 
rather than by farmers, not all animals were available to be sampled and insufficient 
samples were retrieved on occasions at each sampling point. This was most often 
seen on Farm 9, where the number of animals sampled ranged from 47 to 68, 
compared with Farm 22, where 67 or 68 animals were sampled (Figure 5.2). On 
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Farm 9, 30 samples from 19 animals had to be excluded from the study for a variety 
of reasons. These included insufficient faeces being obtained to calculate an epg, the 
animal lacking an ear tag and thus being unidentifiable between samplings, and/or 
the treatment given not being disclosed by the farmer. On Farm 22, only 4 samples 
from 4 animals had to be excluded for some of the same reasons. Of the samples 
collected pre-treatment, each farm had 68 samples which were suitable for analysis. 
Lastly, only animals which tested positive for liver fluke by both FEC and cELISA at 
0 dpt, and were successfully sampled at each subsequent sampling point, were 
included in the analysis of samples collected post-treatment (including 0 dpt). This 
resulted in 174 faecal samples from 29 animals on Farm 9 and 255 faecal samples 
from 51 animals from Farm 22, in total. Of these animals, 14 and 25 were treated 
with TCBZ whilst closantel treatment was given to 15 and 26 ewes on Farm 9 and 
Farm 22, respectively. 
 
Figure 5.2 Number of ewes sampled at each sampling point on Farm 9 (blue bars) and Farm 22 
(red bars) during the course of the evaluation of the CRT. 
5.4.1.2  Infection levels at the pre-screening sampling 
 
At the pre-screening sampling, 66 ewes were cELISA positive and 56 were FEC 
positive of the 68 sampled on Farm 9, with 56 being positive by both tests. On Farm 
22, 63 and 57 of the 68 ewes tested positive for liver fluke by cELISA and FEC, 
respectively, with 57 being positive by both tests. FECs on Farm 22 ranged from 0 to 
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132.3 epg (mean = 23.2 epg, median = 9 epg) (Figure 5.3). The cELISA ODs ranged 
from 0.042 to 1.961 (mean = 1.106, median = 1.154) and from 0.011 to 2.090 (mean 
= 1.126, median = 1.210) on Farm 9 and Farm 22, respectively (Figure 5.4).  
 
Figure 5.3 Distribution of FEC (epg) of ewes on Farm 22 at the pre-screening sampling. 11 
samples had 0 epg in the first bar.  
 
 
Figure 5.4 Distribution of cELISA OD for Farm 9 and 22 at the pre-screening sampling. ---- 
indicates the positive cut-off (0.15). 
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5.4.1.3  FEC and FECRT 
 
Only animals which were both FEC and cELISA positive at the 0 dpt sampling were 
included in the post-treatment analysis. FECs of the 0 dpt samples ranged from 1.5 to 
229.6 epg (mean = 37.7, median = 19.5) on Farm 9 and from 0.2 to 104.8 epg (mean 
= 18.8, median = 14) on Farm 22. Group mean pre-treatment epg did not differ 
significantly between the two treatment groups on either Farm 9 (P = 0.22) or Farm 
22 (P = 0.28). The FEC results of all groups included in the study can be seen in 
Figure 5.5 and Table 5.2. All TCBZ-treated ewes retained a positive egg count, until 
they were treated with closantel 21 days after the initial TCBZ treatment. A 
proportion of closantel-treated ewes, ranging from 7 to 40%, also retained a positive, 
albeit low, egg count. At 7 dpt, on both farms, a number of ewes in the closantel-
treated groups maintained a positive, albeit low, FEC (Farm 9, n = 6; Farm 22, n = 
7). At 14 dpt, a number of closantel-treated animals retained a positive FEC, 2 and 4 
ewes on Farm 9 and Farm 22, respectively. At 21 dpt, on Farm 9, only 1 closantel-
treated ewe had a positive FEC, whilst 2 ewes on Farm 22 were FEC positive. Once 
again, at 35 dpt in Farm 9, low FECs were seen, with 3 animals in each group 
showing positive FEC. At the final sampling, 56 dpt, no closantel-treated ewes on 
Farm 9 had a positive FEC, whereas 3 TCBZ+closantel-treated ewes did. On Farm 
22, 6 ewes in each treatment group had a positive FEC. The proportion of animals in 
each treatment group testing positive at each sampling point on each farm is shown 
in Table 5.2. 
The results of the average FECRT for all groups on both farms at all sampling points 
are shown in Table 5.2. On Farm 9, a FECR of >95% was seen in the closantel-
treated group at 7, 21, 35 and 56 dpt. At 14 dpt, the FECR was 83.7%, 1 ewe had a 
positive FEC of 49.7 epg. On Farm 22, the closantel-treated group had a >95% 
FECR at all sampling points. Prior to the closantel treatment at 21 dpt, all TCBZ-
treated groups had a <95% FECR, ranging from -15.3% to 60.3%. At 35 dpt, a FECR 
of 99.6% was seen in the TCBZ+closantel-treated group on Farm 9. The FECR of 
the TCBZ+closantel-treated group on Farm 9 at 56 dpt was 99.6% and 98.8% in the 
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5.4.1.4 cELISA and CRT 
 
All animals included in the analysis of post-treatment samples tested positive by 
cELISA at 0 dpt. Prior to treatment, cELISA OD did not differ significantly between 
TCBZ- and closantel-treated groups on either farm (P = 0.75 and P = 0.57 on Farm 9 
and 22, respectively). On Farm 9, the OD ranged from 0.213 to 3.908 (mean = 2.492, 
median = 2.599) and from 0.203 to 3.642 (mean = 2.262, median = 2.988) in the 
TCBZ- and closantel-treated groups, respectively. On Farm 22, the OD ranged from 
0.206 to 2.111 (mean = 1.198, median = 1.268) and from 0.15 to 2.451 (mean = 
1.128, median = 1.112) in the TCBZ-treated and closantel-treated groups, 
respectively. The cELISA results of the TCBZ-treated and closantel-treated ewes on 
both farms over the duration of the study are shown in Figure 5.6 and Table 5.3. 
One closantel-treated ewe tested positive on Farm 9 at 14 dpt (OD = 1.527), this ewe 
also had a positive FEC (49.7 epg). Two animals were cELISA positive in the 
closantel-treated group on Farm 9 at 21 dpt (ODs = 1.134 and 0.199), these were 
different animals to the one which had been positive at 14 dpt and neither animal had 
a positive FEC. One ewe in the closantel-treated group of Farm 9 at 35 dpt was 
positive by cELISA, with an OD of 0.279 and a negative FEC. This was again a 
different ewe to the ones which tested positive at 14 or 21 dpt. The closantel-treated 
group of Farm 22 at 56 dpt had 2 animals with positive ODs (0.15 and 0.349). 
The results of the CRT and the proportion of animals testing cELISA positive at each 
sampling point on both farms can be seen in Table 5.3. A <95% CR was seen in both 
TCBZ-treated groups at 7, 14 and 21 dpt, ranging from 38.8% to 56.4% and from -
48.5% to 9.4% on Farm 9 and Farm 22, respectively. Following closantel treatment 
of the groups which were initially dosed with TCBZ, a >95% CR was seen on both 
farms. For the closantel-treated groups, the CR was >95% on 7 of 9 occasions and 
just between 94% and 95% on the remaining 2 occasions (Table 5.3). This CR 
ranged from 95.1 to 100.1% and from 98 to 99% on Farm 9 and Farm 22, 
respectively. At 14 dpt on Farm 9, a reduction in mean OD of 94.9% was seen in the 
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closantel-treated group. On Farm 22, a 94.3% CR was seen at 56 dpt in the closantel-
treated group. 
5.4.1.5  FECRT and CRT agreement 
 
A near perfect agreement was seen across all sampling points between treatment 
outcome according to the FECRT and according to the CRT, when using a ≥95% CR 
as the criterion for successful treatment in the CRT (Kappa = 0.89) (Table 5.4). The 
one instance of disagreement between the two tests was seen in the closantel-treated 
group on Farm 22 at 56 dpt. By FECRT at this sampling point, the treatment had 
been successful, but a 94.3% CR indicated a marginal treatment failure. If a ≥90% 
CR is used as the criterion for successful treatment, a near perfect agreement is again 
seen (Kappa = 0.88), with one disagreement. In this case, the 14 dpt sampling of the 
closantel-treated group on Farm 9 would indicate treatment failure as judged by the 
FECRT but successful treatment according to the CRT. If the FECRT is taken to be 
the gold standard, the CRT, with a cut-off of 95%, has a sensitivity of 90.9% and a 
specificity of 100% (PPV = 100%, NPV = 87.5%) when determining treatment 
success. If the FECRT is taken to be the gold standard and the CRT cut off is 90%, 
the CRT has a sensitivity of 100% and a specificity of 85.7% (PPV = 91.7%, NPV = 
100%) when determining treatment success. 
Table 5.4 Number of sampling points with either successful treatment or treatment failure, 
according the FECRT and CRT, respectively. A CR of ≥95% was required for a treatment to be 
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5.4.2 Composite sampling evaluation 
5.4.2.1  Study uptake and farmer compliance 
 
Sampling packs were sent to 26 farmers (1 pack each) and 5 veterinarians (3 packs 
each). Of the 41 packs sent out in total, 25 were returned with pre-treatment samples. 
Six of the returned packs only contained samples for one group. One farmer 
submitted 9 samples for one group, rather than the requested 10. This gave a total of 
439 pre-treatment samples from 44 groups. This was reduced to 358 samples from 36 
groups post-treatment, due to non-submission by 6 farmers, 3 of whom had only 
submitted samples from 1 pre-treatment group and 1 who returned post-treatment 
samples from only 1 of their 2 pre-treatment groups.  Two farmers, who submitted 
post-treatment samples from just one group, only returned 9 samples per group 
instead of 10. Groups containing <9 samples were excluded from the study. The 
participating farms were located in England, Scotland and Wales (Figure 5.7).  
Despite the instructions given, there was variation between farmers in sample 
collection methodology. Five farmers collected samples from 10 individual animals 
rather than penning 12 and collecting 10 samples from the floor. Ten farmers 
submitted more than 10 samples for a group. In these instances, the first 10 from the 
group were counted as being the group and any others counted as excess and separate 
from the group. Excess samples were not included in composite formation, nor were 
they used to establish group infection status. Two farmers submitted an insufficient 
number of samples for a group (<9 samples), resulting in these groups subsequently 
having to be excluded from the study. Although the second sampling was requested 
at 21 dpt, with a date for sampling being communicated with the pre-treatment FEC 
results, the timing of the second sampling varied, ranging from 14-35 dpt (mean = 
23.3 dpt, median = 22.5 dpt, n = 36).  
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Figure 5.7 Map of the UK showing location of farms which participated in this study. 
5.4.2.2  Farmer selection of animals 
 
Not all farmers gave information on the sheep selected for the study, and of those 
that did, not all gave full information. From the information given, sheep of different 
ages, sexes and parities were among the animals sampled. Various breeds of sheep 
were reported as being sampled in this study. Cross-bred sheep included mules, 
Texel cross, Lleyn cross, Cheviot cross, Lleyn x Charollais, Lleyn x Suffolk, Beltex 
x Cheviot and Cheviot x Blackface. Pure-bred sheep sampled included Bluefaced 
Leicester, Texel, Poll Dorset, Blackface, Herdwick, Shetland, Romney, Cheviot, 
Beltex and Hebridean. One farmer attempted to classify sheep body condition score, 
submitting sample pots with either ‘fat’, ‘fit’ or ‘thin’ written on them.  
5.4.2.3  Detection of liver fluke infection 
 
Evidence of liver fluke infection was detected on 22 out of the 25 farms. The number 
of groups positive by either average or composite FEC or cELISA testing is shown in 
Table 5.5. The percentage of samples per group which tested positive for liver fluke 
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by FEC and cELISA are shown in Figure 5.8, for the group with 9 samples the 
percentages were rounded to the nearest 10. The group average FECs ranged from 0 
to 139.8 epg (mean = 11.1 epg, median = 1.5 epg), with the lowest positive FEC 
being 0.03 epg. Composite pre-treatment FECs ranged from 0 to 102.5 epg (mean = 
9.6 epg, median = 1.3 epg), with the lowest positive FEC being 0.2 epg. Rumen fluke 
eggs were detected in samples from 2 groups of sheep on 1 farm pre- and post-
treatment by both average and composite FEC. In addition, on a second farm, rumen 
fluke eggs were detected post-treatment by average FEC only. The group average 
pre-treatment cELISA results ranged from -1.21% to 97.42% (mean = 22.38%, 
median = 8.94%), with the lowest positive cELISA being 7.71%. Composite pre-
treatment cELISAs ranged from -0.53% to 106.91% (mean = 25.71%, median = 
11.32%), with the lowest positive cELISA being 7.46%. 




Figure 5.8 Proportions of individual samples positive for liver fluke per group by FEC (red) and 
cELISA (blue) pre-treatment. 
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5.4.2.3.1  Average vs. composite FEC 
 
The arithmetic mean FEC (epg) was calculated for each group, pre- and post-
treatment. This was compared to the composite FEC (epg) for the corresponding 
group (Figure 5.9). The agreement between the average and composite sampling, 
when determining the infection status of a group, was substantial pre-treatment 
(Kappa = 0.69) and moderate post-treatment (Kappa = 0.43) (Table 5.6). These low 
agreements by Kappa are in contrast to the high R
2
 values shown in Figure 5.9. This 
is likely due to disagreements in low FEC samples. A difference of 0.1 or 0.5 epg 
between average and composite FECs will have little effect on the R
2
 value but can 
result in a disagreement in treatment outcome, and affect the Kappa value, if one of 
the FECs happens to be 0 epg and the other 0.5 epg. In the 16 instances of 
disagreement between the two tests, all were positive by average FEC but negative 
by composite FEC (n = 5 pre-treatment, n = 11 post-treatment). Using the average 
FEC as the gold standard, the composite pre-treatment FEC had a sensitivity of 
86.1% and a specificity of 100% (PPV = 100%, NPV = 61.5%) whilst the composite 
post-treatment FEC had a sensitivity of 47.6% and a specificity of 100% (PPV = 
100%, NPV = 57.7%). 
5.4.2.3.2  Average vs. composite cELISA 
 
The arithmetic mean cELISA (PD) was calculated for each group, pre- and post-
treatment. This was compared to the composite cELISA (PD) for the corresponding 
group (Figure 5.9). A group was considered positive for infection if the mean PD 
was greater than the batch cut-off of the cELISA plate used to test individual samples 
(as determined by the manufacturer). The agreement between the average and 
composite sampling, when determining the infection status of a group, was almost 
perfect pre-treatment (Kappa = 0.95) and post-treatment (Kappa = 0.80) (Table 5.6). 
In the 3 instances of disagreement between the two tests, all were negative by 
average cELISA but positive by composite cELISA (n = 1 pre-treatment, n = 2 post-
treatment). If the average cELISA is taken to be the gold standard, the composite 
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pre-treatment cELISA had a sensitivity of 100% and a specificity of 95% (PPV = 
96%, NPV = 100%) whilst the composite post-treatment cELISA had a sensitivity of 
100% and a specificity of 93.6% (PPV = 71.4%, NPV = 100%).  
5.4.2.3.3   Average FEC vs. average cELISA pre-treatment 
 
Moderate agreement was seen between the average FEC and average cELISA pre-
treatment (Kappa = 0.42) (Table 5.7), with all disagreements (n = 12, 27.3% of all 
groups) being FEC positive but cELISA negative. If FEC is taken to be the gold 
standard, the cELISA had a sensitivity of 66.7% and a specificity of 100% (PPV = 
100%, NPV = 40%). If the cELISA is taken to be the gold standard, the FEC had a 
sensitivity of 100% and a specificity of 40% (PPV = 67.7%, NPV = 100). 
5.4.2.3.4  Composite FEC vs. composite cELISA pre-treatment 
 
The FEC and cELISA results from composite pre-treatment samples are shown in 
Figure 5.10. Substantial agreement was seen between the composite FEC and 
composite cELISA pre-treatment (Kappa = 0.71) (Table 5.7), with all disagreements 
(n = 6, 13.6%) being FEC positive but cELISA negative. If FEC is taken to be the 
gold standard, the cELISA had a sensitivity of 80.7% and a specificity of 100% (PPV 
= 100%, NPV = 68.4%). If the cELISA is taken to be the gold standard the FEC had 
a sensitivity of 100% and a specificity of 68.4% (PPV = 80.7%, NPV = 100). 
5.4.2.3.5 Average FEC vs. average cELISA post-treatment 
 
Fair agreement was seen between average FEC and cELISA post-treatment (Kappa = 
0.21) (Table 5.7). Disagreement between tests was seen in 16 samples (44.4% of 
samples), which were FEC positive but cELISA negative. If the FEC is taken to be 
the gold standard, the cELISA had a sensitivity of 23.8% and a specificity of 100% 
(PPV = 100%, NPV = 48.4%). If the cELISA is taken to be the gold standard the 
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5.4.2.3.6 Composite FEC vs. composite cELISA post-treatment 
 
The FEC and cELISA composite results from post-treatment samples are shown in 
Figure 5.10.  Moderate agreement was seen between composite FEC and cELISA 
post-treatment (Kappa = 0.62) (Table 5.7). Disagreement between tests was seen in 5 
samples (13.8% of samples), 4 of which were FEC positive but cELISA negative. 
The composite sample from group 30 had a low positive cELISA result (PD = 
6.82%, positive cut off = 6.07%) but had a negative FEC result. This was the only 
sample in average and composite sampling, pre- or post-treatment, to have a positive 
cELISA result, but a negative FEC result. If the FEC is taken to be the gold standard, 
the cELISA had a sensitivity of 60% and a specificity of 96.2% (PPV = 85.7%, NPV 
= 86.2%). If the cELISA is taken to be the gold standard the FEC had a sensitivity of 
85.7% and a specificity of 86.2% (PPV = 60%, NPV = 96.2%). 
5.4.2.4 Treatment of liver fluke and determination of treatment outcome 
 
Of the 25 farmers taking part in this study, 68% reported that they used a method of 
weighing animals to determine treatment dosage, with two farmers submitting an 
indication of sheep weight (individual or a range of weights). Methods of weighing 
included the use of a weigh crate on some or all animals, as well as the use of 
bathroom scales in one instance. 12% of farmers reported that they estimated the 
weight of sheep by eye or by lifting, whilst 20% of farmers did not give a method of 
dosage calculation. The farms which did not indicate that a method was used to 
calculate the dosages are marked in Appendix 4.6 and 4.7. 
TCBZ was the treatment of choice, used in 22 of the 44 groups, this was followed by 
closantel treatment used in 17 groups and albendazole used in 2 groups. Treatment 
choice was not disclosed by the farmers for three groups. Treatment outcomes were 
calculated for the 36 groups with post-treatment samples by both FECRT (based on 
mean and composite epg) and CRT (based on mean and composite PD). The 
percentage of samples positive by FEC and cELISA per group post-treatment is 
shown in Figure 5.11. The median FEC before treatment was 0 epg whilst the mean 
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was 11.1 epg. Positive post-treatment FECs ranged from 0.2 to 344.8 epg, with a 
mean of 9.72 epg and median of 0 epg once negative samples are also included. 
 
Figure 5.11 Histogram showing the percentage of individual samples positive for liver fluke per 
group by FEC (red) and cELISA (blue) post-treatment. 
5.4.2.4.1 Treatment outcome as determined by FEC 
 
Seven of the 36 post-treatment groups had no evidence of liver fluke infection pre-
treatment, based on average or composite FEC, whilst one group had a positive pre-
treatment average FEC (0.03 epg) but pre-treatment composite FEC of 0 epg. Details 
of the FECR in all groups can be seen in Appendix 4. 
To determine the agreement between tests, only groups that were positive by average 
and composite FEC pre-treatment were included (n = 28), the FECR of these groups 
can be seen in Figure 5.12. There was substantial agreement (Kappa = 0.62) on the 
FECRT outcome between the two testing methods (average vs. composite) (Table 
5.8). Agreement for treatment outcome was seen in 23 out of 28 groups (79%). In 
contrast to the results for determination of infection status, there was no clear 
superiority of one test over the other in terms of determining outcome.  
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Table 5.8 Agreement between composite and average treatment outcome by FECRT. The 
Kappa value is shown. 
 
 
Figure 5.12 Scattergraph showing the FECR (%) by group average and composite samples. 
Negative FECRs are shown as 0% reduction. Only groups which were positive pre-treatment by 
both average and composite FEC are shown. --- indicates a 95% reduction. The number of data 
points appears reduced as there are 11 at 100,100 and 3 at 0,0 
There was a disagreement in treatment outcome between the two sampling methods 
in 5 groups, the details of which can be seen in Table 5.9. Of the groups where 
average FECR showed that a treatment had failed but the composite FECR showed it 
to be successful, the average pre-treatment FECs were all <4 epg, whilst the average 
post-treatment FECs were <1 epg. The same was true for one of the groups with 
success based on average FECR but not based on composite FECR. In the final 
group, the composite pre-treatment FEC was 35.5 epg and the composite post-
treatment FEC was 2.5 epg. In this last group, a cut-off of 90% to define successful 
treatment would have resulted in agreement between average and composite FECRT 
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results, but this was not true for the groups with low FEC prior to treatment (Table 
5.10). Using the FECRT based on a group average value as the gold standard, the 
FECRT based on composite samples had a sensitivity of 88.2% and a specificity of 
72.7% (PPV = 83.3%, NPV = 80%). 
Table 5.9 Pre- and post-treatment FEC (epg), cELISA (PD), FECR and CR of average and 
composite results that did not result in treatment outcome agreement between sampling 
methods. 
 
5.4.2.4.2  Treatment outcome as determined by cELISA 
 
Fourteen of the 36 groups showed no sign of liver fluke infection pre-treatment by 
either composite or group cELISA. One further group tested positive pre-treatment 
by composite cELISA, but none of the individual samples within that group had 
tested positive. These 15 groups were omitted when determining the agreement 
between the sampling methods with regards to treatment outcome. Details of CRT 
outcome for all groups can be seen in Appendix 4. By the Kappa test, there was 
almost perfect agreement on CRT outcome between the two methods in the 
remaining 21 groups (Kappa = 0.90) (Table 5.10), the CRs of which can be seen in 
Figure 5.13. In the case of the one disagreement between average and composite CR, 
the composite CR was 84.96% but the average CR was >100%, however, the 
composite post-treatment cELISA tested negative (PD = 3.62%). If the CRT based 
on a group average value is taken as the gold standard, the CRT based on composite 
samples had a sensitivity of 90% and a specificity of 100% for determining treatment 
success (PPV = 100%, NPV = 91.7%).  
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Table 5.10 Agreement between composite and group treatment outcomes by cELISA. The 
Kappa value is shown. 
 
 
Figure 5.13 Scattergraph showing the CR (%) by group average and composite samples. 
Negative CRs are shown as 0% reduction. Only groups which were positive pre-treatment by 
both average and composite cELISA are shown. --- indicates 95% reduction. 
5.4.2.4.3  Composite FECRT vs. composite CRT 
 
Of the 36 groups for which farmers returned post-treatment samples, 22 were 
suitable for both FECRT and CRT. That is, these groups had both FEC and cELISA 
positive composite results pre-treatment. A moderate agreement was seen between 
composite FECRT and composite CRT, with 6 disagreements (Kappa = 0.47) (Table 
5.11). Of these 6 disagreements, 5 were instances of treatment success by FECRT 
but treatment failure by CRT. All 5 of these groups were instances where the post-
treatment PD was lower than the cELISA positive cut-off (6.07%), but the CR was 
<95%. The final case of treatment outcome disagreement occurred in group 3, where 
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the FECRT deemed treatment unsuccessful with a 93% FECR, but CRT deemed 
treatment successful with a 99.2% CR. If the FECRT is taken to be the gold standard 
the CRT has a sensitivity of 61.5% and a specificity of 88.9% (PPV = 88.9%, NPV = 
61.5%). 
Table 5.11 Agreement between composite FECRT and composite CRT outcomes. The Kappa 
value is shown. 
 
If the criterion for treatment success by CRT is amended to be a CR of ≥95% or a 
negative cELISA result post-treatment, a better agreement is seen (Kappa = 0.70) 
(Table 5.12). Disagreements are only seen where the composite FECRT deemed the 
treatment to have failed but the CRT deemed the treatment to be successful. Of the 3 
disagreements, two were instances where the pre-treatment FEC was <3 epg. The 
final disagreement was in group 3, which is described above. If the cut-off for 
FECRT were set at 90%, this disagreement would be resolved. If the FECRT, using 
the 95% cut-off, is taken to be the gold standard the amended CRT has a sensitivity 
of 100% and a specificity of 66.7% (PPV = 81.3%, NPV = 100%). 
Table 5.12 Agreement between composite FECRT and amended composite CRT outcomes. The 
Kappa value is shown. 
 
 
Fasciola hepatica infection in sheep: Current and novel diagnostic tests 
Chapter 5: Investigation of existing diagnostic tests in naturally exposed sheep: 
Studies at a group level   122 
5.5  Discussion 
5.5.1  Farmer compliance and practicalities 
 
This chapter had three main aims (1) to evaluate the CRT in sheep naturally exposed 
to F. hepatica, as part of a treatment trial; (2) to evaluate the use of a composite 
cELISA for detecting F. hepatica infection status and determining treatment outcome 
in UK sheep flocks, in the form of a pilot study using group average as the gold 
standard; and (3) to provide a preliminary assessment of farmer compliance with the 
proposed composite sampling protocol for diagnosis and treatment evaluation. 
In the evaluation of the CRT, although the sampling team performed all samplings, 
only 29 out of the 68 animals (42.6%) on Farm 9 were successfully sampled each 
week. This is in contrast to a >98% successful sampling rate at Farm 22. Both teams 
were led by Danielle Gordon-Gibbs, with pre-labelled sampling pots and an animal 
number check list for each sampling at each farm. The main difference between 
farms was the lengths to which the farmers had gone in order to facilitate the study. 
On Farm 22, animals were housed for the duration of the study, allowing for all to be 
rounded up for sampling. Farm 22 also had the facilities for animals which were 
‘empty’ (i.e. no faeces could be retrieved from the rectum) to be penned until all 
other animals had been sampled. These animals were then re-sampled for faeces, at 
which point a sample could be retrieved. The one animal from Farm 22 which could 
not be included in the study was excluded as a result of a lost ear tag, rendering the 
animal unidentifiable. This also occurred on Farm 9, but in more animals. 
On Farm 9, due to the impracticalities of penning ‘empty’ animals, insufficient faecal 
samples were often taken. The composite sampling protocol aims to overcome this 
problem by collecting 10 faecal samples from the floor of a pen containing 12 
animals (Daniel et al., 2012). In addition, in the composite sampling study, a ‘fill-to’ 
line was also marked on each sampling pot to ensure that sufficient sample was 
collected. Despite this, some farmers collected samples from 10 specific animals and 
some were more creative in the choice of packaging of faecal samples; foregoing the 
supplied marked pots in favour of food bags, medicine pots and gloves. This reliance 
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on specific animals and alternative sample containers may have contributed to the 
submission of insufficient samples. 
Although 80% of farmers in the composite sampling evaluation reported that animal 
weight was used to determine treatment dosage, this does not guarantee that animals 
were correctly dosed. The methods used by farmers most frequently indicated that all 
animals were dosed to the heaviest, and that the weight of the heaviest animal was 
determined using inaccurate methods such as estimating by eye, lifting animals or 
use of bathroom scales. Indeed, only 2 farmers gave data of the weights of animals, 
one which gave a range and a second which gave individual animal weights. This of 
course allows for potential under dosing of animals in this study, which is an inherent 
risk when sampling teams are not used. However, as the purpose of this particular 
study was to compare FEC and cELISA data, rather than to investigate instances of 
possible flukicide resistance, the data is still valid for this purpose. 
Sample timings were very much controlled in the evaluation of the CRT. In the 
composite sampling evaluation, a post-treatment sampling date was communicated to 
farmers. Despite this, sampling times did vary between 14 and 35 dpt. This variation 
is no doubt related to the most convenient time for the farmer to gather his/her 
animals. As the study specified post-treatment sampling at 21 dpt, it is not possible to 
know when farmers would have re-sampled if no guidance had been given. A 
convenient sampling date would have been an interesting addition to the sampling 
questionnaire. It is also possible that the specification of a 21 dpt sampling was off-
putting to farmers and could have contributed to the reduction in participating groups 
post-treatment. 
Of course, allowing farmers to return post-treatment samples at any point is not 
always practical. One farmer returned post-treatment samples over 56 dpt; these were 
not included in the evaluation of the composite sampling. As flukicides typically 
have no residual or persistent therapeutic effect, a new infection can be picked up 
from the time the animal is returned to pasture. Diagnostic test results obtained at a 
21 dpt sampling point would not be affected by re-infection as cELISA can only 
detect from 4 wpi whilst FEC can detect from 9 wpi (Chapter 3). This means that at 
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56 dpt (8 wpi), animals may be positive despite earlier successful treatment if they 
subsequently acquired a new infection.  
An interesting observation in the composite sampling evaluation study is the number 
of groups which were treated but had no signs of fluke infection. This occurred in 7 
of the 36 groups for which farmers returned post-treatment samples. Of the 8 groups 
for which post-treatment samples were not returned, one had no evidence of fluke 
infection by average FEC, 6 had average FECs of <3 epg whilst the last group had an 
average of 16.32 epg. The cELISA and composite data were not returned to farmers. 
It is a common belief that farmers treat for fluke without evidence due to the 
perception that it is cheaper than testing animals and then treating combined with the 
knowledge that a FEC cannot detect early infection (Besier and Love, 2012). Indeed, 
sample testing can be very expensive. A farmer’s time is also valuable. In order to 
have evidence of infection, animals must be brought in to be sampled. The farmer 
must then wait for results, likely having to return the animals to grazing or incur 
further feed costs, and then gather the animals a second time for treatment. This extra 
animal handling is often unattractive to farmers but cannot be avoided unless a pen-
side test is developed. 
Indeed, in the study to evaluate the composite sampling option, free testing was 
offered to 41 farmers, 26 of whom had volunteered for the study. Only 25 farmers 
returned samples, indicating that cost of testing was not the only factor preventing 
them from seeking evidence of fluke infection. Although non-evidence-based 
treatment may at first appear financially attractive to farmers, it may be detrimental 
to animal health if other illnesses are not considered and, as such, result in increased 
costs for treatment of other conditions or even loss of stock down the line.  
Results with respect to farmer behaviour support the need for a test that is more 
sensitive than FEC in detection of pre-patent infections, e.g. cELISA as reported in 
the literature, the need for simple protocols and cheap testing options, such as 
composite testing, as well as the development of convenient testing procedures, such 
as pen-side testing. 
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5.5.2  CRT 
 
Biologically, early in infection (>4 wpi), it would be expected that FEC would be 
negative (pre-patent infection), but cELISA would be positive (Mezo et al., 2004). 
Once an infection had become patent, it would be expected that there would be no 
disagreement between the two tests, as long as an effective treatment had not been 
implemented. If treatment was successful, it would be expected that the FEC may 
remain positive, due to the release of sequestered eggs from the gall bladder being 
released, albeit with a FEC which is much lower than pre-treatment, whilst the 
cELISA would test negative.  
The predicted agreement between FEC and cELISA at different stages of infection is 
based on the biology of infection and the principle of the diagnostic assay, whereby 
cELISA can detect coproantigen from immature as well as mature fluke, whilst FEC 
can only detect mature fluke that excrete eggs. This should result in a higher 
sensitivity of cELISA compared to FEC. This does appear to be the case in early 
infections in experimental challenge situations, where single high doses of infective 
metacercariae are given, but it does not appear to be the case in natural infections, 
where a trickle infection over time is more common. This difference in cELISA 
performance, dependent on whether an infection is natural or experimental, has been 
shown in Chapters 3 and 4, as well as in published reports on the performance of the 
cELISA in individual sheep and CRT (Flanagan et al., 2011a; Flanagan et al., 2011b; 
Gordon et al., 2012b; Mezo et al., 2004).  
The predicted post-treatment agreements described above are based upon a 
successful treatment. If the treatment was unsuccessful, and the infection was patent, 
perfect agreement would be expected. This was seen on Farm 22, in the TCBZ-
treated group, but not on Farm 9, where some issues arose in regards to animal 
identification.  
The FECRT was developed for gastrointestinal nematode (GIN) infections, and the 
guidelines state that the group mean pre-treatment FEC should be ≥150 epg (Coles et 
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al., 1992). By this criterion, neither farm would be suitable for a FECRT to be carried 
out. It is worth noting that in F. hepatica infections FECs >150 epg are uncommon, 
whilst a GIN FEC of <150 epg would be considered to be low. As such a new 
minimum FEC should be proposed in the development of a F. hepatica FECRT, this 
would take into account the lower FECs seen in F. hepatica infections than in GIN 
infections. In this study low mean FECs were seen on both farms, which follow on 
from the low individual FECs in natural infections commonly seen in Chapter 4. 
Although a ≥95% FECR is commonly used to determine successful treatment, it is a 
somewhat arbitrary cut-off. Indeed, in nematode infections, the 95% is used to 
indicate how efficacious the treatment has been, as egg shedding ceases once a 
treatment has been successful. Due to the sequestering of eggs that occurs in 
trematode infections, it can only be used to indicate a reduction in egg shedding, 
which is not directly linked to the number of parasites remaining in the liver, at least 
until the sequestered eggs have been released. Other cut-offs have been used, such as 
a 90% reduction (Brockwell et al., 2013; Levecke et al., 2012; McKenna, 1994). 
Indeed the Australian Pesticides and Veterinary Medicine Authority recommends the 
use of a >90% cut off for the FECRT when used to evaluate flukicides in ruminants 
(APVMA, 2001). 
The biology of F. hepatica infection results in eggs being sequestered in the gall 
bladder, and shed in small number for weeks after a successful treatment has been 
given (Valero et al., 2002). This was seen in the closantel-treated groups of the CRT 
evaluation on both farms, with the number of animals shedding eggs decreasing as 
the study progressed. However, at 35 dpt and 56 dpt, the proportion of closantel-
treated ewes shedding eggs increased. This may be due to immature fluke which 
were not targeted by closantel now maturing and producing eggs, or due to the 
sporadic shedding of eggs from the gall bladder. 
If, at the time of treatment, immature fluke are present that are not killed by the 
treatment product, or a sub-effective dose was given, diagnostic results at a 21 dpt 
sampling point or later could be affected by the maturation of fluke which were 
present but not killed at the time of treatment. In this situation, the CRT should still 
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be able to give an accurate indication of treatment outcome, whereas a FECRT 
would indicate successful treatment despite the presence of pre-patent fluke. 
On Farm 9 at 14 dpt, an 83.7% FECR was seen in the closantel-treated group. This 
would indicate treatment failure and is a worrying result at face value. When the 
group is observed at the individual level it becomes apparent that this low FECR is 
the result of a single animal with a FEC of 49.7 epg. This animal also had a similarly 
high cELISA OD at the same sampling point, but tested negative by cELISA and had 
a very low FEC at 7, 21, 35 and 56 dpt. The negative results at all post-treatment 
samplings, other than 0 and 14 dpt, make it unlikely that the animal was under-dosed 
through poor calibration or partial ingestion of the dose. A mix-up of samples within 
the laboratory is also unlikely as no animals in the TCBZ-treated group had a low 
FEC or negative cELISA result at this sampling point and no other fluke studies were 
ongoing at the time. Animal identification on Farm 9 had been difficult and it is 
highly likely that this 14 dpt sample was taken from a different ewe, with a similar 
identification number, and the lowered FECR is a result of animal misidentification 
rather than closantel treatment failure. One other point to note is the low number of 
animals used in analysis from the closantel-treated group of Farm 9 (n = 15). If the 
mean FEC from all closantel-treated animals sampled at 0 and 14 dpt on Farm 9 are 
used in the FECRT the reduction is higher at ~91%.  
The Farm 9, closantel-treated, animal which was strongly positive by FEC and 
cELISA at 14 dpt is also likely responsible for the reported closantel treatment 
failure by the CRT with a CR of 94.9%. However, this animal was not the only one 
which had fluctuating cELISA results. This also occurred in different animals on 
Farm 9 at 21, 35 and 56 dpt. Whilst it is possible that these positives at 35 and 56 dpt 
are due to the maturation of immature fluke which had not been targeted by 
closantel, it is unlikely in the case of the 21 dpt sampling due to the fact that the 
animals then tested negative at a later date. This phenomenon has been reported 
before and it was suggested that these ‘positive blips’ could be due to the breakdown 
of successfully killed fluke releasing coproantigen (Flanagan et al., 2011a). 
However, this does not seem likely at 21 dpt. It is worth noting that no fluctuations 
were seen on Farm 22, where animals were housed and animal identification was not 
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problematic, until 56 dpt in the closantel-treated group, which may well have been 
the maturation of immature fluke which are not targeted by closantel.  
Flanagan et al. (2011b) has suggested a CRT which has an ‘all or nothing’ criterion. 
That is, if any animal is cELISA positive at the post-treatment sampling the 
treatment is deemed to have failed. This is based upon the claim that a cELISA 
positive result can only be due to live fluke being present in the animal, although in 
the original paper detailing the cELISA, it was reported that coproantigens were 
released for 1-3 weeks post-treatment (Bio-X, 2010; Flanagan et al., 2011b; Mezo et 
al., 2004). Despite this criterion, in the paper where the CRT was suggested and in a 
subsequent paper by the same authors, one of the six animals tested positive at both 7 
and 14 dpt in an experimental challenge study (Flanagan et al., 2011a; 2011b). This 
is also seen in the original cELISA report by Mezo et al. (2004) where one of the six 
animals continued shedding coproantigens until 3 wpt and was reported by Flanagan 
et al. (2011b) as being most likely due to the release of coproantigens from dying 
fluke. The use of an ‘all or nothing’ criterion in light of these ‘anomalous’ results in a 
sample size of 6 animals is worrying indeed.  
For the CRT presented in this study, the same criterion was used as for the FECRT. 
This cut-off has been arbitrarily chosen and will need further evaluation. In the CRT 
evaluation, on two occasions the closantel-treated group would have been deemed to 
have had treatment failure, based upon the ≥95% cut-off (94.9% and 94.3%). A 
≥90% reduction criterion for the CRT would have given better agreement with the 
FECRT. However, if the criterion for a successful treatment is lowered, it may 
reduce the specificity of the test, allowing treatment failures to be wrongly identified 
as successful treatments. The CRT will need further evaluation in situations where 
the treatment outcome is known in order to truly understand the dynamics of 
coproantigen shedding post-treatment and determine a suitable CR cut-off. 
Another suggestion for the improvement of the CRT would be to use an actual 
reduction criterion such as ≥95% but also have treatment automatically deemed 
successful if the post-treatment cELISA has a negative result. In both cases of 
apparent closantel treatment failure mentioned above, the mean OD would return a 
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negative cELISA result. These new criteria of ≥95% CR or an OD/PD value which 
returns a negative cELISA result would have indicated successful treatment. The 
downside of such criteria would be that if a large number of animals are sampled, i.e. 
>10 animals, and a low number have a very low positive cELISA result, it may be 
diluted down so that the mean OD/PD is a negative cELISA result. These criteria 
would be suitable for the average or composite CRT presented in this chapter. 
From the evaluation of the CRT on Farm 9 and Farm 22, it can be seen that the CRT 
can give a good indication of treatment outcome from 7 dpt but the use of an ‘all-or-
nothing’ criterion or the use of a ≥95% CR in isolation may return inaccurate results.  
5.5.3  Composite sampling 
 
The evaluation of a composite sampling strategy for cELISA testing followed the 
same protocol for the collection of samples as developed by Daniel et al. (2012), 
using 10 samples from a group of 12 animals. 
At both the pre- and post-treatment samplings, disagreements between the average 
and the composite FEC result were always in the same direction i.e. where the 
average was positive but the composite sample was negative. This was not surprising 
considering the low mean FEC seen in this study. It is already known that fluke eggs 
are not distributed evenly in faeces (Hall, 1982). Samples were mixed with a spatula, 
with all pellets broken up, prior to sub-sampling for FEC in order to try to overcome 
this potential problem. Without the addition of water, it is not possible to ensure that 
the faeces used in tests have come from a truly homogenous mixture. Thus, taking 1 
g from each sample limits the possibility of selecting an egg in samples with low 
epg. This results in the potential for a lowered sensitivity in composite testing and, 
indeed, this is what was seen in this study.  
In the paper which proposed the composite sampling strategy, Daniel et al. (2012) 
performed FECs on the entire 50 g composite sample and calculated the number of 
eggs per 5 g. This counting of a larger volume of faeces will increase the sensitivity 
of the FEC but may not be practical for routine laboratory use. In addition, this 
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composite eggs per 5 g was compared against the average when counting between 20 
and 40 g of faeces from 10 individual animals. This is a smaller volume of faeces per 
animal than is viewed for the composite, which may explain the improved 
performance of the composite FEC in the original paper. Lastly, composite FECs 
presented by Daniel et al. (2012) were higher than those presented in this study, 
ranging from 0 to 585.8 epg (mean = 58.3, median = 9.6).   
The agreement between average and composite FECs was better pre-treatment than 
post-treatment in this study and this is again likely to be due to the very low epg seen 
in the post-treatment samples, a result of successful treatments. Further investigation 
may yield a better agreement in those groups where treatment failure occurred. 
In the cELISA samples, it is interesting to note that the opposite was true. That is, the 
disagreements in cELISA test results between the average and the composite samples 
all occurred where average samples were negative but composite samples were 
positive. In this situation, it is likely to be a form of dilution in the average samples 
as a result of the way the test results are reported. In FEC, if a single sample is 
positive then the mean epg will be positive, resulting in a positive group result. 
However, if a single sample is cELISA positive, but the other 9 are cELISA negative, 
with a negative PD value, it is likely that the group mean cELISA PD will indicate a 
negative result, giving the group a negative infection status, especially if that single 
positive sample has a low PD.  
This dilution of a single positive animal is not seen in a composite sample as only 
one result is reported. As such, it would appear that the composite cELISA is more 
sensitive than the average cELISA if only the mean PD is taken into account. If a 
smaller group is used to form the composite sample this dilution effect may not be an 
issue. Indeed in cattle samples Brockwell et al. (2013) found that 1 positive cattle 
sample could be detected by cELISA in a composite with 4 negative samples. If the 
infection status of each animal is taken into account when determining group 
infection status, the sensitivity of the average cELISA may increase. It is worth 
noting that less disagreement was seen between the average and composite cELISA 
results than between the average and composite FEC results. This is likely due to 
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coproantigens being more evenly distributed within the faeces, or being more 
abundant in the faeces than eggs. 
Farm 7, used in the composite sampling evaluation, is worth an individual mention. 
Neither group on this farm tested positive by cELISA, nor were any individual 
samples cELISA positive. In contrast, low positive FECs were seen in both groups 
by average and composite testing. The cELISA was repeated, with the same 
supernatant and with a freshly made supernatant, and the samples did have a second 
FEC carried out. The initial results were confirmed. Although rumen fluke eggs had 
been seen in samples from some farms, they were not present in the samples from 
Farm 7. It is not clear why the cELISA was unable to detect F. hepatica infection on 
this farm. One explanation could be that a treatment had been given to animals prior 
to the study starting, however, if this was the case, it was not disclosed by the farmer. 
This could possibly represent a population- or strain-specific lack of reactivity with 
the MM3 MAb in the cELISA kit. To determine if it was a true characteristic of the 
strain of F. hepatica present on Farm 7, further work would need to be carried out, 
including FEC and cELISA testing of animals other than those included in this study. 
Unfortunately, there was no chance to return to this farm for further investigation.  
In the composite CRT evaluation, low mean and composite FECs are seen, making 
many groups unsuitable for a FECRT by the criteria adopted for nematodes (Coles et 
al., 2006). This was also seen for the two farms used in the CRT evaluation study. 
The composite CRT, using a ≥95% CR  for successful treatment, has the same 
specificity issue as the average CRT i.e. groups with no evidence of fluke infection 
post-treatment had  <95% CR and, as such, were deemed to have had treatment 
failure. This is again due to the fact that for cELISA, a result that indicates no fluke 
can have a positive value (>0), whereas a FEC can be no lower than 0. If a pre-
treatment FEC is positive and a post-treatment FEC is negative (0 epg), the FECR 
will automatically be 100%, but this is not the case in cELISA as a negative result, 
indicating no fluke infection, can have a positive PD value. This is illustrated by the 
composite samples in group 24. This group had a pre-treatment PD of 24%, which is 
not unusually low, but had a post-treatment PD of 3.6%. Whilst the post-treatment 
PD indicated that no fluke were present, the CR was only 84.96%. 
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If the criteria of a ≥95% CR, together with a negative cELISA result, are used to 
determine treatment success, a near perfect agreement between average and 
composite CRT is seen. The only disagreement is in group 15, where the treatment is 
successful according to average CRT but has failed according to composite CRT. 
The number of successfully treated groups also rises from 9 to 15. A good agreement 
is also seen between the amended composite CRT and the composite FECRT with 
only 3 disagreements where composite FECRT indicates treatment failure but 
composite CRT indicates treatment success. In two of these cases the pre-treatment 
FEC is low, <5 epg. When there are low pre-treatment FECs, the release of 
sequestered eggs can result in low FECRs in the case of successful treatment. The 
last disagreement had a reasonable pre-treatment FEC (35.5 epg) but only achieved a 
93% FECR, the average FECRT did indicate treatment success. It is also worth 
noting that the 95% FECR cut-off is based on nematode infections and that use of 
90% cut-off has been suggested to give a truer indication of treatment outcome 
(APVMA, 2001; Brockwell et al., 2013; Levecke et al., 2012; McKenna, 1994). The 
95% FECRT cut-off may require optimisation for F. hepatica FECRT. 
The usefulness of the composite CRT may be limited  by the lower sensitivity of a 
composite cELISA in comparison to composite FEC. Twenty-eight groups could be  
analysed by FECRT, that is they were positive by average and composite FEC pre-
treatment. Only 21 groups were positive by average and composite cELISA pre-
treatment and thus could be analysed by CRT. Of the 7 groups which were analysed 
by FECRT but not CRT, 6 had composite FECs of ≤1.33 epg, the remaining group 
had no evidence of fluke by average cELISA and the average FEC was 2 epg. 
5.5.4  Conclusion 
 
In conclusion, from initial evaluation, the CRT is a promising method to allow for 
the early determination of treatment outcome in naturally infected flocks of sheep. 
However, optimisation of test interpretation criteria to define treatment success is 
needed. Whilst composite sampling may appear attractive, to increase the uptake of 
evidence-based treatment decisions by farmers, care should be taken as to what 
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situations it is used in. In farms with a low prevalence of infection, or low fluke 
burdens, the composite FEC may not perform well. Composite CRT is a promising 
alternative to composite FECRT but may be limited by poor sensitivity of the 
cELISA in low burden situations. Once an infection has been detected pre-treatment 
by composite cELISA, the composite CRT performs very well in comparison to 
composite FECRT. Further optimisation of the criteria for a positive cELISA result 
would also be useful. Lastly, despite efforts by the scientific community to make 
diagnostic tests for F. hepatica more rapid, sensitive, specific, affordable and 
convenient for farmers, effort is still needed on the part of farmers. If farmers will 
not submit samples for testing, even if the testing is free, it will not matter how 
useful the tests are. More communication with the farming community, knowledge 
exchange to advertise the advances that have been made and to understand the needs 
of farmers are needed to ensure that evidence-based treatment can become common 
practice. 
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6.1 Abstract 
 
The currently available diagnostic tests to detect Fasciola hepatica infection all have 
their limitations. Faecal egg counting (FEC) can only detect a patent infection and 
samples may be falsely labelled positive due to the presence of rumen fluke eggs or 
the release of sequestered eggs following a successful treatment. Detection of GLDH 
and GGT enzyme concentrations are not specific to liver fluke and there is lack of 
clarity on normal levels. Anti-Fasciola antibody ELISA (AbELISA) testing cannot 
distinguish between a current or historic infection. The coproantigen ELISA 
(cELISA) appears to detect early or low levels of in infection in experimentally 
challenged animals only, but not in naturally exposed animals. A rapid and reliable 
test for detecting F. hepatica infections is needed. A faeces-based DNA detection 
method may fill this niche. This chapter aims to (1) assess the analytical specificity 
of existing PCR and LAMP assays for F. hepatica, (2) if required, develop a F. 
hepatica-specific faeces-based LAMP assay, and (3) evaluate the clinical sensitivity 
of PCR and LAMP based assays using samples obtained from a challenge study (0 to 
17 weeks post-challenge (wpc)), and compare these with FEC and cELISA results 
from the same samples. 
To assess the analytical specificity of primer sets, a number of liver fluke, rumen 
fluke and gastrointestinal nematode DNA samples were used. The published ITS-2+ 
and IGS LAMP primer sets were found to lack analytical specificity because they 
amplified C. daubneyi as well as F. hepatica DNA, necessitating the development of 
new LAMP primers. The Cox_1 and the Fh ITS-2 primer sets were found to amplify 
F. hepatica DNA but not rumen fluke DNA. DNA extracts from 17 ovine faecal 
samples were used to develop a LAMP assay and to implement PCR assays. PCR 
amplification of DNA extracted from faeces was inconsistent regardless of the 
primer set used. This inconsistency was seen to a lesser extent when DNA was 
amplified using the LAMP assay. The LAMP assay performed best when an 
incubation time of 2 hours at 61°C was used, with a 2 minute 80°C stop. When 
evaluated with samples from a challenge study, the LAMP assay had the earliest 
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detection (3 wpc), followed by cELISA (7 wpc), FEC (10 wpc) and PCR (13 or 14 
wpc depending on the choice of primer set). However, the number of animals testing 
positive by the LAMP assay fluctuated between sampling points. In conclusion, a 
faecal F. hepatica LAMP assay has been developed which can detect infection from 
3 wpc and does not cross-react with rumen fluke DNA. Further work to characterise 
the analytical specificity and to improve the sensitivity of this assay is needed. 
6.2 Introduction 
 
Acute and sub-acute fasciolosis, caused by the immature stages of Fasciola hepatica, 
both have a significant clinical impact on sheep, often resulting in sudden death. A 
rapid, simple diagnosis in the live animal can be difficult due to the absence of fluke 
eggs in faeces. A robust and reliable diagnostic test for acute/sub-acute fasciolosis is 
an urgent industry need, especially for sheep farmers, and has become a research 
priority. An early diagnosis may be made when using a serum anti-Fasciola antibody 
ELISA (AbELISA) or a coproantigen ELISA (cELISA), but both these tests can be  
time consuming and expensive, and, in the case of  AbELISA, obtaining samples is 
invasive, requiring a veterinarian to take the sample.  
The faecal egg count (FEC) is unable to diagnose a pre-patent infection, by 
definition, but is routinely used to diagnose chronic fasciolosis. However, 
intermittent shedding of eggs and the recent emergence of rumen fluke, which have 
morphologically similar eggs to F. hepatica, reduces the reliability of FEC (Gordon 
et al., 2013; Valero et al., 2011).  
The cELISA has been evaluated within this thesis and was found to perform well in 
experimental challenge situations, but poorly in naturally exposed animals, in terms 
of detecting the onset of infection in individual animals and in detecting existing 
infection at both the individual and group level (Chapters 3, 4 and 5). As such, it is 
not a reliable diagnostic test in naturally exposed animals.  
DNA-based assays have the potential to offer specific and sensitive diagnosis of F. 
hepatica infection. PCR is known to be inhibited by substances within faecal 
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samples, making amplification difficult (Wilson, 1997). Despite this, PCR performed 
on DNA extracted from faecal samples has been used to identify F. hepatica 
infection from 2 weeks post-challenge (wpc) in sheep (Martínez-Pérez et al., 2012; 
Robles-Pérez et al., 2013). This approach does indicate that liver fluke DNA can be 
detected in host faeces before eggs appear and, therefore, has obvious and attractive 
potential from a diagnostic standpoint. Even so, the cost, requirement of expensive 
laboratory equipment and lengthy DNA extraction and amplification procedures 
make it impractical for routine diagnosis. 
Loop-mediated isothermal amplification (LAMP) is a new technique, which 
specifically amplifies DNA under isothermal conditions, rather than the thermal 
cycling required for PCR. LAMP assays are typically set up in a single tube, and can 
produce results in as little as 45 minutes, and these can be read by eye without the 
need for sophisticated equipment (Notomi et al., 2000).  The use of 3 sets of primers 
allows for very specific amplification of even low concentrations of DNA. LAMP is 
also less sensitive to inhibitory substances typically found in faecal samples than 
PCR (Mukhopadhyay et al., 2012). Due to the nature of LAMP, the turbidity of the 
reaction mix, resulting from successful amplification, can give a visual indication of 
the amount of DNA amplified; this can also be visualised using coloured or 
fluorescent dyes.  
There is also the potential for LAMP to be developed to a pen-side test. In order for 
LAMP to be used as a pen-side (or bed-side) test it would require simplification and 
standardisation of  DNA extraction and assay set-up, including the lyophilisation of 
the LAMP reagents, and a suitable detection method which could be translated onto a 
lateral-flow device or similar (Njiru, 2012). The company which produces the LAMP 
reagents, MAST Group Ltd, is currently developing a version of the kit which uses 
lyophilised reagents and that may yield results in as little as 10 minutes (I. 
McElarney, personal communication to P. Skuce, 2014). Lateral flow devices have 
been used to detect parasite, bacterial and viral DNA amplified by LAMP assays 
(Kiatpathomchai et al., 2008; Njiru, 2011; Rigano et al., 2010).  
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A LAMP protocol has recently been published, which successfully differentiates F. 
hepatica from F. gigantica using DNA extracted from adult parasite and egg samples  
(Ai et al., 2010b). A faeces-based LAMP assay, which uses a simple freeze/thaw 
DNA extraction protocol, has been developed for canine parvovirus, but has not yet 
been evaluated for use with trematode infections (Mukhopadhyay et al., 2012). 
This chapter aims to evaluate, and if required develop, faeces-based PCR and LAMP 
assays to detect liver fluke infection, assessing both the analytical sensitivity and 
specificity, using a range of trematodes and gastrointestinal parasites, and the clinical 
sensitivity, using material obtained through a challenge study. 
6.3 Materials and Methods 
6.3.1 Primer evaluation 
6.3.1.1 Parasite material 
 
Control F. hepatica genomic DNA was obtained from a single parasite retrieved 
from the liver of animal A1074 (Chapter 3). Sequencing of the ITS-2 region 
confirmed species identity. F. gigantica control DNA was obtained from a single 
parasite kindly donated by Dr Alan Trudgett, Queen’s University, Belfast. The 
parasite originated from Chennai, Tamil Nadu, India. Species identification was 
based on sequencing of the ITS-2 region. Dicrocoelium dendriticum control DNA 
was obtained from several parasites collected on the Isle of Coll in the Outer 
Hebrides, these were a generous gift of Mr. Graham Baird, SAC C VS, Perth. 
Species identification was based on sequencing mitochondrial DNA. 
Calicophoron daubneyi (rumen fluke) control DNA was obtained from a single 
parasite which had been stored in an unknown concentration of ethanol. It had been 
retrieved from a 47 month-old Aberdeen Angus cow in 2009 and was kindly donated 
by Helen Carty, SAC C VS, Ayr. Paramphistomum cervi/leydeni control DNA was 
obtained from a pool of 6 parasites retrieved from a Slovakian red deer and kindly 
donated by Dr Marian Varady, Parasitological Institute, Slovak Academy of 
Sciences, Kosice. Nucleotide sequencing of the PCR amplicon in plasmids purified 
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from three transformed bacterial colonies revealed two P. cervi whilst one was 
identified as P. leydeni. 
Preparation of material for sequencing was performed by Danielle Gordon-Gibbs, 
Stuart Dawes and Gillian Mitchell (MRI) as described in Gordon et al. (2013). 
Gastrointestinal nematode (GIN) DNA samples were supplied by Lynsey Melville 
(MRI) and comprised of Haemonchus contortus, Trichostrongylus vitrinus, T. axei, 
T. colubriformis, Teladorsagia circumcincta, Cooperia curticei, Chabertia ovina and 
Nematodirus battus. All samples were ethanol fixed and morphologically speciated 
by staff at Moredun Research Institute, UK (MRI).  
The aim of using this reference collection was to establish the analytical specificity 
of the primers for F. hepatica, i.e. to confirm that they would amplify DNA from F. 
hepatica only and not from other liver fluke species, rumen fluke species or GIN 
species that might be present in faecal samples of animals at risk of liver fluke. 
To assess the analytical sensitivity of PCR, i.e. the range of amplifiable DNA 
template concentrations, a dilution series was created from the F. hepatica control 
DNA described above. The undiluted DNA was at a concentration of 200 ng/µl, and 
the dilution series ran from 10
1
 ng/µl to 10
-7
 ng/µl.  
6.3.1.2 DNA extraction 
 
DNA was extracted from the parasites described in Section 6.3.1.1 using the 
DNEasy
®
 Blood and Tissue kit (Qiagen) as per the manufacturer’s guidelines. Full 
details of the protocol can be seen in Section 2.5.1 and Appendix 1. Extracted DNA 
was tested on a NanoDrop 1000 Spectrophotometer (Thermo Scientific) to determine 
quantity and purity of extracted DNA. 
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6.3.1.3 DNA amplification 
6.3.1.3.1  Primers 
 
Previously published primers were used in this chapter. These included a PCR primer 
set based upon F. hepatica mitochondrial DNA; Cox_1 (Martínez-Pérez et al., 2012), 
a PCR primer set based upon the trematode ITS-2 region; ITS-2+ (Itagaki et al., 
2003), and a F. hepatica LAMP primer set, IGS LAMP (Ai et al., 2010b). Three 
LAMP primer sets were also designed for this chapter by the MAST Group Ltd, 
using their proprietary Primer Explorer software; two of these primer sets were based 
upon the ITS-2 region of F. hepatica and of C. daubneyi; Fh ITS-2 and Cd ITS-2, 
respectively. The full sequences of all primers used in this chapter can be seen in 
Table 6.1. 
Table 6.1 Primer sequences for detection of liver fluke (Cox_1, ITS-2+, IGS LAMP, Fh ITS-2) 
or rumen fluke (Cd ITS-2, Cd MAST) by means of PCR or LAMP assay. 
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6.3.1.3.2 PCR 
 
PCR was carried out as described in Section 2.6.1. In all PCRs, a 10 reaction 
mastermix was used, comprising 25 µl 10x reaction buffer (Invitrogen), 25 µl 10x 
forward primer, 25 µl 10x reverse primer, 7.5 µl 50mM MgCl2 (Invitrogen), 2.5 µl 
dNTPs (Invitrogen), 2 µl Platinum
®
 Taq polymerase (Invitrogen) and 138 µl 
nuclease-free (NF) H2O (Sigma).  Each reaction contained 2.5 µl of template DNA. 
PCR run conditions can be seen in Table 6.2. PCR products were run on agarose gels 
and viewed on a transilluminator (Section 2.6.1). Specificity was initially tested by 
PCR using the F3 and B3 primers of the respective LAMP primer set as this primer 
pair determines the specificity of the LAMP reaction.  




LAMP reactions were carried out as described in Section 2.6.2. The volumes and 
concentrations of reagents used in the mastermix and primer mix were the same for 
each run, regardless of primer set. Each 25 µl reaction mix contained 12.5 µl of 
reaction mix, 1 µl Loopamp
®
 fluorescent detection reagent, 1 µl Bst polymerase, 3.5 
µl NF H2O, 2 µl primer mix and 5 µl DNA. A primer mix contained 0.4 µl FIP, 0.4 
µl BIP, 0.2 µl FLP, 0.2 µl BLP, 0.05 µl F3, 0.05 µl B3 and 0.7 µl NF H2O per 
reaction. Primer sequences are shown in Table 6.1. Both the IGS LAMP and the Fh 
ITS-2 primer sets were used with an incubation temperature of 61˚C and a final 2 
minute incubation at 80˚C. Finished reactions were viewed on a transilluminator. 
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6.3.2 PCR and LAMP assay development 
6.3.2.1 Samples 
 
As part of challenge study 1 (Chapter 3), adult parasites were retrieved from the 
livers of animals and allowed to lay eggs overnight in Earls Balance Salt Solution at 
37˚C. Eggs were then washed in distilled H2O prior to being stored in RNAlater
®
 
(Qiagen) at room temperature. Full details of this procedure can be seen in Section 
2.4.4. These fluke eggs were used for PCR and LAMP assay development.   
Faecal samples used in this chapter originated from 17 sheep from 4 different farms. 
Details of individual samples can be seen in Table 6.3. Samples were stored at 4˚C 
until they could be homogenised and weighed prior to freezing at -20˚C. 
Samples F2994 to F3000 were composite samples. Each sample was made up of 1g 
of homogenised faeces taken from 5 individual sheep samples. The composite 
sample was then homogenised prior to use in any DNA extraction, FEC or cELISA 
methods.  
Table 6.3 Details of faecal samples used for DNA extraction, origin, FEC (epg), cELISA (PD) 
and DNA extraction method. * indicates sample is a composite, ^ indicates rumen fluke eggs 
were also present, bold indicates a positive test result for FEC or cELISA. 
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6.3.2.2 DNA extraction 
 
DNA was extracted from F. hepatica eggs using DNEasy
®
 Blood and Tissue kit 
(Qiagen), as described in Section 2.5.1. Parasite egg samples were subject to one of 5 
pre-DNA extraction treatments in order to obtain DNA from within the egg; (1) 
microwave heating, (2) vortexing, (3) freeze/thawing, (4) grinding in liquid nitrogen 
or (5) no pre-treatment. In each case, 200 µl aliquots of eggs collected from adult F. 
hepatica parasites (Section 6.3.1.1) were used. In all cases other than treatment 4, 
only 1 aliquot of eggs was used.  
For method 1, the sample was placed in a 2 ml screw cap microcentrifuge tube with a 
pierced lid, and heated at full power for 1 minute in a 600W (category E) microwave. 
In method 2, glass beads were added to the sample at a 1:1 volume ratio in a 2 ml 
screw cap microcentrifuge tube and vortexed for 20 minutes. The freeze/thaw 
method consisted of freezing the sample at -80˚C for 10 minutes followed by 
incubation at 60˚C for 10 minutes, repeated three times. For method 4, samples were 
frozen in liquid nitrogen, ground using a pestle and mortar, thawed and re-suspended 
in NF H2O (Sigma).  
Four different DNA extraction methods were used on faecal samples in this study. 
Details of which sample was used in which method are presented in Table 6.3. DNA 
was extracted from some faecal samples using either the QIAmp
®
 DNA Stool Mini, 
or the QIAmp
®
 FAST DNA Stool Mini Qiagen DNA extraction kits, as per the 
manufacturer’s guidelines, or using a freeze-thaw protocol. Full details of the 
protocols can be found in Section 2.5 and Appendix 1. The QIAmp
®
 DNA Stool 
Mini kit was discontinued during the final testing of the F. hepatica faecal LAMP, so 
the QIAmp
®
 FAST DNA Stool Mini kit was used as a replacement. For samples 
F2897 and F2904, 3 g of homogenised faeces was used in a FEC procedure (Section 
2.2.1.2) up until the point of the addition of methylene blue. At this point the 
sediment was collected and 200 µl used in the DNEasy
®
 Blood and Tissue kit 
(Qiagen), as described in Section 2.5.1.  
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The freeze/thaw DNA extraction protocol was based upon that described by 
Mukhopadhyay et al. (2012). Briefly, 0.25 g of homogenised faeces was mixed with 
either 250 µl, 500 µl or 1000 µl of NF H2O (Sigma). This mixture was heated to 
96˚C for 10 minutes then immediately placed on ice for 1 minute prior to 
centrifugation at 12,000 g for 10 minutes. The supernatant was removed and used in 
a DNA amplification method, PCR and/or LAMP, either neat or diluted 1:10 in NF 
H2O (Sigma). 
6.3.2.3 DNA amplification 
 
DNA extracts from eggs and from faecal samples described in Section 6.3.2.1 were 
used in a PCR or LAMP reaction as described in Section 2.6. Only the ITS-2+, IGS 
LAMP and Fh ITS-2 primer sets were used for this aspect of the study. 
6.3.3  PCR and LAMP evaluation for diagnostics 
6.3.3.1 Samples 
 
Faecal samples originated from 6 one-year-old castrated male sheep which had been 
challenged with F. hepatica metacercariae of the triclabendazole resistant Moredun 
isolate as part of a vaccine trial (Chapter 3). Sample collection occurred between 0 to 
18 weeks post challenge (wpc), and 0.25 g of homogenised faeces from each animal, 
at each sampling, was frozen for use in this study. Details of the liver burden at 
slaughter as well as the FEC and cELISA results at each sampling can be seen for 
each animal in Appendix 5.  
6.3.3.2 DNA extraction and amplification 
 
DNA was extracted using the QIAmp
®
 DNA Stool Mini kit (Qiagen) for the 18 wpc 
samples and the QIAmp
®
 FAST DNA Stool Mini kit (Qiagen) for all other samples. 
The freeze/thaw method based upon that described by Mukhopadhyay et al. (2012), 
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with faeces diluted in 500 µl NF H2O (Sigma) was also used on a second 0.25 g sub-
sample for the 18 wpc samples. 
Extracted DNA samples were used in two PCR assays, one using the Cox_1 primer 
set and the other using the ITS-2+ primer set, and in a LAMP assay using the Fh 
ITS-2 primer set.  
6.3.4 Statistical analysis 
 
In the testing of faecal samples the agreement between FEC and both PCR and 
LAMP were evaluated using Cohen’s unweighted Kappa test (1960) via the 
“confusionMatrix()” function (Kuhn, 2014). The sensitivity of both PCR and LAMP 
was also calculated using FEC as the gold standard. 
6.4 Results 
6.4.1 Primer evaluation 
6.4.1.1 Evaluation of analytical specificity 
 
A summary of analytical specificity of the PCR and LAMP assays can be seen in 
Table 6.4. Due to time constraints not all primer sets were tested against all available 
DNA samples. Additional specificity testing was conducted by Gillian Mitchell 
(MRI). Details of all parasite DNA samples can be seen in Section 6.3.1.1.  
Table 6.4 Analytical specificity of primer sets.  indicates DNA was amplified,  indicates no 
DNA was amplified, red symbols indicate samples tested by Gillian Mitchell (MRI) ND = no 
data available, GIN = gastrointestinal nematodes – see Section 6.3.1.1 for full list, individual 
species DNA was tested.  
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The Cox_1 primer set (Martínez-Pérez et al., 2012) was found to amplify F. hepatica 
DNA but not C. daubneyi DNA, and was the only F. hepatica-specific primer set in 
this study. The trematode ITS-2 primer set (ITS-2+) (Itagaki et al., 2003) was found 
to amplify DNA extracted from adult parasites of both F. hepatica and rumen fluke 
species, with bands of distinctly different molecular weight being produced (Figure 
6.1).  
 
Figure 6.1 Specificity testing of ITS-2+ primer set. Gel image of F. hepatica and rumen fluke 
species DNA amplified using the ITS-2+ primer set. Well 1 = control F. hepatica DNA, well 2 = 
C. daubneyi DNA, well 3 = NF H2O. 1Kb Plus DNA ladder (Invitrogen) 
The F3/B3 primer set of the IGS LAMP primer set (Ai et al., 2010b) were found to 
amplify DNA extracted from adult parasites of both F. hepatica and rumen fluke 
species, the bands could not be differentiated by molecular weight. 
Newly designed F3/B3 primer sets were then tested for specificity for F. hepatica 
and rumen fluke species DNA. The Fh ITS-2 F3/B3 primer set was found to amplify 
F. hepatica DNA but not rumen fluke species DNA when used in PCR, under 
standard conditions, or LAMP amplification with a 1 hour incubation at 61˚C (Figure 
6.2). This primer set was also found to amplify F. gigantica and D. dendriticum 
DNA when used in the 2 hour 61˚C LAMP assay (data not shown), i.e. it is not 
specific to F. hepatica alone.  DNA from 8 GIN species was tested individually and 
no amplification was seen (data not shown). The Cd ITS-2 F3/B3 primer set was also 
found to be non-specific, and amplified both liver fluke and rumen fluke DNA, albeit 
producing bands of different molecular weight. The Cd MAST F3/B3 primer set was 
found to be specific for rumen fluke species, with amplification of both C. daubneyi 
and P. cervi¸ but not F. hepatica. 
1         2         3 
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Figure 6.2 LAMP reaction using Fh ITS-2 primers. 1 = MAST Isoplex
®
 DNA kit control, 2 = F. 
hepatica DNA, 3 = C. daubneyi DNA, 4 = P. cervi DNA, 5 = NF H2O. White contents indicate 
positive results, grey contents indicate negative results. 
6.4.1.2 Evaluation of analytical sensitivity 
 
A F. hepatica DNA dilution series described in Section 6.3.1.1 was used in a PCR 
assay with the ITS-2+ primer set. No amplification was seen in the 200 or 100 ng/µl 
concentrations but amplification was seen from 10 to 0.001 ng/µl (Figure 6.3). 
 
Figure 6.3 Gel image of F. hepatica DNA amplified using the ITS-2+ primer set. Well 1 = NF 




 ng/µl dilution series of F. 
hepatica DNA. 100bp DNA ladder (Invitrogen) 
6.4.2 PCR and LAMP assay development 
 
A summary of the samples used (Table 6.3) and the associated outcome of PCR and 
LAMP amplification can be seen in Appendix 5. 
 
   1           2             3           4            5 = 
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6.4.2.1 DNA from eggs 
 
DNA was extracted from eggs which had been collected from the gall bladders of F. 
hepatica-infected sheep. DNA extraction was carried out as described in Section 
6.3.2.2 using 5 pre-DNA extraction treatments, namely, microwaving, vortexing with 
glass beads, freeze/thawing, freezing in liquid nitrogen and grinding, and no 
treatment. The quantity of DNA recovered was highest in the freeze/thawing 
treatment (240 ng/µl) and lowest in the liquid nitrogen grinding treatment (13 ng/µl). 
In each case, PCR amplification was successful using the ITS-2+ primer set, 
irrespective of extraction method (Figure 6.4).  
 
Figure 6.4 Gel image of PCR products of F. hepatica egg DNA after different DNA extraction 
methods. Wells 1 and 9 = NF H2O, well 2 = F. hepatica control DNA, well 3 = no pre-treatment, 
well 4 = microwaving, well 5 = vortexing with glass beads, well 6 = freeze/thawing, wells 7 and 8 
= liquid nitrogen and grinding. 1Kb Plus DNA ladder (Invitrogen) 
DNA was extracted from the eggs and faecal sediment of subsamples of samples 
F2897 and F2904, as described in Section 6.3.2.2, using the DNEasy
®
 Blood and 
Tissue kit. Whilst no amplification was observed after PCR using the ITS-2+ primer 
set on those DNA extracts, DNA was amplified from the F2904 sample using the 
IGS LAMP assay (data not shown); demonstrating that F. hepatica DNA was present 
in the sample.   
 
 
    1     2     3     4      5     6    7       8     9   = 
Fasciola hepatica infection in sheep: Current and novel diagnostic tests 
Chapter 6: Non-invasive diagnosis using DNA-based methods  149 
6.4.2.2 DNA from faeces 
 
Three 0.25 g sub-samples of ovine faeces with a FEC of 17.83 epg (F3543) were 
used for freeze/thaw DNA extraction, diluted in either (a) 250 µl, (b) 500 µl, or (c) 
1000 µl (Section 6.3.2.2). The resulting DNA was diluted 1:10 with NF H2O (Sigma) 
and used for amplification by PCR with the ITS-2+ primer set and by LAMP with 
the Fh ITS-2 primer set. No amplification occurred by PCR (data not shown), but 
amplification by LAMP was seen in the sample extracted by method (b) when 
incubated at 61˚C for 1 hour 45 minutes (Figure 6.5). 
 
Figure 6.5 Results of LAMP with the Fh ITS-2 primer set used on DNA extracted from F3543 
using 3 different DNA extraction techniques. 1 = MAST Isoplex
®
 DNA kit control, 2 = NF H2O, 
3 to 5 = methods (a) to (c) of freeze/thaw DNA extraction. White contents indicate positive 
results, grey contents indicate negative results. 
DNA was extracted from 0.2 g of a known negative faecal sample (F3578), two low 
FEC faecal samples (F3582 = 0.67 epg and F3586 = 3.83 epg) and a medium FEC 
faecal sample (F3590 = 34.5 epg), using the QIAmp
®
 FAST DNA Stool Mini kit, at 
95˚C. Amplification was seen in F3582 and F3590 by LAMP with the Fh ITS-2 
primer set (data not shown). 
DNA was extracted from 0.2 g subsamples of 7 composites (F2994-F3000), 
described in Section 6.3.2.1, using the QIAmp
®
 DNA Stool Mini Kit as described in 
Section 6.3.2.2. Two of the DNA extracts, F2995 and F2998, were amplified by PCR 
using the ITS-2+ primer set (Figure 6.6). Two bands were amplified from the F2998 
DNA extract, indicating both F. hepatica and rumen fluke DNA. In addition, the 
DNA samples were used in a PCR using the Cox_1 primer set; only DNA from 
sample F2995 was successfully amplified (data not shown). 
           1          2          3         4           5         
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Figure 6.6 Gel image of PCR amplification of DNA from faecal composite samples F2994-F3000 
using the ITS-2+ primer set. DNA extracted using QIAmp
®
 DNA Stool Mini kit with incubation 
at 95˚C. NF H2O = negative control, F. hepatica and C. daubneyi DNA used as positive controls. 
1Kb Plus DNA ladder (Invitrogen) 
These samples were also used in a 2 hour LAMP reaction using the Fh ITS-2 primer 
set. All samples, except F2994 and F2998, were positive by LAMP (Figure 6.7). 
Sample F2998 had been positive by PCR amplification with the ITS-2+ primer set. 
 
Figure 6.7 LAMP amplification of composite faecal sample (F2994 – F3000) DNA extracted 
using QIAmp
®
 DNA Stool Mini kit with incubation at 95˚C. F. hepatica and P. cervi DNA used 
as positive and negative controls, respectively. White contents indicate positive results, grey 
contents indicate negative results.  
6.4.2.3 LAMP Incubation times 
 
DNA was extracted, using a freeze/thaw method, from four 0.25 g faecal samples 
mixed with 500 µl NF H2O (Sigma). These four samples, F3205, F3207, F3208, 
F3210, had faecal egg counts which ranged from 50 to 208 epg. The resulting DNA 
extracts were used either as they were or diluted 1:10 with NF H2O (Sigma) for 
amplification by LAMP using the Fh ITS-2 primer set. After 1 hour at 61˚C, only the 
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two further positive results for DNA extracts that had been diluted, i.e. from F3205 
(208 epg) and F3208 (82 epg) (Figure 6.8). The diluted DNA extract from the sample 
of F3210 (50 epg) was not tested by LAMP. 
 
 
Figure 6.8 LAMP results of freeze/thaw faecal DNA extraction after 1 or 2 hours incubation at 
61˚C. 1 = NF H2O, 2 = MAST Isoplex
®
 DNA kit control, 3 = F. hepatica positive control, 4-7 = 
undiluted faecal DNA extracts, 8 = F3205 diluted DNA extract 1:10, 9 = F3207 diluted DNA 
extract 1:10, 10 = F3208 diluted DNA extract. 1:10. White contents indicate positive results, grey 
contents indicate negative results. 
6.4.2.4 Test sensitivity 
 
If FEC is taken to be the gold standard and all results are included, regardless of 
primer set, then in the limited number of samples tested, PCR had a sensitivity of 
20% (Table 6.5), whilst LAMP had a sensitivity of 68.8% (Table 6.6). 
 
 
       1               2              3              4             5             6              7             8              9              10   
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Table 6.5 Agreement between FEC and PCR testing of faecal samples 
 
Table 6.6 Agreement between FEC and LAMP testing of faecal samples 
 
6.4.3 PCR and LAMP evaluation for diagnostics 
 
The number of samples positive at each wpc, by FEC, cELISA and each faecal DNA 
amplification method, can be seen in Figure 6.9. Amplification of DNA was rarely 
seen following PCR with either primer set, apart from a spike in PCR positives at 13 
to 15 wpc, with the Cox_1 PCR performing consistently better than the ITS-2+ PCR. 
Amplification following LAMP fluctuated, with a series of LAMP positives in early 
samples (3 to 6 wpc), followed by a noticeable dip at 7 to 8 wpc and a steady rise to a 
peak of 100% of animals positive by 12 wpc. The individual results for each animal 
are presented in Appendix 5. Results in Figure 6.9 are based on DNA extracts 
obtained with the QIAmp® (FAST) DNA Stool Mini kit. No amplification was seen 
with any of the DNA-based methods when using freeze-thaw derived DNA extracts 
from samples obtained at 18 wpc. 
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Figure 6.9 Number of animals positive by faecal-based tests following experimental challenge 
with F. hepatica. 
6.5 Discussion 
 
This chapter aimed to evaluate, and if required develop, faeces-based PCR and 
LAMP assays to detect liver fluke infection, with emphasis on the analytical 
specificity of the respective primers and the clinical sensitivity of the tests by way of 
a challenge study. 
As only a small number of samples was tested, and repeat testing was not performed, 
this chapter represents a proof-of-concept analysis rather than a rigorous evaluation 
of primers, DNA extraction methods, PCR and LAMP assays. 
6.5.1 Primer evaluation 
 
When selecting primers it is important to ensure that they are suited to both the DNA 
amplification method being used and to the geographical area from which the 
samples originate. In this case, F. hepatica is the predominant liver fluke in UK with 
D. dendriticum only found in specific geographic locations and no natural F. 
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gigantica infections. Hence, primers for F. hepatica that cross-react with F. 
gigantica might be of diagnostic use in the UK, whereas they would be of limited 
diagnostic used in geographic areas where both Fasciola species exist together. Co-
infections with gastrointestinal nematodes and with the rumen fluke, C. daubneyi, are 
often seen in the UK. Thus, for use in the UK, it is important that primers for 
detection of F. hepatica do not cross-react with C. daubneyi. P. cervi, a rumen fluke 
species previously thought to occur in the UK and Ireland, has not been identified by 
DNA-based methods from UK samples (Gordon et al., 2013; Willmott, 
1950)(unpublished data). Therefore, all primers were tested against C. daubneyi but 
not against P. cervi. Given that P. leydeni has recently been reported from deer in 
Ireland (O’Toole et al., 2014) and that the geographical distribution of rumen fluke 
species is often based on morphological studies, which have been contradicted by 
DNA-based identification, further evaluation of primer specificity relative to a range 
of rumen fluke species would be useful.   
The two PCR primer sets in this chapter were tested for specificity to F. hepatica and 
C. daubneyi, respectively. Those published by Martínez-Pérez et al. (2012) (Cox_1) 
were found to not amplify C. daubneyi DNA. The primer set published by Itagaki et 
al. (2003) (ITS-2+) amplified both F. hepatica and C. daubneyi but, as the PCR 
product for each fluke species was of a different molecular weight, they could be 
differentiated when the results were viewed on an agarose gel. These primers are not 
suitable for methods that do not include detection of amplicon size, e.g. real-time 
PCR or LAMP, which is a major drawback if the assay is to be developed into a pen-
side diagnostic with quick turn-around.  
Whilst the new F. hepatica LAMP primers presented in this chapter (Fh ITS-2) do 
not amplify rumen fluke DNA, they do amplify other liver fluke DNA i.e. F. 
gigantica and D. dendriticum. Despite this, the primer set is suitable for samples 
originating from UK as F. gigantica is not present and D. dendriticum is rarely seen. 
Further work on demonstrating specificity of F. hepatica primers or on development 
of specific primers will be needed to ensure that they are suitable for the geographic 
location and host species they are to be used in i.e. use of these primers on DNA 
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extracted from bovine faecal samples will require further specificity testing against 
GIN species found in bovines. 
6.5.2 PCR and LAMP assay development 
 
It is generally assumed that fluke eggs must be disrupted in order for DNA to be 
extracted from within them (Ai et al., 2010a; McNally et al., 2013). Therefore, the 
amplification of DNA from eggs which had not undergone a pre-DNA extraction 
treatment was somewhat unexpected. These eggs had been laid by adult parasites and 
washed in distilled water during the storage process. It is possible that free, i.e. 
soluble, DNA was still present following the washes and resulted in successful 
amplification. 
PCR and LAMP assays were used to amplify DNA extracted from FEC positive 
faeces, which had been diluted and allowed to sediment for 3 minutes. In these 
instances, no pre-DNA extraction treatment was performed on the sample to crack 
eggs, and the sample was diluted in water prior to sedimentation. PCR was unable to 
amplify DNA from either sample, although LAMP amplified DNA from the sample 
with 31.17 epg. It is likely that the second sample, which had a FEC of 4 epg, had 
too few eggs or not enough free DNA present for amplification to occur. Because the 
aim of this chapter was to provide proof-of-concept for the utility of PCR or LAMP 
as diagnostic methods for liver fluke, full optimisation of DNA extraction methods 
and full analysis of analytical sensitivity were not undertaken.  
DNA amplification by LAMP but not PCR was also seen when DNA, extracted 
using a freeze/thaw method from faeces, was used in PCR and LAMP assays. In this 
case, the faecal sample had a FEC of 17.83 epg. When using the QIAmp
®
 DNA 
Stool Mini Kit, PCR was able to amplify DNA from 2 of 7 samples (FECs of 112.67 
and 150.5 epg), although these had neither the highest nor lowest FEC or cELISA 
results. When the same DNA extracts were used in a 2 hour LAMP assay, DNA 
amplification occurred in one of the samples amplified by PCR and in 4 other 
samples (5 of 7 in total), with FECs ranging from 103.5 to 318.5 epg. Again these 
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samples included neither the highest nor the lowest FEC or cELISA results. DNA 
from sample F2998 was amplified by PCR but not LAMP this is an unexpected 
result. It is unlikely to be due to the DNA extraction process, as the same DNA 
extract was used. If the mastermix was not sufficiently mixed prior to pipetting 
aliquots for each sample it could have affected the reaction in this tube. This is 
unlikely as positive and negative controls were normal and samples which had not 
been amplified by PCR were amplified by LAMP. The lack of amplification of this 
sample by LAMP is likely a false negative result. 
When tested against DNA extracted from low FEC samples, LAMP amplified DNA 
from samples with 0.67 and 34.5 epg, but not 3.83 epg. These results indicate that 
successful DNA amplification by PCR or LAMP assays may not be dependent on the 
level of FEC or cELISA. As there is a positive relationship between both FEC epg 
and cELISA PD and the burden of fluke in the liver, this may suggest that there is no 
direct correlation between DNA amplification and fluke burden using either PCR or 
LAMP. Testing of a larger number of samples would be useful to determine if this is 
truly the case. 
 DNA extracted from a faecal sample from an uninfected animal was not amplified 
by a 2 hour LAMP assay. Whilst this may indicate that genuinely negative faecal 
samples will test negative by LAMP, it was only one sample, tested once and may be 
the result of the low sensitivity shown by LAMP. Again, testing of a larger number 
of samples would be useful. 
It is possible that rather than fluke burden it is the DNA extraction process which is 
affecting the amplification of fluke DNA by PCR. When extracting DNA from egg 
positive faeces, Ai et al. (2010a) vortexed 5-10 g of faeces with glass beads to disrupt 
egg shells prior to DNA extraction with the Wizard
®
 SV genomic DNA purification 
system (Promega, WI). Both Martínez-Pérez et al. (2012) and Robles-Pérez et al. 
(2013) did not use any pre-DNA extraction treatments but used an alternative DNA 
extraction kit (SpeedTools Tissue DNA Extraction kit, Biotools, Spain), which was 
not available for use in this study. To improve the quality of extracted DNA, Robles-
Pérez et al. (2013) added an ethanol precipitation step following DNA extraction. In 
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both cases, DNA amplification by PCR using the Cox_1 primers was successful. 
Other than the use of different buffers, the SpeedTools kit differs from the QIAmp
®
 
kit in that it does not have the initial incubation at 95˚C and discards the supernatant 
formed from the initial centrifugation step, using the pellet for DNA extraction 
instead.  
For the extraction of DNA from faecal samples containing nematode eggs, McNally 
et al. (2013) used a different approach to those described so far. Faecal samples were 
stored in ethanol. To prepare the sample, ethanol precipitation and grinding was 
followed by the use of glass beads to disrupt egg shells and the addition of 
polyvinylpolypyrrolidone to remove inhibitory substances prior to DNA extraction 
using magnetic capture (MagMax Total Nucleic Acid extraction kit, Ambion, USA). 
The use of a pre-DNA extraction treatment (i.e. disrupting eggs with glass beads) or 
a post-DNA extraction treatment (i.e. ethanol precipitation) or the use of an alternate 
DNA extraction method, may have increased the sensitivity of the PCR assays. 
Further work to optimise a DNA extraction protocol would be of value, potentially 
including the use of a pre-DNA extraction treatment. 
In the case of the LAMP assay, incubation time was found to affect the amplification 
of DNA, with more samples being successfully amplified with longer (2 hours) 
incubation times. Although, even with a 2 hour incubation, only 2 of 3 samples were 
amplified (82 and 208 epg) and a high FEC sample (121 epg) was not amplified. One 
of the attractive features of the LAMP assay was the rapid amplification it is capable 
of (45 minutes), which is lost if the incubation time is extended to 2 hours. With 
modifications to the DNA extraction process, such as those mentioned above, it may 
be possible to reduce this incubation time. 
6.5.3 PCR and LAMP evaluation 
 
The FECs of the 6 animals in the challenge study were moderate, with eggs first 
being detected 10 wpc and ranging from 13.83 to 48 epg at 17 wpc. Coproantigens 
were detected later than expected, first being seen at 7 wpc, with all animals positive 
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by 10 wpc. The cELISA PD values were also moderate, ranging from 31.88% to 
71.62%. This is likely due to the low challenge the animals received (~90 infective 
cysts), and the resulting low fluke burdens seen (22 - 44). 
The lack of DNA amplification by LAMP on 18 wpc samples extracted using the 
freeze/thaw method was disappointing. Amplification had been successful using the 
method during the assay development in 3 of the 4 samples tested, with egg counts 
from 17.83 epg. The addition of pre- and post-DNA extraction treatments, as 
mentioned above, may improve this method. It is also worth noting that these 
samples had been stored at -20˚C for several months prior to DNA extraction, 
whereas the samples used in the assay development were fresh. This may have 
resulted in degradation of the DNA. Storage in ethanol, as performed by McNally et 
al. (2013), who stored samples for a year prior to DNA extraction, may result in 
better preservation of the sample. 
In the PCR assays, although only a small proportion of samples were amplified, more 
samples were amplified using the Cox_1 primer set than the ITS-2+ primer set 
(12/108 vs. 3/108). It is unclear why this occurred but it may be due to the Cox_1 
primer set amplifying mitochondrial DNA (mtDNA) whilst the ITS-2+ primer set 
amplifies nuclear DNA. It is possible that mtDNA is more abundant or more easily 
extracted than nuclear DNA. Both primer sets failed to amplify DNA in early 
samples, the ITS-2+ primer set had earlier detection (13 wpc), but this was only in 
two samples, with a third sample testing positive at 17 wpc. The two 13 wpc ITS-2+ 
positive samples were not amplified with the Cox_1 primer set. Although the Cox_1 
primer set had slightly later detection (14 wpc), amplification was seen in more 
samples. However, although DNA amplification was successful from 14 wpc, it did 
not remain so for the duration of the study. Only faecal samples from one animal 
(A1333) had DNA which was consistently amplified (14 – 17 wpc). That the Cox_1 
primers were unable to detect early infection is contrary to the published account, 
stating that DNA can be amplified from faecal samples taken at 2 wpc (Martínez-
Pérez et al., 2012; Robles-Pérez et al., 2013). Once again, it is possible that this is 
due to the difference in DNA extraction kit used in the published and current studies. 
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Other research groups have also reported difficulties with PCR-based detection of F. 
hepatica DNA in faeces (D. Williams, personal communication to R. Zadoks, 2014).  
The LAMP assay was able to amplify DNA extracted from 3 wpc faecal samples. 
This very early detection is a promising indication of the potential of a LAMP assay 
and was seen in 5 of the 6 samples. Despite this the number of samples that tested 
positive for infection by LAMP fluctuated until, at 7 and 8 wpc, no samples tested 
positive. At 9 wpc, the number of samples testing positive began to rise again and 
consistent amplification was seen in samples from 3 animals.  
It is possible that the fluctuations in numbers of samples positive each week could be 
reduced with a modified DNA extraction method, but it is clear that the LAMP assay 
is able to amplify DNA in samples where the PCR assays cannot. The literature 
highlights the increased sensitivity of LAMP compared to that of PCR, reporting its 
ability to detect even low numbers of DNA copies (Notomi et al., 2000). It may be 
that whilst PCR assays would benefit from a more refined DNA extraction method 
than used in this study, that LAMP assays do not require this. It is worth noting that 
each sample only had one DNA extraction made and that DNA extract was only used 
in one LAMP assay. As such, if DNA is present in the sample, but it is low 
sensitivity of the LAMP assay causing the fluctuations, testing samples in duplicate 
or triplicate would highlight this.  
Sample storage may also affect test results, due to degradation of DNA. All faeces 
were collected, homogenised, sub-sampled and frozen in the same way, with samples 
being frozen on the day of collection. However, when the time came for DNA 
extraction, the 0 wpc samples had been frozen for 18 weeks longer than the 17 wpc 
samples.  
In this study, and in the previously published studies by Martínez-Pérez et al. (2012) 
and Robles-Pérez et al. (2013), which saw successful DNA amplification from 2 
wpc, the source of the detected DNA is not known. As such, it is difficult to fully 
explain the kinetics of the release of DNA. It is unlikely at 2 or 3 wpc that the DNA 
being detected was from non-viable metacercarial cysts, these would likely have 
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been passed out with faeces in the first week post-challenge. At 3 wpc, the parasites 
have excysted, immature fluke are within the liver and have begun shedding 
tegument and excretions (Reddington et al., 1984). From this shed tegument and 
excretions excretory-secretory antigens can be detected in ovine serum from 1 wpc 
via an ELISA, but these antigens are not detectable in faeces via cELISA until 5 wpc 
(Duménigo et al., 2000; Mezo et al., 2004). It is possible that, being more sensitive 
than cELISA, the PCR and LAMP assays are amplifying DNA from the shed 
tegument and excretions within the faeces. Eggs may also be the source of DNA in 
successful amplification once an infection has become patent.   
The cause of the drop in the proportion of animals testing positive by LAMP at 7 and 
8 wpc is not clear. This may be due to fluctuations in the quality of the DNA extracts 
as mentioned above, or may be due to an aspect of the biology of F. hepatica. It is at 
around this time that fluke migrate into the bile ducts; this transition may play a role 
in the release of DNA into faeces. However, as excretory-secretory antigens were 
detected at 7 and 8 wpc by cELISA, LAMP should thus be able to amplify DNA 
from the shed tegument and excretions at these times. It is possible that storage of 
these samples is the cause of the lack of amplification. Samples were stored for a 
year and it is possible that the box these samples were stored in was closer to the 
door, or taken out to access other samples, thus resulting in a degradation of sample. 
As has been mentioned previously, this chapter is a proof-of-concept and testing of a 
larger number of samples would be beneficial in understanding both the potential and 
limitations of the faecal LAMP assay.  
6.5.4 Conclusion 
 
This study provides proof-of-concept that LAMP can be used to detect Fasciola 
hepatica infections in sheep during the pre-patent and patent stages of infection using 
faecal samples. These promising results warrant further effort into development of 
species-specific primers, optimisation of DNA-extraction methods, and evaluation of 
clinical and epidemiological sensitivity and specificity of the assay in sheep and 
other host species. 
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This thesis aimed to evaluate currently available and novel diagnostic tests for F. 
hepatica in sheep. To achieve this the coproantigen ELISA (cELISA), along with the 
faecal egg count (FEC), and where feasible the anti-Fasciola antibody ELISA 
(AbELISA) and the use of glutamate dehydrogenase (GLDH) and gamma-glutamyl 
transferase (GGT) concentrations, were evaluated in (1) an experimental challenge 
model (Chapter 3), (2) individual naturally exposed sheep, in early infection as well 
as in pre- and post-treatment situations (Chapter 4), (3) groups of naturally exposed 
sheep, including composite samples, in pre- and post-treatment situations and 
evaluating the FEC reduction test (FECRT) and the coproantigen reduction test 
(CRT) (Chapter 5), and lastly existing PCR assays and a newly developed loop-
mediated isothermal amplification (LAMP) assay were evaluated against cELISA 
and FEC for the detection of F. hepatica infection in experimentally challenged 
sheep (Chapter 6). 
7.1 Serum-based diagnosis 
 
The AbELISA and the use of GLDH and GGT concentrations to indicate liver and 
bile duct damage are commonly used serum-based diagnostic tests for the detection 
of F. hepatica infection in sheep. The data presented in Chapter 4 of this thesis calls 
into question the use of GLDH and GGT concentrations to indicate liver fluke 
infection using current SAC C VS criteria. When used in lambs both GLDH and 
GGT concentrations were above SAC C VS “normal” ranges at the start of the study, 
when the lambs were 2 months old and unlikely to be infected with the adult fluke 
needed to stimulate an increase in GGT concentrations. It is possible that the young 
age of these animals contributed to the high concentrations of GLDH and GGT seen. 
If this is the case then work would be needed to evaluate the age at which GLDH and 
GGT concentrations are suitable as indicators of liver fluke infection. It is not clear 
how the “normal” range for these enzyme concentrations have been determined by 
SAC C VS. No information on “normal” ranges for these enzymes could be found in 
the literature. Instead, each published study consulted that uses GLDH and GGT 
concentrations to indicate liver fluke infection do so by comparing the concentrations 
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of the infected group to those of a control and requiring a significant increase from 
the control in order for liver fluke infection to be indicated (Ferre et al., 1996; Ferre 
et al., 1997; Raadsma et al., 2007). The control is either pre-infection concentrations 
of these same sheep or concentrations from an uninfected group of sheep of a similar 
age, parity, breed and sex, kept under the same conditions. Indeed, the control 
concentrations of these enzymes vary between studies, as do the characteristics of the 
animals used, with concentrations in adult control animals being higher than the 
“normal” range set by SAC C VS. When the GLDH and GGT concentrations from 
the first sampling of the lambs in this study were used as a control, the enzyme 
concentrations gave a better indication of infection, with GLDH and GGT 
concentrations significantly higher than the control concentrations in October and 
September, respectively. To use a single “normal” range for GLDH and GGT 
concentrations to indicate liver fluke infection, regardless of animal age, appears 
misguided and is likely to result in misdiagnosis of animals. If a pre-infection or 
control group concentration of GLDH or GGT is not available then these tests should 
not be used in isolation to diagnose liver fluke infection.   
In the studies presented in this thesis involving adult sheep (Chapter 3), the 
AbELISA performed as would be expected based upon the reports in the literature 
(Zimmerman et al., 1982). Positive AbELISA titres were seen from 3 weeks post-
challenge (wpc) in experimentally challenged adult sheep. The titres of the animals 
remained consistently positive throughout the studies. No studies within this thesis 
used the AbELISA in sheep which had been successfully treated for liver fluke 
infection. It is known however that anti-Fasciola antibodies persist following 
successful treatment (Ibarra et al., 1998; Sánchez et al., 2001). In naturally exposed 
lambs, early positive AbELISA titres were followed by a period of negative 
AbELISA titres and finally positive AbELISA titres, which remained so until the end 
of the study and death of the animals (Chapter 4). These early positive AbELISA 
titres are likely to be due to anti-Fasciola maternal antibodies in these young lambs, 
2 months old at the time of the first positive. Indeed, when the AbELISA results of 
all lambs in the study are looked at, a decreasing AbELISA titre was seen between 
June and August in all but 2 animals. The dynamics of anti-Fasciola maternal 
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antibodies in lambs does not appear to be fully understood; at the time of writing no 
published reports could be found. In calves, anti-Fasciola maternal antibodies 
persisted for between 7 and 12 weeks, depending on the number of infective 
metacercarial cysts the mother was exposed to prior to birth (Mezo et al., 2010). In 
the absence of data from lambs, it would be inadvisable for the AbELISA to be used 
on samples from sheep younger than 12 weeks old. 
Both the AbELISA and measuring GLDH and GGT concentrations rely on obtaining 
serum samples. In the UK, this can only be done by a veterinarian for routine 
diagnostic purposes. This leads to an increase in the costs of the tests, which may 
limit uptake by sheep farmers. However, it is worth noting that these tests can give 
very early indication of F. hepatica infection, which may reduce potential financial 
losses through early detection and treatment, and that the AbELISA is still a valuable 
test if used in an animal’s first grazing season. Until other tests can reliably indicate 
pre-patent F. hepatica infections the AbELISA and potentially, if the criteria for 
interpretation is optimised, the use of GLDH and GGT concentrations, will remain a 
valuable tool for farmers and veterinarians in the control of F. hepatica. 
7.2 Faeces-based diagnosis 
 
As for the AbELISA, the FEC performed as was expected in the studies within 
Chapters 3, 4 and 5 of this thesis (Chowaniec and Darski, 1970; Valero et al., 2006). 
In the experimental challenges described in Chapter 3, FECs became positive no 
earlier than 9 wpc and in both naturally exposed and experimentally challenged 
animals FECs fluctuated between sampling points (Chapters 3, 4 and 5). The 
shedding of sequestered eggs following successful treatment was seen in Chapter 5, 
where low FECs were seen in a number of animals following successful closantel 
treatment. Rumen fluke eggs were seen in samples alongside F. hepatica eggs in 
Chapters 4 and 5. Care must be taken when performing FECs to ensure that F. 
hepatica and rumen fluke eggs can be distinguished. This includes not only training 
to differentiate between the two fluke eggs when seen side-by-side or in isolation, 
but also time and care to ensure the microscope is correctly set up to help 
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differentiate between the eggs. Poor lighting can make distinguishing the eggs of 
these two trematodes near impossible, especially when only one type of trematode 
egg is present.  
The FEC was also used on composite samples in Chapter 5, which were collected 
using a modified version of the protocol proposed by Daniel et al. (2012). Infection 
was detected from fewer composite samples than when FEC was performed on 
individual samples and an average calculated. This is understandable in low FEC 
samples. If a single sample has a FEC of 1 epg whilst all other samples in the group 
are FEC negative it is unlikely that that the one egg will be included in the 3 g of 
composite sample viewed for FEC. However, when the average of that group is taken 
the FEC will be 0.1 epg resulting in a positive group average FEC. Although the 
lower sensitivity of composite FEC compared to individual FEC is understandable it 
is contrary to the findings of Daniel et al. (2012). This is likely due to the larger 
composite sample used in the original study, 50 g, compared to the 10 g composite 
sample prepared in this study. In addition, in the original study the whole 50 g was 
used in a FEC, whereas only 3 g of the composite was used in this study. Lastly, the 
FECs of the original study were higher than those seen within this thesis.  
These factors are important. The composite FEC was performed with the smaller 
volume and in a standard FEC procedure in order to evaluate how it would likely be 
used. In several studies within this thesis the collection of insufficient faecal samples 
was an issue, despite ‘fill-to’ lines being used or the volume of faeces required being 
communicated. Often samples which were sent in had less than 4 g available, only 
just enough to perform a single FEC and cELISA. Obtaining a 5 g sample from 10 
animals may not be practical. Even if a sufficient volume of faeces were collected it 
is not practical to perform FECs on a 50 g sample using the method employed in this 
thesis. Large volumes of water and containers would be required, sedimentation 
would be difficult and a longer period of sedimentation may be needed to ensure that 
all eggs sediment. Counting would need to be performed in batches to prevent plates 
from drying out on the microscope. The issue of the difference in burdens is also one 
that must be taken into consideration. Low burdens were seen on most farms which 
took part in the studies within this thesis (Chapters 4 and 5). The prevalence of 
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infection on farms did not follow a normal distribution, with either very few or 
nearly all animals being positive. Whilst the composite FEC using 10 g samples may 
perform well when used on samples from farms with high prevalence and moderate 
burden, it does not when used on samples from farms with low prevalence or low 
burden.  
The BIO K201 cELISA appeared to be a very promising diagnostic test for the 
detection of pre-patent F. hepatica infection based upon its use in experimental 
challenge situations (Flanagan et al., 2011a; 2011b; Mezo et al., 2004). Indeed this 
was seen in the experimental challenge studies described in Chapter 3. However, 
when used in 2 month old lambs grazing pasture known to support the liver fluke life 
cycle, early detection was not seen (Chapter 4). The cELISA became positive in the 
same month that FEC did. Advertising from the company that produces the cELISA, 
(Bio-X Diagnostics, Belgium) and the published reports of the test’s performance in 
experimental studies would indicate that the cELISA will detect early infections 
(Bio-X, 2010; Flanagan et al., 2011a; 2011b). Contrary to this, in the original report 
of the MM3 cELISA, in low burden infections the cELISA did not become positive 
until 7 wpc (Mezo et al., 2004). This reflects what was seen in the naturally exposed 
lambs, where burden was no more than 10 fluke.  
It is also worth noting that the dynamics of an infection arising from an experimental 
challenge differs from those seen in a naturally acquired infection. Other than in the 
case of acute fasciolosis, naturally acquired infections often occur in the form of a 
trickle challenge, with metacercariae being ingested over a period of time ranging 
from hours to months. This is in contrast to an experimental challenge where 150 to 
200 metacercariae are ingested all at once. Indeed in the experimental challenge 
studies of Chapter 3 all externally visible liver damage occurred on the left lobe of 
the liver, a contrast to the widespread damage which is often seen in the livers of 
naturally infected animals. This difference in the route of infection (experimentally 
challenged vs. naturally acquired) and in parasite burden (high in the case of 
experimental challenge but often low in natural infections) must be taken into 
account before tests are offered to farmers and veterinarians. 
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Although the cELISA was shown to not have the advantage of detection pre-patent 
infection in low burden situations in Chapter 4, it was still expected to be able to 
detect patent infections, except in the case of low positive FECs following successful 
treatment (Mezo et al., 2004; Valero et al., 2002). This detection of patent infections 
was not seen when the cELISA was evaluated using individual and group samples 
from adult sheep which may have been naturally exposed to F. hepatica (Chapters 4 
and 5). The lowered sensitivity of the cELISA (85.1%) in comparison to the FEC 
may be due to the low burdens seen in both studies evaluating the cELISA in adult 
sheep (Chapters 4 and 5). Although livers were only recovered for a small minority 
of these animals FECs indicated low infections, with FECs of <10 epg in cELISA 
negative samples.  
A study by Novobilský et al. (2012), carried out at the same time as the study on 
Farm 9 and Farm 22 (Chapter 5), aimed to evaluate the CRT in naturally exposed 
sheep. Three groups of 8 sheep were used but whilst 7 animals in each group were 
FEC positive, only 4 animals were positive by cELISA. This is another example of 
poor sensitivity by the cELISA compared to FEC in naturally exposed animals. As 
the FECs were not disclosed in the publication and livers were not recovered it is not 
possible to determine if fluke burden could be responsible for the low cELISA 
sensitivity. It is also worth noting that on two farms with high FECs the cELISA 
detected more infections than FEC did (Farm 9 and Farm 22, Chapter 5), again 
indicating that low burden may be the cause of the lowered sensitivity of the cELISA 
in comparison to FEC seen in studies involving naturally exposed sheep within this 
thesis (Chapters 4 and 5) and in the literature (Novobilský et al., 2012).  
The lack of detection by cELISA in patent low burden infections is in contrast to the 
original description of the MM3 cELISA, where the presence of a single fluke was 
detected in sheep (Mezo et al., 2004). Changes to the cELISA between original 
publication and commercialisation may explain this change in sensitivity (Bio-X, 
2010; Mezo et al., 2004).  
Current guidelines from Bio-X Diagnostics (Belgium) use the same cut-off for the 
cELISA, regardless of the species the sample originated from. An extensive study by 
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Palmer et al. (2014) had the benefit of access to known negative samples. Together 
with known positive samples (positive by FEC), custom cut-offs were created for the 
cELISA depending on the species the samples originated from. By using these 
custom cut-offs the sensitivity of the cELISA was increased from 88%, which is 
similar to the sensitivity seen in the studies within this thesis, to 100% when used on 
ovine samples. This indicates that, despite being presented as a standardised 
commercial assay, further optimisation of the cELISA kit, including the use of 
species specific cut-offs, could improve its performance when used on samples from 
animals naturally exposed to F. hepatica. 
When the cELISA was used in a composite sampling strategy in Chapter 5, modified 
from that described by Daniel et al. (2012), it was found to be more sensitive than 
when used on individuals and an average PD calculated. The increased composite 
cELISA sensitivity may not be seen if the results of the individual cELISAs of the 
samples making up the composite sample are taken into account. This is due to the 
fact that in a low prevalence flock the cELISA positive result of a single animal can 
be “diluted” when viewed with 9 other cELISA negative animals i.e. the mean PD 
will not indicate a positive cELISA result.  
The issue of low burdens, as described by FEC, has been mentioned several times in 
this discussion. It is worth noting firstly that FEC is not always indicative of burden. 
The fluctuations in FEC epg between sampling points makes calculating true 
correlations difficult (Valero et al., 2002). One published report which did look at 
correlations with liver burden found no relationship in cattle and an inverse 
relationship in sheep; that is an increasing adult burden lead to a lower FEC epg 
(Valero et al., 2006). Secondly, if the low FECs are representative of a low fluke 
burden in the liver, is it truly an issue that the cELISA and composite FEC fail to 
detect these infections? Are these low infections clinically relevant? If they are not 
clinically relevant, i.e. not causing the animal distress and not significantly affecting 
production qualities (wool yield, weight gain, milk yield and fecundity), then not 
treating would reduce costs for farmers and help preserve the efficacy of treatments. 
The relationship between fluke burden and production losses has been explored in 
cattle and indicates that low burden infections have less of an effect on animals 
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(Charlier et al., 2014). The idea of only treating animals which are affected by 
disease has been proposed in gastrointestinal nematode (GIN) infections as targeted 
selective treatment (TST)(Kenyon and Jackson, 2012). 
7.3 Diagnosis using DNA amplification methods 
 
The commercially available diagnostic tests for the detection of F. hepatica are 
limited in their use depending on the age of animal, potential co-infections, 
prevalence and intensity of infection and the criteria used to interpret them. More 
work is needed before the use of DNA-based diagnosis for F. hepatica could replace 
or be used alongside any of the existing diagnostic tests. Despite this the promise of a 
test which is able to detect pre-patent F. hepatica infection, is highly sensitive and 
specific and could be rapid and cost-effective is highly attractive. 
 In Chapter 6 of this thesis PCR was performed on DNA extracted from faeces using 
previously published primers. In previous publications these primers and PCR assay 
were reported to detect infection from 2 wpc (Martínez-Pérez et al., 2012; Robles-
Pérez et al., 2013). This was not seen in the study in Chapter 6, no DNA 
amplification occurred until 13 wpc, and the infection status of animals according to 
this PCR assay fluctuated. There are two possible explanations for the lack of DNA 
amplification. Firstly, the use of a different kit for the extraction of DNA from faecal 
samples may have affected the quality and/or quantity of DNA extracted from faeces. 
The kit used by Martínez-Pérez et al. (2012) and Robles-Pérez et al. (2013) 
(SpeedTools Tissue DNA Extraction kit, Biotools, Spain) was not available for use 
in this study. It is possible that the SpeedTools Tissue DNA Extraction kit (Biotools, 
Spain) is more effective at extracting DNA from faecal samples. The second 
explanation is the length of time samples were stored for. In the study presented in 
Chapter 6 of this thesis samples were stored at -20˚C for ~1 year. This extended 
storage, without the use of a preservative, may have degraded DNA samples. More 
work is needed to evaluate and optimise the DNA extraction process from faecal 
samples, including investigation into the effect of different storage conditions on 
samples. 
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Although a LAMP assay exists for the detection of F. hepatica it was found in 
Chapter 6 of this thesis that this assay also amplified the DNA of Calicophoron 
daubneyi, a rumen fluke commonly found in the UK (Ai et al., 2010b; Gordon et al., 
2013). New primers were developed which amplify liver fluke DNA (F. hepatica, F. 
gigantica and Dicrocoelium dendriticum) but not rumen fluke DNA (C. daubneyi 
and Paramphistomum cervi/P. leydeni), and are thus suitable for use in the UK. 
When these primers were used in a 2 hour 61˚C LAMP assay, with DNA extracted 
from ovine faeces, amplification was seen at 3 wpc. This is a very promising result, 
particularly in light of the poor performance of PCR when used on the same DNA 
extracts. If the DNA extraction and sample storage procedures are optimised it may 
be possible to shorten the LAMP assay. Development for use on a real-time platform, 
such as has been done for the Haemonchus contortus LAMP assay, would allow for 
the quantification of DNA and potentially indicate burden in the animal (Melville et 
al., 2014). In addition, MAST Group Ltd, who produce the LAMP reagents, are 
developing a lyophilised version of the kit which would be more thermostable than 
the current reagents. LAMP products have also been visualised using a lateral flow 
device for parasite, bacterial and viral DNA extracts (Kiatpathomchai et al., 2008; 
Njiru, 2011; Rigano et al., 2010). Together, these two developments would make a 
pen-side F. hepatica LAMP a realistic possibility. 
7.4 Determining treatment outcome 
 
Currently there is no practical, standardised test to determine treatment outcome on 
working farms. In light of the increasing reports of TCBZ treatment failure, and 
confirmed cases of TCBZ resistance, such tests are of increasing importance 
(Álvarez-Sánchez et al., 2006; Gordon et al., 2012a; Lane, 1998; Mitchell et al., 
1998; Moll et al., 2000; Olaechea et al., 2011; Ortiz et al., 2013; Overend and 
Bowen, 1995; SAC, 1998; Thomas, 2000). To perform a controlled efficacy trial the 
farmer would need to be willing to not treat a portion of his flock, leaving them at 
risk of suffering from F. hepatica infection, and to slaughter another portion of his 
flock whilst they are still in the meat withdrawal stage and thus not suitable for 
selling into the food market.  
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The FECRT is frequently used on farms to indicate treatment outcome. This has not 
been standardised for F. hepatica infections and this lack of standardisation presents 
issues. When used for sheep infected with gastrointestinal nematodes, the FECRT is 
not recommended for use if the FEC is <150 epg. For the studies within Chapters 4 
and 5 of this thesis over 800 pre-treatment FECs were performed on samples from 
naturally exposed sheep. Of these, only 8 had FECs ≥150 epg and only 26 had FECs 
≥100 epg. The criteria of samples having to have a FEC of ≥150 epg simply will not 
work for many British F. hepatica infections. As such it is ignored more often than 
not. This is far from ideal. Using the FECRT without a minimum FEC criterion can 
lead to misleading results. Within this thesis, in cases of very low pre-treatment FEC 
the FECRT proved unreliable when compared to the cELISA (Chapter 5). This is due 
to the release of small numbers of sequestered eggs from the gall bladder following 
successful treatment. If the pre-treatment FEC is less than 1 epg then even if a single 
sequestered egg is seen in the post-treatment FEC the treatment will be deemed to 
have failed. Work is needed to identify what the minimum FEC for the use of the 
FECRT in F. hepatica infections should be. 
In GIN infections the timing of the post-treatment sampling varies depending on the 
class of anthelmintic used. Again this has not been standardised for F. hepatica 
infections and as such post-treatment sampling tends to occur between 14 and 21 dpt, 
generally depending on when is suitable for the farmer and veterinarian. Only one 
anthelmintic for F. hepatica is able to target all stages of the liver fluke and thus the 
anthelmintic given should be taken into account when determining the timing of the 
post-treatment sampling. For example, treatment with closantel can target F. 
hepatica from 7 weeks post-infection (wpi) but eggs can appear in faeces from 9 wpi, 
as such, at 3 wpt, eggs may be seen in the faeces from fluke which were ≤7 weeks 
old at the time of treatment and have now developed into egg producing adults.  
Lastly, as eggs are stored in the gall bladder and the number of eggs is not always 
indicative of the number of fluke in the liver, a FECRT can only give information on 
the reduction of eggs, not the reduction of parasites. This was seen in bovines with a 
discrepancy in treatment efficacy being reported depending on if a FECRT or CET 
was used (Malone et al., 1982). Indeed, even determining the reduction of eggs is 
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unreliable due to the sporadic shedding of eggs and fluctuations that can be seen 
within two samples from the same animal. The 95% cut-off for the FECRT is used in 
F. hepatica simply because it is used in the FECRT for sheep infected with GINs. 
Work is needed to determine an appropriate cut-off for the FECRT in sheep infected 
with F. hepatica.  
A CRT has been proposed to determine treatment outcome in sheep infected with F. 
hepatica (Flanagan et al., 2011a; 2011b). This requires all animals to be negative 
following successful treatment and is based upon the premise that the cELISA is 
specific to live fluke. In both of the studies where this CRT was presented, 1 of the 6 
animals remained cELISA positive for 1 to 3 weeks following successful treatment 
(Flanagan et al., 2011a; 2011b). This suggests that ‘all or nothing’ criterion is not 
suitable. Indeed, if the publication the cELISA was originally presented in is 
consulted, it is stated that coproantigens can be detected for 3 weeks following 
successful treatment (Mezo et al., 2004). 
 In Chapter 5 of this thesis an alternative CRT was proposed, which was based upon 
the FECRT and required a ≥95% CR in order for the treatment to be deemed 
successful. This new criteria was also found to be unsuitable. This was due to the 
way in which cELISA results are reported. A sample could test negative by cELISA 
post-treatment yet the PD value be <95% than that of the pre-treatment PD value, 
resulting in the CRT indicating treatment failure even though there is no evidence of 
F. hepatica infection post-treatment. A third proposal was made of a CRT which 
incorporates a reduction in cELISA PD but also takes into account the post-treatment 
infection status of the animal or group according to the cELISA. As such, in order for 
a treatment to be deemed successful the CR must be ≥95% and the post-treatment 
cELISA result must indicate no F. hepatica infection.  This third version of the CRT, 
when used on composite samples, had good agreement with the FECRT. As the CRT 
cut-off of ≥95% has been selected based on its use in the GIN FECRT, more work is 
needed to optimise the CRT.  
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7.5 Conclusion 
 
In conclusion (1) the current use of “normal” ranges of GLDH and GGT 
concentrations is unsuitable and should be revised to avoid misleading results, (2) 
care should be taken when using the AbELISA in very young sheep due to the 
presence of anti-Fasciola maternal antibodies, (3) practitioners should be aware of 
the possible presence of both F. hepatica eggs following successful treatment and 
rumen fluke eggs pre- or post-treatment and the implications these can have on FEC, 
(4) in low burden situations the cELISA may not be able to detect pre-patent or 
patent F. hepatica infections, (5) the use of 10 g composite samples has promise for 
cELISA testing but  is not suitable for either FEC or cELISA in low burden 
situations, (6) further work is needed to standardise the FECRT, whilst a new set of 
criteria for the CRT has been proposed and lastly (7) a faeces-based LAMP has been 
developed for the detection of F. hepatica from 3 wpc, with potential for 
development into a pen-side assay that may increase the uptake of evidence-based 
treatment by farmers, although more work is required to optimise this assay. 
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1.1  Modified BIO K201 coproantigen ELISA protocol 
 
Before using the kit, the concentrated dilution buffer (5x) and washing buffer (20x) 
must be diluted to a 1x concentration.  Bring all reagents to 21°C +/- 3°C before use. 
Homogenise faecal sample using a metal spatula and take a 0.5 g (± 0.03 g) 
subsample.  
Add 2 ml of dilution buffer to the subsample and vortex for 10 seconds.  
Centrifuge for 10 minutes at 1,000 g, collect the supernatant into a 1.5 ml Eppendorf. 
Add 100 µl aliquots of the supernatant to two wells, a test well and control well; test 
wells are on rows A, C, E and G, while control wells are on rows B, D, F and H. 
Reconstitute the freeze-dried positive control with distilled water and add to two 
wells in the same manner. 
Incubate the plate at 21°C (±3°C) for 2 hours on a plate agitator, cover with film. 
Rinse plate with washing solution as follows. Flip plate sharply over a sink and fill 
wells with washing solution using a plastic wash bottle, avoiding the formation of 
bubbles. Empty the plate by flipping again. Rinse twice more. Remove excess wash 
solution by drumming the plate upside down against paper towel. 
Dilute the biotin-linked anti-Fasciola hepatica conjugate fiftyfold in the dilution 
buffer. Mix gently avoiding the formation of bubbles. 
Add 100 µl of diluted biotin-linked anti-Fasciola hepatica conjugate to each well 
Incubate at 21°C (±3°C) for 1 hour on a plate agitator, cover with film. Rinse plate 3 
times as described above. 
Dilute the avidin-peroxidase conjugate fifty-fold in the dilution buffer. Mix gently, 
avoiding the formation of bubbles. 
Add 100 µl of diluted avidin-peroxidase conjugate to each well. 
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Incubate at 21°C (±3°C) for 1 hour on a plate agitator, cover with film. Rinse plate 3 
times as described above. 
Add 100 µl of chromogen tetramethylbenzidine (TMB) solution to each well. The 
chromogen should be colourless when added to wells; if a blue colour is present the 
solution has been contaminated.  
Incubate at 21°C (±3°C) for 10 minutes. Do not cover. A blue colour will appear in 
some samples. 
Add 50 µl of stop solution to each well. The blue colour will become yellow. 
Read the optical densities of the wells using a plate reader and a 450 nm filter. 
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1.2 Liver fluke extraction 
 
If eggs are required from the gall bladder, it must be clipped off prior to removal 
from the liver and processed as described for the liver fluke egg recovery protocol. 
The liver may then be processed as described. 
If eggs are not required, cut open the gall bladder and place any fluke present in cold 
tap water.  
Cut the liver along the main bile duct and apply pressure to aid in the removal of 
fluke.  
Slice the remaining liver into 1 inch wide slices from the central point outwards and 
apply pressure as above. Any fluke present, including partial fluke, should be placed 
with fluke from the gall bladder. 
Fill a bucket with lukewarm water (~25˚C) and apply pressure to a liver slice whilst 
under the water. Set the slice aside in a tray or on a chopping board and repeat for the 
remaining liver slices. 
Examine the slices for fluke.  
Transfer the water to a second bucket via a 300 µm sieve. Pour this water through the 
sieve a second time prior to disposal.  
Wash the contents of the sieve onto a chopping board and examine for the presence 
of whole or partial fluke.  
Fill a bucket with lukewarm water (~25˚C).  
Place one to three pieces of disrupted liver in a square of muslin (35 cm x 35 cm) and 
apply pressure whilst under the water to fully disrupt the tissue.  
Examine the disrupted tissue and muslin square for whole and partial fluke. Repeat 
until all pieces of liver have been processed. 
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Pass the water through a 300 µm sieve to recover whole or partial fluke as above. 
Count and measure all recovered fluke prior to storing in 100% ethanol.  
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1.3  Liver Fluke Egg Recovery 
 
Make an incision between the main bile duct and the liver (image 1). Place a clip 
around the main bile duct (image 2). 
 
Cut the bile duct above this clip (image 3) and carefully remove the remaining bile 
duct and gall bladder from the surface of the liver using a knife, working downwards, 
towards the gall bladder (image 4). 
 
Remove the clip and tip the gall bladder over a 150 µm sieve, eggs and fluke present 
will be caught on the sieve surface, the bile that passes through can be discarded. 
Cut the bile duct open and rinse it with cold tap water over the sieve using a plastic 
wash bottle.  
Remove any fluke and rinse with tap water over the sieve. Place fluke with those 
recovered from the liver. 
Wash eggs with water to remove bile. 
1      2 
3     4 
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Wash eggs from sieve into a beaker. 
Allow eggs to sediment and remove excess water. Wash sediment into a universal 
tube for storage. 
Allow eggs to sediment and remove excess water. 
For DNA extraction re-suspend eggs in 100% ethanol and store at room temperature. 
For hatching re-suspend eggs in distilled water and store at 4˚C. 
  
  
Fasciola hepatica infection is sheep: Current and novel diagnostic tests                                                                                                                                                             




 Blood And Tissue Kit – Animal 
Tissues (Spin-Column Protocol) protocol 
 
Cut up to 0.25 g of parasite tissue and place in a 1.5 ml Eppendorf tube and add 180 
µl Buffer ATL. 
Add 20 µl proteinase K. Vortex and incubate in a water bath at 56˚C overnight to 
completely lyse tissue. 
Dry sample tubes and vortex for 15 seconds. Add 200 µl Buffer AL, vortex, add 200 
µl 100% ethanol and vortex. 
Pipette mixture into a DNeasy Mini spin column placed in a 2 ml collection tube. 
Centrifuge at 6,000 g for 1 minute. Discard flow through and collection tube. If the 
volume of the mixture exceeds the volume of the spin column repeat this step with 
the excess mixture. 
Place the DNeasy Mini spin column in a new 2 ml collection tube, add 500 µl Buffer 
AW1, and centrifuge for 1 minute at 6,000 g. Discard flow through and spin column. 
Place the DNeasy Mini spin column in a new 2 ml collection tube, add 500 µl Buffer 
AW2, and centrifuge for 4.5 minutes at 15,000 g. Discard flow through and spin 
column. 
Place the DNeasy Mini spin column in a clean 1.5 ml centrifuge tube and pipette 100 
µl Buffer AE directly onto the DNeasy membrane. Incubate at room temperature for 
1 minute and then centrifuge at 6,000 g for 1 minute to elute the DNA. 
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1.5  Modified QIAmp
®
 DNA Stool Mini Kit (Stool 
Pathogen Detection) protocol 
  
Weigh 200 mg (±30 mg) stool into a 1.5 ml Eppendorf tube and place on ice if 
performing DNA extraction immediately. If not store at -20˚C for future use. Do not 
allow frozen samples to thaw until Buffer ASL has been added. 
Add 1.2 ml Buffer ASL to each sample. Vortex for 2 minutes to homogenise. 
Heat at 70˚C for 5 minutes in a water bath (can be increased to 95˚C). Dry sample 
tubes then briefly centrifuge to remove condensation.  
 Vortex for 15 seconds and centrifuge at 15,000 g for 1.5 minutes. 
 Pipette 1.2 ml of supernatant into a new 2ml tube. 
Add 1 InhibitEX® Tablet to each tube and vortex immediately and continuously for 
2 minutes. Incubate at room temperature for 1 minute. 
Centrifuge at 15,000 g for 4.5 minutes. 
Pipette supernatant into a new 1.5 ml tube. Centrifuge at 15,000 g for 4.5 minutes. 
Pipette 15 µl of proteinase K into new 1.5 ml tube. 
Pipette 200 µl of supernatant into the tube containing proteinase K. 
Add 200 µl of Buffer AL and vortex for 15 seconds. 
Incubate at 70˚C for 10 minutes in a water bath. Dry sample tubes and briefly 
centrifuge to remove condensation. 
 Add 200 µl of ethanol (100%) and vortex. 
Transfer lysate to spin column without moistening rim. Centrifuge at 15,000 g for 1.5 
minutes. Place column in new collection tube. 
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Add 500 µl Buffer AW1. Centrifuge at 15,000 g for 1.5 minutes. Place column in 
new collection tube. 
Add 500 µl Buffer AW2. Centrifuge at 15,000 g for 4.5 minutes. 
Place column in new collection tube and centrifuge at 15,000 g for 4.5 minutes. 
Transfer spin column to 1.5 ml tube. Pipette 100 µl Buffer AE. Incubate at room 
temperature for 1 minute, then centrifuge at 15,000 g for 1.5 minutes. 
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1.6  Modified QIAmp
®
 Fast DNA Stool Mini Kit (Stool 
Pathogen Detection) protocol 
 
Weigh 200 mg (±30 mg) stool into a 1.5 ml Eppendorf tube and place on ice if 
performing DNA extraction immediately, if not store at -20˚C for future use. Do not 
allow frozen samples to thaw until the InhibitEX Buffer has been added. 
Add 1ml of InhibitEX Buffer to each sample. Vortex until homogenised. 
Heat at 95˚C for 5 minutes in a water bath. Dry sample tubes and vortex for 15 
seconds. 
Centrifuge at 15,000 g for 1.5 minutes. 
Pipette 15 µl of proteinase K into new 1.5 ml tube. 
 Pipette 200 µl of supernatant into the tube containing proteinase K. Do not transfer 
any solid material. 
Add 200 µl of Buffer AL and vortex for 15 seconds. 
Incubate at 70˚C for 10 minutes in a water bath. Dry sample tubes and briefly 
centrifuge to remove condensation. 
Add 200 µl of ethanol (100%) and vortex. 
Transfer 600 µl lysate to spin column without moistening rim. Centrifuge at 15,000 g 
for 1.5 minutes. Place column in new collection tube. 
Add 500 µl Buffer AW1. Centrifuge at 15,000 g for 1.5 minutes. Place column in 
new collection tube. 
Add 500 µl Buffer AW2. Centrifuge at 15,000 g for 4.5 minutes. 
Place column in new collection tube and centrifuge at 15,000 g for 4.5 minutes. 
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Transfer spin column to 1.5 ml tube. Pipette 100 µl Buffer ATE. Incubate at room 
temperature for 1 minute, then centrifuge at 15,000 g for 1.5 minutes.
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FEC (epg) and FECR (%) of ewes naturally infected with a potential TCBZ-R isolate 
of F. hepatica, at each week post treatment (wpt) with TCBZ. Per animal, two 
treatments are shown. The TCBZ-R isolate harvested from these animals was 
subsequently used for propagation through snails and challenge studies.  
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Fluke burdens in the liver after treatment with triclabendazole of the donor ewes and 
the experimentally challenged wethers. 
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2.3 FEC results of challenge experiment 1 
 
 
Results show epg. Bold indicates a positive result. * indicates a TCBZ treatment. 
wpc = weeks post challenge. Column headers represent animal identification. 
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2.4 cELISA results of challenge experiment 1 
 
 
Results show PD. Bold indicates a positive result (≥6.07%). * indicates a TCBZ 
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2.5 AbELISA results of challenge experiment 1 
 
 
Results show antibody titre. Bold indicates a positive result (>30%). * indicates a 
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2.6 FEC results of challenge experiment 2 
 
 
Results show epg. Bold indicates a positive result. * indicates a TCBZ treatment. 
wpc = weeks post challenge. Column headers represent animal identification. 
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2.7 cELISA results of challenge experiment 2 
 
 
Results show PD. Bold indicates a positive result (≥7.49%). * indicates a TCBZ 
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2.8 AbELISA results of challenge experiment 2 
 
 
Results show antibody titres. Bold indicates a positive result (>30%). * indicates a 
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Bold indicates a result outside of the SAC healthy reference range (2-10 IU/L) 
 
Fasciola hepatica infection is sheep: Current and novel diagnostic tests                                                                                                                                                             
Appendix 3  210 
 




Bold indicates a result outside of the SAC healthy reference range (27-31 IU/L) 
 
  
Fasciola hepatica infection is sheep: Current and novel diagnostic tests                                                                                                                                                             
Appendix 3  211 
 




Bold indicates a positive AbELISA result (>30%) 
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Bold indicates a positive FEC result (0 epg), NS = no sample retrieved 
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3.5  cELISA OD of lambs naturally exposed to F. hepatica 
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4.1 Composite evaluation pre-treatment letter to 
farmers 
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4.3 Composite evaluation sampling instructions 
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4.4  Composite evaluation post-treatment letter to 
farmers 
 
Fasciola hepatica infection in sheep: Current and novel diagnostic tests                                                                                                                                                             
Appendix 4   221 
 
4.5  Composite evaluation post-treatment 
information slip 
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4.6 Group average and composite FEC and FECR 
 
*indicates farms which did not report estimating weight prior to dosing 
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4.7 Group average and composite cELISA and CR 
 
*indicates farms which did not report estimating weight prior to dosing 
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5.1 Summary of DNA amplification by PCR and LAMP 
 
 
* indicates a composite sample, ^ indicates rumen fluke eggs present in faecal sample, bold 
indicates a positive test result,  indicates DNA amplification,  indicates no DNA 
amplification. ND = not done. 
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a  b  s  t  r  a  c  t
The  liver  fluke,  Fasciola  hepatica,  is a  cause  of  significant  economic  losses  in  sheep  farming.
Lack of  convenient  and  sensitive  diagnostic  tests  in  the  live  animal  hampers  the  ability  to
monitor  infection  status  and  treatment  efficacy.  Use  of  a  coproantigen  ELISA  and  coproanti-
gen reduction  test,  based  on  this  ELISA,  may  address  these  issues  but  has,  to date,  only  been
evaluated in experimental  challenge  studies.  We  evaluated  the  coproantigen  ELISA  under
working  farm  conditions  in  Scotland  to  assess  its  usefulness  as a diagnostic  test  for  liver
fluke infection  and  as  a diagnostic  test  to  help  determine  the  efficacy  of flukicide  treat-
ment in  sheep.  First,  liver  fluke  infection  status  was  monitored  longitudinally  in  a group  of
lambs,  using  monthly  blood  samples  for biochemical  assays  and  serum  antibody  ELISA  and
using  monthly  faecal  samples  for faecal  egg  count  (FEC)  and  coproantigen  ELISA. The aver-
age  serum  antibody  ELISA  titre  became  positive  in  September,  two  months  ahead  of  faecal
indicators  of fluke  infection.  In  contrast  to results  from  experimental  challenge  studies,
FEC and  coproantigen  ELISA  became  positive  at the  same  time  point.  Secondly,  treatment
efficacy  was  measured  in  100  ewes,  from  two  farms,  after  treatment  with  triclabendazole
(TCBZ)  or  closantel.  Group  level  estimates  of  treatment  efficacy  were  similar  between  faecal
egg  count  reduction  testing  and  coproantigen  reduction  testing  at 7, 14  and 21 days  post
treatment.  For  individual  animals,  some  inconsistencies  between  tests  were  observed.  TCBZ
treatment  failure  was noted  on both  farms,  despite  accurate  weighing  of  animals  and  dosing
of  treatment  products.  We  conclude  that  (1)  coproantigen  ELISA  is  a more  convenient  test
than  faecal  egg  counts  and  holds  promise  as  a diagnostic  tool  for  natural  fluke  infections  in
sheep  but  further  evaluation  of  interpretation  criteria  may  be  needed;  (2)  the coproantigen
ELISA  has  performed  differently  in the  field  compared  with  experimental  challenge  studies
in sheep  and  (3) TCBZ-resistant  fluke  were  present  on  both  farms.
© 2012 Elsevier B.V. All rights reserved.
1. Introduction
The liver fluke, Fasciola hepatica, is a common trematode
parasite of ruminants, which causes significant economic
∗ Corresponding author. Tel.: +44 (0)131 445 5111;
fax: +44 (0)131 445 6111.
E-mail address: Danielle.Gordon@Moredun.ac.uk (D.K. Gordon).
losses to the sheep industry. In Scotland, fluke have
traditionally been seen in the wetter western areas, how-
ever, over recent years, cases have been reported in the
eastern and north-eastern regions in increasing numbers
(Mitchell, 2002; Kenyon et al., 2009). Factors that are
thought to contribute to the increasing prevalence of liver
fluke include climate change, animal movements, treat-
ment failure and changes in farming practices associated
with climate change (e.g. extended grazing periods) or
0304-4017/$ – see front matter ©  2012 Elsevier B.V. All rights reserved.
doi:10.1016/j.vetpar.2012.02.009
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environmental regulations (e.g. preservation of wetlands)
(Daniel and Mitchell, 2002; Pritchard et al., 2005; Kenyon
et al., 2009). With the increase in prevalence, accurate diag-
nostics are needed to manage and control the spread of this
parasite.
Diagnosis in the live animal is commonly per-
formed via one of the following methods; abnormal liver
(glutamate dehydrogenase (GLDH)) or bile duct (gamma-
glutamyl transferase (GGT)) enzyme levels (Mitchell, 2002;
Matanović et al., 2007), detection of anti F. hepatica anti-
bodies in serum (serum antibody ELISA) (Levieux and
Levieux, 1994) and faecal egg count (FEC) (Dennis et al.,
1954). A coproantigen ELISA, (BIO K201, Bio-X Diagnos-
tics), based upon the MM3  monoclonal antibody (Mezo
et al., 2004) is now commercially available. This has shown
promise in experimental infections of sheep due to the
reported ability to detect antigen from a single parasite
(Mezo et al., 2004) and the ability to detect infection
from 5 weeks post infection (wpi) (Flanagan et al., 2011b),
considerably earlier than FEC, which becomes positive at
9–15 wpi (Valero et al., 2006).
However, these tests are not without their limitations.
For example, due to the persistence of anti-F. hepatica anti-
bodies in serum after successful treatment (Ibarra et al.,
1998; Sánchez et al., 2001), the serum antibody ELISA is
limited in its ability to determine current infections and is,
rather, an indicator of previous exposure. An increase in
GLDH and GGT levels is not pathognomonic for fasciolo-
sis and should not be used for fluke diagnosis in isolation.
In addition, tests which require blood samples are inva-
sive and require the presence of a trained professional for
sample collection. Faecal samples are more convenient and
less invasive in terms of collection. However, eggs are typ-
ically not released until months after infection, at which
point they may  be excreted intermittently from the host
(Mezo et al., 2004), leading to potential false negatives by
FEC. Furthermore, due to sequestration in the gall bladder,
eggs may  be seen up to 3 weeks post successful treatment
(Chowaniec and Darski, 1970), leading to potential false
positives, as here the eggs are indicators of past infection.
Whilst the coproantigen ELISA shows promise as a sensi-
tive and specific indicator of live infection with F. hepatica
(Mezo et al., 2004, 2007; Ubeira et al., 2009; Valero et al.,
2009; Flanagan et al., 2011a,b), it has yet to be evaluated in
natural infections of sheep.
The main strategies for liver fluke control have been
grazing management to avoid intermediate host snail
habitats and the use of strategic flukicide treatments
(Sargison and Scott, 2011a).  The most commonly used
flukicide is triclabendazole (TCBZ) due to its unique abil-
ity to target fluke from 1 wpi in sheep (Boray et al.,
1983). It is immature fluke which are responsible for
acute cases of fasciolosis and hence, a large portion of the
economic losses. However, there have been widespread
reports of treatment failure and suspected resistance
to TCBZ (Overend and Bowen, 1995; Anon, 1998; Lane,
1998; Moll et al., 2000; Thomas et al., 2000; Mitchell,
2002; Álvarez-Sánchez et al., 2006; Olaechea et al.,
2011). Although there is debate in the veterinary press
as to the usefulness of such declarations (Fairweather,
2011b; Sargison and Scott, 2011b),  it is clear that reliable
diagnostic tests to monitor treatment outcomes are
urgently needed.
The only tests currently available to evaluate drug effi-
cacy in fluke infections are dose and slaughter trials (Coles
et al., 2006). Because this test requires the euthanasia
of animals, it is highly impractical for farmers. The most
widely used indicator of treatment failure is the faecal egg
count reduction test (FECRT) (Fairweather, 2011b). Whilst
detailed guidelines exist for conducting and interpreting
FECRT of nematodes, no equivalent guidelines exist for
trematodes (Coles et al., 1992, 2006; Torgerson et al., 2005).
As an alternative to the FECRT, use of a coproantigen reduc-
tion test (CRT), based on the coproantigen ELISA, has been
proposed for evaluation of flukicide efficacy (Flanagan et al.,
2011a). This was  shown to be effective in experimental
infections of sheep, using isolates of known resistance sta-
tus (Flanagan et al., 2011a).  However, it has yet to be trialled
under field conditions in naturally infected sheep.
In this study, we report the kinetics of coproantigen
detection alongside other standard diagnostic tests includ-
ing biochemistry, serology and FEC, in lambs with natural
exposure to F. hepatica. In addition, we compared the
performance of the FECRT and CRT, under genuine farm
conditions with sheep naturally infected with suspected
TCBZ resistant fluke.
2. Materials and methods
2.1. Longitudinal monitoring of infection status
A convenience sample of 27 Scottish Black-
face × Blueface Leicester lambs was  selected from a
flock in Dumfries and Galloway (Farm 1). Lambs were
born in April and sampled at the end of each month from
June through November 2010. Individual blood and faecal
samples were collected and investigated by biochemical
assay, serum antibody ELISA, FEC and coproantigen ELISA,
as detailed below. Serum samples were processed on
the day of collection and faecal samples were stored at
4 ◦C until investigation. One lamb died after the August
sampling (not due to fasciolosis).
A subset of 10 animals could be followed to slaughter
in November or January and livers were investigated for
the presence of parasites as, described below, to obtain an
indication of fluke burden.
2.2. Treatment trial
Two farms with an anecdotal history of TCBZ treat-
ment failure were selected for the treatment trial. Farm 1
is described in Section 2.1 and housed the ewes for this
study. Farm 2 was located in the southeast of Scotland
and kept Scottish Blackface × Blueface Leicester ewes on
pasture. Animals from both farms (n = 70 and n = 68, respec-
tively) were pre-screened by FEC and coproantigen ELISA
for evidence of fluke infection in December 2010, using
individual faecal samples.
In January 2011, 56 ewes from Farm 1 and 44 ewes from
Farm 2, which had tested positive by both coproantigen
ELISA and FEC at pre-screening, were alternately allo-
cated to a TCBZ (Fasinex®, Novartis Animal Health) or a
Author's personal copy
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closantel (Flukiver®, Janssen Animal Health) treatment
group, based upon the order in which they were sampled.
Farm 1 ewes were weighed individually and dosed accord-
ing to the manufacturer’s guidelines, with the modification
that the dosage was rounded to the nearest ml  and 1 ml
added to allow for loss in the syringe during dosing. Farm 2
ewes were dosed to 80 kg as no animals were estimated to
exceed this weight. All dosing was performed using a 20 ml
syringe to ensure accuracy (Coles et al., 1992). Because the
study took place on working farms with in-lamb ewes, ani-
mals that did not respond to the initial treatment were
treated with the alternative product at 21 days after the ini-
tial treatment. This ensured that the welfare of the animals
was not compromised. For the same reason, an untreated
control group was not included (Mooney et al., 2009). Rec-
tal faecal samples were taken at 0, 7, 14, 21 and 56 days post
treatment (dpt) to observe the kinetics of egg and antigen
production post-treatment. Samples were collected using
clean gloves for each animal and individually stored in
50 ml  Falcon tubes at 4 ◦C until testing.
2.3. Diagnostic tests
2.3.1. Diagnosis of infection using invasive tests
Serum was tested using commercial biochemical assay
kits for the determination of GLDH and GGT levels (Randox
Ltd. and Instrumentation Laboratory UK Ltd., respec-
tively) on an IL600 random access analyser using standard
methods. Current Scottish Agricultural College Consult-
ing: Veterinary Services (SAC C VS) reference ranges
are <25 IU/L and <50 IU/L, for GLDH and GGT, respec-
tively. The Pourquier Fasciola hepatica serum ELISA (Institut
Pourquier, France) was performed and interpreted accord-
ing to the manufacturer’s guidelines.
Fluke were extracted from livers at slaughter following
the method outlined in Clery et al. (1996),  with the addition
that livers were frozen on receipt for investigation at a later
date, as examination was not always possible on the day of
collection. Retrieved fluke were placed in water and exam-
ined under a light microscope. Indicators of adult status,
such as development of the reproductive system and width
of shoulders, were noted. For partial flukes recovered, the
numbers of anterior and posterior ends were counted and
the larger figure added to the number of whole fluke seen
in order to determine liver burden.
2.3.2. Diagnosis of infection using faecal samples: FEC
and coproantigen ELISA
FECs were performed on all samples within 1 week of
collection using 3 g of faeces per animal. For the longitudi-
nal study, FEC was performed by SAC C VS, Dumfries, using
standard methods. Briefly, samples were homogenised
with water, sieved through 710, 150 and 38 m sieves in
sequence and sedimented in water for 4 min. The super-
natant was then removed and the sediment re-suspended
in water. This was repeated as necessary until the super-
natant was clear. The final sediment was viewed in a petri
dish, with a few drops of 0.1% aqueous malachite green.
For the treatment trial, FEC was performed at the More-
dun Research Institute using a modified version of the
method outlined by McCaughey and Hatch (1964).  Briefly,
3 g of each sample was  homogenised with 42 ml  of water
and poured through a strainer into a beaker. The filtrate was
then poured through a 150 m sieve into a conical measure.
The beaker was half-filled with water and poured through
the sieve again to wash any remaining eggs through to the
conical measure. The conical measure was allowed to sit
at a slight angle for 3 min  at which point the supernatant
was  siphoned off. A drop of 1% (w/v) methylene blue was
added to the sediment, which was examined on a marked
petri dish at 16× magnification using a light microscope.
Each sample dish was counted twice and an average taken,
which was divided by 3 to calculate the epg. An animal was
considered positive when at least 1 egg was  detected.
The coproantigen ELISA was  performed according to
manufacturer’s guidelines with the following modifica-
tions. All samples were homogenised prior to weighing out
the 0.5 g (±0.03 g) used in the ELISA and all samples were
vortexed for 10 s prior to centrifugation. Samples were pre-
pared to supernatant stage and stored in 1.5 ml  Eppendorf
tubes at −20 ◦C until testing, no longer than 6 weeks fol-
lowing collection. A titre of ≥0.15 is considered positive by
the BIO K201 kit criteria.
2.3.3. Diagnosis of treatment efficacy using faecal
samples: FECRT and CRT
The reduction in the FEC from 0 dpt to each subsequent
sampling point was calculated using the formula below
(Coles et al., 1992), which was  developed for nematodes,
and where FEC0 is the group arithmetic mean FEC at 0 dpt
and FECt is the group arithmetic mean FEC at a subsequent







The CRT was  interpreted as proposed by Flanagan et al.
(2011b), who stated that if all animals are negative at
14 dpt, the treatment is deemed successful. In addition,
the proportion of animals testing negative by FEC and
coproantigen ELISA was noted at all sampling points
2.4. Statistics
All statistical tests were performed using GraphPad
Prism. Because the data were not normally distributed, a
non-parametric t-test (Mann–Whitney) was  used to com-
pare differences between treatment groups and farms.
3. Results
3.1. Longitudinal study
3.1.1. Diagnosis of infection using invasive assays
Blood samples were collected from all animals at each
sample point (n = 27 from June through August, n = 26 from
September through November). Mean GLDH and GGT lev-
els are shown in Fig. 1. Mean values for GLDH were normal
in June and July and increased beyond reference levels
(<25 IU/L) from August onwards, indicating onset of infec-
tion in July (Sandeman and Howell, 1981; Ferre et al., 1994,
1996, 1997; Phiri et al., 2007; Raadsma et al., 2007). At an
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Fig. 1. Changes in group mean test results are shown on the left axis for FEC (epg), coproantigen ELISA (Optical Density) and on the right axis for biochemical
changes (GLDH, GGT) and serum antibody ELISA (serology).  indicates the mean value at which the group first exceeded reference value. Stated detection
limits  indicate infection occurring in April (GGT), May  (FEC), July (GLDH), or September (antibody ELISA and coproantigen ELISA).
individual level, 4 animals were positive in June, 6 in July,
11 in August, 16 in September, 22 in October and 23 at the
last sampling in November (Supplementary Table S1).
The mean level of GGT was above reference levels
(<50 IU/L) at the start of the study with marginally nor-
mal  mean values in August (49.33 IU/L), followed by an
increase from then on. Positive results in June indicate that
onset of infection would have been in April (Sandeman and
Howell, 1981; Ferre et al., 1994, 1996, 1997; Phiri et al.,
2007; Raadsma et al., 2007). At the individual level, results
fluctuated by this test, with 23 animals positive in June, 17
in July, 8 in August, 11 in September, 16 in October and 20
in November (Table S1).
The results of the serological antibody ELISA are shown
in Fig. 1. Mean values were above the positive cut-off
value by late September and remained so until the end
of the study. The estimated point of infection was early
September based on this test (Reichel, 2002). At the indi-
vidual level, the number of positive animals per month
was 4, 4, 3, 16, 18 and 24 for the months June through
November. The infection status of three animals fluctuated
between months, changing from positive to negative and
back. In November, all animals except one were positive;
this animal had not achieved a positive result throughout
the study. The results of individual animals are presented
in Supplementary Table S1.
Ten livers from lambs in this study were examined at
slaughter. Fluke burdens ranged from 2 to 10 adult para-
sites (mean = 5.71, median = 5). No juvenile fluke were seen
(Table S1).
3.1.2. Faecal tests
Rectal faecal samples could be collected from 27 ani-
mals in June and July, 25 in August, 26 in September and 23
in October and November, although the quantity of mate-
rial was occasionally insufficient to determine FEC (4 and 3
samples, respectively, in October and November; Table S1).
The results of the FEC are shown in Fig. 1. All animals were
negative in June. A low mean egg count was seen in July
(0.07 epg) and August (0.03 epg). No eggs were seen in the
group in September and low group egg counts were seen
in October and November (0.03 and 0.61 epg, respectively).
Individual animals first had a positive egg count in July,
resulting from 3 animals (mean = 0.66 epg). In August, only
1 animal was  positive, with a FEC of 0.66 epg. No eggs were
seen in the samples collected in September, but in October
two animals were positive (mean = 0.33 epg). In November,
14 animals were positive (mean = 0.88 epg) and the group
mean was  0.33 epg. The estimated point of infection, based
on a group level positive faecal egg count in July, was  May
(Valero et al., 2006).
The changes in mean coproantigen titres are shown in
Fig. 1. The mean value was above the positive threshold in
November. One animal tested positive in July (Table S1), but
negative in August, September and October. The number of
positive animals started to increase in October (n = 4) and
was highest in November (n = 13). The estimated point of
infection by coproantigen ELISA, based on group level pos-
itive results in November, was  September (Flanagan et al.,
2011b).
3.2. Treatment trial
3.2.1. FEC and FECRT
All animals in this study had a positive FEC at 0 dpt (0.17
to 229.6 epg). All TCBZ treated ewes retained a positive egg
count, until they were treated with closantel 21 days after
the initial TCBZ treatment. A proportion of closantel treated
ewes, ranging from 13 to 38%, also retained a positive, albeit
low, egg count. The proportion of animals in each treatment
group testing positive at each sampling point on each farm
is shown in Table 1.
On Farm 1, individual epg ranged from 0.17 to 165 at
0 dpt with a mean of 33.43 and a median of 23.08. The indi-
vidual epg on Farm 2 ranged from 1.5 to 229.67 at 0 dpt
with a mean of 36.06 and a median of 21.5. Group epg prior
to treatment was  not different between the two  treatment
groups on either farm (P = 0.08 and P = 0.24 for Farms 1 and
2, respectively), as can be seen in Fig. 2.
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Table  1
Faecal egg count reduction and proportion of animals positive by faecal egg count (FEC), on Farms 1 and 2, treated with TCBZ or closantel, at 0, 7, 14, 21
and  56 days post treatment.
dpt Faecal egg count reductiona Proportion of animals FEC positive
Farm 1 Farm 2 Farm 1 Farm 2
TCBZ Closantel TCBZ Closantel TCBZ Closantel TCBZ Closantel
0 – – – – 100% 100% 100% 100%
7  47.4% 97.5% 14.6% 96.8% 100% 30% 100% 38%
14  12.2% 99.3% 58.9% 97.8% 100% 19% 100% 13%
21 36.7%  99.7% 19.2% 99.3% 100% 11% 100% 13%
56* 99.6% 99.4% 100.0% 99.4% 22% 22% 6% 21%
* indicates 35 days post closantel treatment of the TCBZ group.
a Based on 29 observations for the TCBZ group on Farm 1, with the exception of 56 dpt (n = 27); 27 observations for the closantel group on Farm 1; 20
observations for the TCBZ group on Farm 2, with the exception of 14 dpt (n = 19) and 56 dpt (n = 16); 24 observations for the closantel group on Farm 2,
with  the exception of 21 dpt (n = 23) and 56 dpt (n = 14).
At 7 dpt, a significant difference in epg between treat-
ment groups was seen on both farms (P = 0.0001), with the
mean epg in the TCBZ group being 23.03 and 37.41 com-
pared to the closantel group at 0.56 and 0.94 epg on Farms
1 and 2, respectively. At 14 dpt, mean epg in the TCBZ group
was 38.49 and 18.03 compared to 0.17 and 0.64 epg in the
closantel groups on Farms 1 and 2, respectively (P = 0.0001).
At 21 dpt, mean FEC decreased in the TCBZ group on Farm 1
(27.74 epg), but increased on Farm 2 (35.41 epg). Both val-
ues were significantly higher than those of the closantel
groups, 0.07 and 0.19 epg, respectively (P = 0.0001).
As FEC indicated that TCBZ treatment had not been suc-
cessful, TCBZ treated ewes on both farms were treated with
closantel at 21 dpt, with the exception of two ewes on Farm
1. Thus, the last sampling was  56 dpt relative to the original
TCBZ and closantel treatments and 35 dpt relative to the
closantel treatment of the TCBZ groups. At this point the
mean epg in the TCBZ + closantel treated groups decreased
to 0.15 and 0.02 epg on Farms 1 and 2, respectively. The
mean FEC of the closantel-only treated groups remained
low at 0.14 and 0.17 epg. The two ewes that had not been
treated with closantel received additional TCBZ treatment
at 35 dpt and 126 dpt and continued to shed eggs at high
levels. Data for those animals were not included in group
level calculations for 56 dpt.
The results of the group FECRT for all groups on both
farms at all sampling points are shown in Table 1. On Farms

































































Fig. 2. Eggs per gram (epg) of the Farm1 TCBZ (a) and closantel (b) and the Farm 2 TCBZ (c) and closantel (d) treatment groups at 0, 7, 14, 21 and 56 days
post  treatment. * indicates 35 days post closantel treatment of the TCBZ group. Whiskers indicate minimum and maximum values, boxes indicate 25th and
75th  percentile values and the dash indicates the mean values.
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groups at each sampling point. The TCBZ treated groups
ranged in percent reduction, from 12.2% to 58.9%, between
7 and 21 dpt, indicating treatment failure. At 56 dpt, a >95%
reduction was seen in both the TCBZ + closantel treated
groups and the closantel-only treated groups.
3.2.2. Coproantigen ELISA and CRT
All animals tested positive by coproantigen ELISA at
0 dpt. Prior to treatment, ELISA optical densities (OD) did
not differ between TCBZ and closantel treated groups on
Farm 1 (range 0.21–2.46, mean 1.36, median 1.6 vs. range
0.15–2.46, mean 1.1, median 1.08, respectively, P = 0.15) or
Farm 2 (range 0.21–3.91, mean 2.30, median 2.35 vs. range
0.18–4.02, mean 2.18, median 2.98, respectively, P = 0.86).
The coproantigen ELISA results of TCBZ and closantel
treated ewes on both farms over the duration of the study
are shown in Fig. 3.
At 7 dpt, all TCBZ treated animals were positive by ELISA
with a mean OD of 1.55 on Farm 1 and 1.01 on Farm 2. There
was a significant difference between the TCBZ and closantel
treated groups on both farms (P = 0.0001), with the mean
OD of the closantel treated groups being 0.02 on both farms,
with all closantel treated animals testing negative.
At 14 dpt, the differences between TCBZ treated
groups and closantel treated groups were also significant
(P = 0.0001). Once again all TCBZ treated animals tested
positive, with a mean OD of 1.18 on Farm 1 and 1.41 on
Farm 2, and all closantel treated animals tested negative
with mean OD of 0.02 on both farms.
On 21 dpt, the TCBZ treated animals were once again
all positive, with a mean OD of 1.89 and 1.47 on Farms 1
and 2, respectively. All closantel treated animals on Farm
1 remained negative with a mean OD of 0.01. However,
one animal was coproantigen ELISA positive in the closantel
treated group on Farm 2 (mean group OD of 0.02).
At 56 dpt, all TCBZ + closantel treated animals (now at
35 dpt with regards to closantel) tested negative with the
mean group ODs being 0.04 and 0.03 on Farms 1 and 2,
respectively. On Farm 1, one closantel-only treated ani-
mal  tested positive and the mean group OD was  0.06.
The closantel-only treated animal on Farm 2 which had
been positive at 21 dpt, returned to negative status and the
closantel-only treated group had a mean OD of 0.02.
4. Discussion
This study aimed to investigate the usefulness of the
coproantigen ELISA as a method for detecting fluke infec-
tion in naturally infected lambs and to assess the potential
of the coproantigen ELISA reduction test to measure treat-
ment efficacy in naturally infected ewes.
In the lambs followed longitudinally, levels of GGT were
above SAC C VS guidelines from the start and rose over the
course of this study, whilst levels of GLDH rose from August
onwards. As expected based on the migration route of fluke
through the liver, the GLDH level, which is an indicator of
liver damage (Mitchell, 2002), started to increase before the
GGT level, which is an indicator of damage to the bile ducts
(Matanović  et al., 2007). This implies that whilst GLDH and
GGT follow the same kinetics in the fluke infection of lambs
as they do in older sheep, different reference ranges may
need to be set for this test to be of use in young animals. It
also supports the notion that these tests, with their current
reference ranges, should not be used in isolation for the
diagnosis of fasciolosis.
The detection of anti-F. hepatica antibodies was  incon-
sistent in some lambs, i.e. lambs that were negative
subsequently became positive before testing negative
again. It is expected that antibody titres would persist for
many months after clearance of parasites rather than fluc-
tuate between apparent positive and negative status. It is
possible that early positive results are due to antibodies
from colostrum (Petzoldt and Von Benten, 1978). There is
also the possibility for false positive results as the ELISA has
a reported specificity of 99.4% (Molloy et al., 2005).
Fluctuations were seen in lamb FEC, where animals
changed from positive to negative to positive again over
the course of the study. The natural fluctuation in epg seen
in fluke infections is well documented (Chowaniec and
Darski, 1970; Mezo et al., 2004) and a known limitation
of the test. However, the positive egg counts in July would
imply exposure of the animals soon after birth. It is pos-
sible that this is the result of a true infection, with lambs
ingesting grass, and hence cysts, from a young age. Alter-
natively, it is possible that this is due to the ingestion and
passage of eggs from contaminated teats. This has been
documented as a potential cause of false positive FEC in
humans after ingestion of liver (Hillyer, 1988). Oral inocu-
lation and faecal shedding in the absence of infection have
also been described for mycobacteria (Sweeny et al., 1992).
Finally, there is also the possibility of cross contamination
during sample processing, leading to false positive results.
Despite considerable variation in age and diet of ani-
mals, results from experimental infections indicate that
the coproantigen ELISA consistently becomes positive
weeks prior to the FEC (1–5 weeks, Mezo et al., 2004;
4–7 weeks, Valero et al., 2009). By contrast, the mean
coproantigen ELISA became positive at the same time as
the FEC in our study of naturally infected animals. Some
experimental infections have involved challenge doses
of ca. 200 metacercariae, which may have contributed to
the large interval between the first positive results for
coproantigen ELISA and FEC in that study (Valero et al.,
2009). Other experimental infections have involved low
doses of metacercariae, i.e. 5–40 per animal, and resulted
in liver fluke burdens of 1–36 flukes (Mezo et al., 2004).
Within this range, fluke burdens of 5 or fewer are associated
with delayed onset of positive coproantigen ELISA results
compared to fluke burdens over 5 (Mezo et al., 2004). Of
10 livers evaluated in our study, 7 had fluke counts of 5 or
lower (Table S1),  suggesting that low fluke burdens may
provide a partial explanation for the fact that coproantigen
ELISA did not become positive before FEC in our study. The
fact that we sampled at monthly rather than weekly inter-
vals may  also have affected our ability to detect positive
coproantigen ELISA results ahead of positive FEC.
As with lambs, the FECs of ewes in this study fluctu-
ated greatly, both between animals at a single sampling
point and between sampling points for individual animals.
This impacts on the test’s ability to detect treatment fail-
ure. Although a FECRT is often used, there has been no
standardisation of the method for fluke infections, unlike
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Days  post  treat ment
d)
Fig. 3. ELISA optical density (OD) of the Farm1 TCBZ (a) and closantel (b) and the Farm 2 TCBZ (c) and closantel (d) treatment groups at 0, 7, 14, 21 and 56
days  post treatment. * indicates 35 days post closantel treatment of the TCBZ group. ELISA ODs are considered positive if ≥0.15, indicated by the dashed
line.  Whiskers indicate minimum and maximum values, boxes indicate 25th and 75th percentile values and the dash indicates the mean values.
for nematode infections, and it is an imperfect test. This
is highlighted in the results presented here. Although the
closantel groups on both farms maintained a >95% reduc-
tion in FEC throughout the study, >10% of animals remained
FEC positive, excreting eggs at a low level for the dura-
tion of the study. Excretion of eggs at low level may  be
due to sequestration of eggs in the gall bladder, although
it could also be an early indicator of treatment failure. The
coproantigen ELISA yielded unambiguous results at 7 and
14 dpt, with all animals testing negative for presence of
fluke.
During the course of this investigation it became appar-
ent that the coproantigen ELISA was superior to the FEC in
terms of convenience. Per animal, the ELISA took much less
time to process than the FEC, required less faecal matter
and it was also possible to store the supernatants for later
use if time did not allow for immediate testing. For gas-
trointestinal nematodes, use of FEC data can lead to failure
to detect low anthelmintic efficacy with commonly used
mathematical techniques such as the FECRT (Torgerson
et al., 2005). Whether the coproantigen ELISA has advan-
tages over FEC in robustness as an indicator of treatment
outcome for fluke infections remains to be established.
It is clear from the results presented here that TCBZ
was not effective on either farm. The reduction in epg of
the TCBZ treated animals fluctuated considerably, and was
never greater than 59% at the group level. In contrast, the
closantel treated groups achieved >95% reduction in epg by
7 dpt at group level and this was maintained throughout
the study with a steady increase in reduction. At an indi-
vidual animal level, a 95% reduction in FEC was not always
achieved, particularly not for animals with low initial epg.
This is in agreement with results reported by Flanagan et al.
(2011a) and underscores the need for a minimum start
value for epg when performing an FECRT. It also empha-
sises the need for a minimum group size to ensure that high
and low epg values are distributed evenly across treatment
groups (Torgerson et al., 2005).
The CRT gave the same indication of treatment success
as the FECRT at 7 and 14 dpt. At 21 dpt, one animal in the
closantel group tested positive on Farm 2, where ewes were
housed outside. This ewe was coproantigen ELISA negative
again at 56 dpt. No treatment had been administered in the
interim. A different animal in the closantel group on Farm
2 tested coproantigen ELISA positive at 56 dpt. It is possible
that the latter animal became coproantigen ELISA positive
due to maturation of early immature fluke that had not
been affected by the closantel treatment. Re-infection was
unlikely during this study because of the weather condi-
tions, i.e. deep snow for prolonged periods. Because 56 dpt
was  the last sampling point of the study, it could not be
determined whether this animal remained positive.
It has been suggested that the definition of treat-
ment success as measured by CRT should be based on
100% negative results after treatment (Fairweather, 2011c).
Both our study and reports from others show that inter-
mittent positive results do occur after treatment that is
deemed successful based on FECRT, with positive results
Author's personal copy
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occurring at 7, 8, 14 and 21 dpt (Flanagan et al., 2011a,b;
our study). Fluctuations in coproantigen ELISA results have
been attributed to disintegrating fluke releasing antigen.
Initially, it was suggested that such fluke disintegration
and antigen release is unlikely to occur to the extent that
it would be an issue for diagnosis. Based on our study of
natural fluke infection and the reports on experimental
fluke infection cited above, the strict criteria for treat-
ment success, i.e. 100% negative results by coproantigen
ELISA, are not compatible with results from treatment tri-
als. We  believe that this is an area of concern that must be
addressed if the CRT is to be of genuine utility in the field.
It is believed that this test will be very useful in monitor-
ing drug efficacy but more work is needed to standardise
methodology and to provide quantitative support for inter-
pretation of results before it can see widespread uptake in
the veterinary community. False positive and false nega-
tive results will continue to occur by FEC and coproantigen
ELISA, as with all tests, but this can be taken into account
by using a minimum reduction threshold alongside a mini-
mum  sample size, rather than an all positive or all negative
criterion, allowing more confidence to be placed in both
FECRT and CRT.
Good diagnostics are a necessity if a distinction is to
be made between failure of a treatment and resistance
of a parasite population to a drug. Apparent treatment
failure could result from numerous factors, including
under-dosing, reduced bioavailability of drug, inadequate
diagnostics or poor drug formulation (Fairweather, 2011a).
In practice, if treatment failure is observed, animals will
be treated with an alternative flukicide and, if the sec-
ond treatment is successful, ‘resistance’ will be declared,
regardless of the possibility of inaccurate timing or dos-
ing. In our study, two ewes from Farm 1 were given TCBZ
rather than closantel at 21 dpt. Both ewes were FEC and
coproantigen ELISA positive before and 35 days after the
second TCBZ treatment. A third TCBZ treatment was admin-
istered in June and the animals were euthanized 7 days
later. At each time point, animals had been dosed by weight
and using a syringe to rule out inaccurate timing or dosing.
At post-mortem, large numbers of live, undamaged fluke
were recovered from the livers of both animals, confirming
the presence of TCBZ resistant fluke.
5. Conclusions
Our evaluation of the coproantigen ELISA and compar-
ison with established diagnostic methods for detection of
liver fluke in naturally infected lambs and sheep showed
that the coproantigen ELISA is superior to the FEC with
regards to convenience characteristics and provides similar
results with regards to infection status. The coproantigen
ELISA did not give an earlier indication of fluke infec-
tion when used at monthly intervals, but it did provide
an unambiguous indication of treatment success at 7
and 14 dpt. FECRT and CRT were useful in assessment
of treatment efficacy but guidelines for the conduct and
interpretation of results from both tests need further
development. Lastly, we report the observation of TCBZ
treatment failure and the presence of TCBZ resistant liver
fluke in sheep in Scotland as well as the effectiveness of
closantel against TCBZ-resistant fluke.
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later, animals entered a dose and slaughter 
trial, that is, triclabendazole treatment was 
repeated and the numbers of fluke present 
were counted at postmortem examination 
14 days later (Fig 1). Between 19 and 70 live 
adult fluke were retrieved from the liver and 
bile ducts of each animal, confirming the 
TCBZ-R status of the fluke isolate.
The dose and slaughter trial-based 
confirmation of TCBZ-R in liver fluke in 
the UK, which was suspected on the basis 
of FECRT and CRT, should be seen as a 
further incentive to apply the best possible 
management strategies for control of liver 
fluke on sheep and cattle farms. This should 
include use of preventive measures where 
possible, treatment where necessary and 
the evaluation of treatment efficacy. Before 
declarations of TCBZ-R are made in the field, 
problems due to inadequate dosing, poor 
product storage or inferior quality products 
need to be ruled out, as triclabendazole is 
still the drug of choice for migrating juvenile 
fluke, particularly in sheep.
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resistance in liver fluke 
in the UK 
WE would like to report confirmation of 
triclabendazole resistance (TCBZ-R) in liver 
fluke, Fasciola hepatica, from the UK, based 
on a dose and slaughter trial. Recently, there 
has been considerable debate regarding 
the usefulness of reports of triclabendazole 
treatment failure in liver fluke infected 
sheep and cattle as an indicator of TCBZ-R 
(Fairweather 2011, Sargison and Scott 2011). 
It has been suggested that the diagnosis of 
TCBZ-R in the field should be based on a 
combination of diagnostic tests (Fairweather 
2011). We used a combination of faecal 
egg count reduction testing (FECRT) and 
coproantigen reduction testing (CRT) to 
demonstrate TCBZ-R in liver fluke in sheep 
from Scotland (Gordon and others 2012). We 
have now confirmed this diagnosis based on a 
dose and slaughter trial, the only method that 
was put forward by a panel considering new 
World Association for the Advancement of 
Veterinary Parasitology (WAAVP) guidelines 
on the detection of anthelmintic resistance 
(Coles and others 2006).
F hepatica eggs were obtained at 
postmortem examination from the gall 
bladder of two naturally infected ewes from 
Dumfries and Galloway, Scotland. Large 
numbers of live adult fluke were present in the 
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FIG 1: Sheep liver in situ showing damage 
to the liver tissue and thickening of the 
bile ducts 17 weeks after challenge with 
Fasciola hepatica
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a  b  s  t  r  a  c  t
The  liver  fluke,  Fasciola  hepatica,  is  common  in many  parts  of Great  Britain.  To  detect  liver
fluke  infection  and  to assess  whether  fasciolicide  treatment  has  been  successful,  the  faecal
egg count  (FEC)  and  faecal  egg  count  reduction  test  (FECRT)  are  widely  used.  Rumen  fluke  is
also  increasingly  reported  from  Great  Britain,  but  its  species  identity  is yet  to be determined.
Liver  fluke  and  rumen  fluke  eggs  are  morphologically  similar,  which  may  lead  to  erroneous
diagnoses  of  liver  fluke  infection  or treatment  failure.  As  an  alternative  to FEC,  a coproanti-
gen  ELISA  (cELISA)  can be used.  The  potential  for this  test  to  cross-react  with  rumen  fluke
species  from  Great  Britain  has not been  evaluated.  Rumen  fluke  specimens  from  cattle
and  sheep  in  Scotland  were  identified  to species  level  using  DNA  sequencing  of the ITS-
2 region.  Subsequently,  rumen  and  liver  fluke  obtained  from  naturally  co-infected  sheep
were subjected  to immunohistochemistry  using  antibodies  from  a commercially  available
cELISA kit  for  F. hepatica.  Finally,  faecal  samples  from  naturally  co-infected  sheep  flocks
were  examined  by FEC  and  cELISA.  Rumen  fluke  from  imported  and  home-bred  cattle  and
sheep in Scotland  belonged  to the  species  Calicophoron  daubneyi,  rather  than  Paramphisto-
mum  cervi,  the  species  presumed  to be  most  common  in  Great  Britain.  Intense  staining  of
the  gastrodermis  was  observed  in  F.  hepatica  but  cross-reactivity  with  C.  daubneyi  was  not
seen.  Faecal  samples  that  contained  rumen  fluke  eggs  but not  liver  fluke  eggs  were  all  neg-
ative by  cELISA.  We  conclude  that C.  daubneyi  is  the  most  common  rumen  fluke  of  domestic
ruminants  in  Scotland  and  that  cELISA  reduction  testing  may  be  a valuable  alternative  to
FECRT in herds  or flocks  that  are  co-infected  with  liver  and  rumen  fluke.
© 2013 Elsevier B.V. All rights reserved.
1. Introduction
The liver fluke, Fasciola hepatica, is a zoonotic trema-
tode parasite with a worldwide distribution (Rojo-Vázquez
et al., 2012). Liver fluke disease or fasciolosis limits pro-
duction in sheep, goats, cattle and buffalo, with economic
losses due to reduced growth and fertility, death and con-
demnation of livers at slaughter (Mezo et al., 2011; Sargison
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and Scott, 2011b; Borji et al., 2012). In recent years, there
has been an increase in the incidence of this disease in Great
Britain and the parasite has spread from western areas,
where it has been known to occur for a long time, to the
east (Mitchell, 2002; Anonymous, 2012). This has possibly
been facilitated by warmer winters and wetter summers,
favouring the liver fluke’s life-cycle, but animal movement
may  also be implicated (Kenyon et al., 2009; Taylor, 2012).
Environmental schemes that encourage wet grassland con-
ditions for breeding and migrating birds and invertebrates
have also been linked with a higher risk of liver fluke in live-
stock (Pritchard et al., 2005). In addition, resistance of liver
fluke to the drug of choice for killing juvenile stages, tri-
clabendazole, has been confirmed in sheep in Great Britain
0304-4017/$ – see front matter ©  2013 Elsevier B.V. All rights reserved.
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and elsewhere (Moll et al., 2000; Gordon et al., 2012a), in
cattle (Olaechea et al., 2011) and, most recently, in a sheep
farmer from the Netherlands (Winkelhagen et al., 2012).
The detection of F. hepatica and determination of the
outcome of fasciolicide treatment are commonly based on
standard sedimentation faecal egg counts (McCaughey and
Hatch, 1964). Due to the biology of the parasite, faecal egg
counting (FEC) can lack sensitivity, e.g. as a result of spo-
radic egg shedding by adult fluke and the long (9–15 weeks)
pre-patent period. In addition, FEC may  lack specificity,
e.g. due to release of eggs from the gall bladder several
weeks after elimination of the adult parasite (Chowaniec
and Darski, 1970; Mezo et al., 2004; Valero et al., 2009). A
commercially available coproantigen ELISA (cELISA), BIO K
201 (BIO-X Diagnostics Belgium), aims to alleviate some of
the difficulty in determining infection status and treatment
outcome in F. hepatica infections. The cELISA is based on
a monoclonal antibody (MM3  MAb) assay that recognises
cathepsin L protease, secreted from the luminal surface of
the fluke’s gut (Mezo et al., 2004; Muiño et al., 2011). The
test is claimed to be able to be sensitive to a single fluke
in sheep and to only detect presence of living fluke. Evi-
dence of liver fluke can be detected as early as 5 weeks
post-infection after experimental challenge, but this inter-
val can be longer following natural infection (Mezo et al.,
2004; Flanagan et al., 2011; Gordon et al., 2012b).
To compound the problems with detection of F. hepat-
ica and assessment of treatment outcome, there has been a
rise in reports of paramphistome (or rumen fluke) infec-
tions in sheep and cattle in Great Britain and Ireland,
often as co-infections with liver fluke (Foster et al., 2008;
Murphy et al., 2008; Mason et al., 2012). The eggs of
rumen fluke are morphologically similar to those of F.
hepatica and may  cause false positive results in the FEC
for liver fluke (Silvestre et al., 2000; Rojo-Vázquez et al.,
2012). Most treatments that are commonly used against
liver fluke, with the exception of oxyclozanide, are not
effective against paramphistomes (Rolfe and Boray, 1987,
1988). Thus, rumen fluke eggs may  remain present in faeces
after treatment with a fasciolicide. If rumen fluke eggs are
mistaken for liver fluke eggs, this could result in a false diag-
nosis of liver fluke treatment failure. The MM3  antibody
based cELISA has been tested for cross-reactivity to the
small lancet fluke Dicrocoelium dendriticum and the rumen
fluke P. cervi (Mezo et al., 2004). However, it is not known
whether the most common rumen fluke in Great Britain
is P. cervi, as often assumed, or whether it is C. daubneyi,
which is the main rumen fluke of cattle, sheep and goats in
mainland Europe (Abrous et al., 2000; Rinaldi et al., 2005;
Díaz et al., 2006). Therefore, this study aimed to determine
the species identity of rumen fluke from cattle and sheep
in Great Britain using molecular methods, and to assess the
potential impact of rumen fluke presence on the specificity
of liver fluke diagnostics.
2. Materials and methods
2.1. Species identification of rumen fluke
Genomic DNA was extracted from four batches of
adult rumen fluke. Batch 1 was recovered in 2012 from a
homebred Scottish heifer. Batch 2 was recovered in 2012
from a cow, which had been imported from Ireland and
grazed in Scotland. Batch 3 was  from a 47 month old home-
bred Aberdeen Angus cross cow submitted for postmortem
examination after it died from ruminal bloat in 2009. Batch
4 was  recovered in 2011 from sheep that had been grazed in
Scotland. The latter sample was also used for immunohis-
tochemistry as described in Section 2.2. We  also processed
a pool of immature rumen fluke recovered from the duode-
num of calves that had died of clinical paramphistomosis
(Millar et al., 2012).
For each batch, parasites were washed in physiological
saline and stored in 70% ethanol prior to molecular analy-
sis. Genomic DNA was extracted from at least 3 individual
fluke per batch, or from a pool of the immatures, using
the DNEasy extraction kit (Qiagen, Germany), according to
the manufacturer’s recommendations. DNA was eluted in
100 l nuclease-free water and stored at −20 ◦C prior to
use. Genomic DNA was also extracted from adult F. hepatica
to act as a control.
The ITS-2 region of rDNA plus the flanking 5.8S
and 28S sequences were amplified from the rumen
fluke specimens by PCR using the generic primers,
ITS-2For 5′-TGTGTCGATGAAGAGCGCAG-3′ and ITS-2Rev
5′-TGGTTAGTTTCTTTTCCTCCGC-3′, as described by Rinaldi
et al. (2005). PCR was conducted in 25 l reaction volumes
comprising ∼10 ng genomic DNA template, 25 pmol of each
primer (Eurofins, Germany), 0.2 mM of each dNTP (Bioline,
UK), 2 mM MgCl2 and 0.1 U platinum Taq polymerase in
1× platinum Taq buffer (Invitrogen). The PCR was carried
out on an applied biosystems 7270 PCR machine under the
following conditions: 94 ◦C for 5 min; 40 cycles of 94 ◦C for
1 min; 53 ◦C for 1 min; 72 ◦C for 1 min; followed by 72 ◦C for
10 min. PCR products were separated on a 1.2% agarose gel
prepared in Tris–acetate–EDTA (TAE) buffer incorporating
GelRed (Cambridge Bioscience, UK) and visualised on an
ultraviolet transilluminator.
PCR products of the appropriate size (∼500 bp) ampli-
fied from individual rumen fluke were excised from
agarose gels and DNA extracted using a QiaQuick gel
extraction kit (Qiagen, Germany) according to the man-
ufacturer’s recommendations. PCR products were eluted
using 30 l nuclease-free water and 1 l used for liga-
tion into the pGEM-T Easy plasmid vector (Promega,
USA), as instructed by the manufacturer. 1 l of each
ligation reaction was  transformed into chemically compe-
tent JM109 Escherichia coli (Stratagene) and the resultant
transformants plated on Luria Bertani (LB) agar plates
impregnated with 0.5Mm 5-bromo-4-chloro-3-indolyl--
galactopyranoside (X-gal) and 80 g/ml isopropyl -d-
1-thiogalacto-pyranoside (IPTG). Plates were incubated
overnight at 37 ◦C and colonies containing insert identified
based on blue/white selection. Individual white colonies
(at least 3 per individual fluke) were picked into 10 ml
LB medium containing 100 g/ml ampicillin and grown
overnight at 37 ◦C with shaking. Mini-prep DNA was pre-
pared from overnight cultures using a Wizard Plus SV
Miniprep DNA kit (Promega, USA), according to manufac-
turer’s instructions. The DNA concentration and quality of
purified plasmids were assessed using a Nanodrop spec-
trophotometer ND-1000 at 260 and 280 nm.  Plasmids were
Author's personal copy
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then diluted to 15 ng/l and submitted to MWG  Eurofins
for sequencing using the SP6 vector primer. Sequences
obtained were compared to reference sequences in Gen-
Bank using BLASTn at the European Bioinformatics Institute
website (http://www.ebi.ac.uk/).
2.2. Immunohistochemistry
Rumen fluke from batch 4 as described in Section 2.1
as well as F. hepatica from the same ewes were recovered
at post-mortem. The parasites were washed in phosphate-
buffered saline (PBS) then fixed in 10% formol saline prior
to being blocked in paraffin wax. Sections 5 m thick, were
cut on a rotary microtome and mounted onto SuperFrost®
Plus (Menzel-Glaser, Germany) microscope slides and
dried at 37 ◦C overnight. Sections were taken to water
through graded alcohols prior to application of immunohis-
tochemistry (IHC). Endogenous peroxidase was removed
by immersing slides in 3% H2O2 (Sigma, UK) in methanol
for 20 min  at room temperature (RT), after which the slides
were washed in water, placed in a Sequenza slide rack and
cover plate system (Thermo Electron Corporation, USA)
and washed twice with PBS. Non-specific binding sites
were blocked by applying 100 l 25% Normal goat serum
(Vector Laboratories, UK) for 30 min  at RT. The sections
were then incubated with 100 l primary antibody, in this
case the anti-F. hepatica coproantigen MM3  monoclonal
antibody (MAb) from the BIO K201 Fasciola coproanti-
gen ELISA kit (Bio-X Diagnostics, Jemelle, Belgium), diluted
1:50 in PBS and incubated at 4 ◦C overnight. Sections were
washed twice with PBS before 100 l goat anti-mouse
horseradish peroxidase (Dako Envision system polymer,
Dako Ltd., UK) was applied for 30 min. Again, sections
were washed twice with PBS and 100 l Dako Envision
substrate-chromagen (20 l DAB chromagen to 1 ml  sub-
strate buffer) was added and incubated for 8 min. Slides
were rinsed in water, removed from the Sequenza system
and washed in running tap water for 5 min. Nuclei were
counterstained with haematoxylin (Thermo Electron Cor-
poration) for 1 min  and slides were washed before being
dehydrated through graded alcohols, immersed in xylene
and mounted using Consul mount (Thermo Shandon, UK).
Negative control sections were prepared as above, except
that PBS was applied instead of the primary MAb.
2.3. Field evaluation of cELISA
As part of a study on the diagnosis of liver fluke infec-
tion and flukicide treatment outcome, sampling packs were
distributed to 38 sheep farmers throughout Great Britain.
Eighteen farmers returned complete sets of faecal samples,
i.e. sets of 10 pre- and 10 post-treatment samples for each of
2 groups of 12 sheep. Faecal samples could be individually
collected or picked up from the floor following protocols
for composite FECRT (Daniel et al., 2010). Pre-treatment
samples were taken on the day of flukicide treatment and
post-treatment samples were collected approximately 3
weeks later. Flukicide treatments were administered by
the farmers using on-farm protocols and their fascioli-
cide of choice. On receipt by the laboratory, faecal samples
were tested for presence of liver fluke and rumen fluke
eggs using standard sedimentation faecal egg count (FEC)
(Gordon et al., 2012b). Liver fluke eggs were differentiated
from rumen fluke egg based on colour and shape following
methylene blue staining (Silvestre et al., 2000). The faecal
egg count reduction test (FECRT) for liver fluke was  per-
formed for each group on each farm (Gordon et al., 2012b).
In addition, all individual pre- and post-treatment sam-
ples were tested by the Bio-X K201 cELISA (Gordon et al.,
2012b).
3. Results
3.1. Species identification of rumen fluke
A ∼500 bp fragment of ITS-2 and its flanking regions
was amplified using generic primers (Rinaldi et al., 2005)
from 4 separate batches of rumen fluke (see Section 2.1).
The amplicons proved to be identical to each other (both
within and between samples) and had 100% (428/428 bp)
homology with C. daubneyi (GenBank accession number
AY790883; Rinaldi et al., 2005). Homology with the next
best match, P. cervi, was 97.2% (277/286 bp; GenBank acces-
sion number HM026462; Bazsalovicsová et al., 2010). The
alignment is shown in Supplementary Fig. 1.
3.2. Immunohistochemistry
Using IHC, the presence of immunoreactive antigen was
clearly demonstrated in F. hepatica. The MM3  MAb  bound
specifically to the lamellae lining the gastrodermis whilst
no specific staining was observed in other fluke tissues or
in negative control sections (Fig. 1). Specific staining was
not observed in any of the rumen fluke sections examined
(at least 3 sections from each of 3 specimens), which were
processed in exactly the same way (Fig. 2).
3.3. Field evaluation of cELISA
Among the ovine faecal samples submitted by 18 farm-
ers, samples from 3 farms showed evidence of co-infection
with liver fluke and rumen fluke based on FEC (Fig. 3).
On farm A, which was located in Scotland, most sam-
ples from both groups were positive for liver fluke and
rumen fluke prior to treatment (Table 1). After treatment
of group A.1 with a closantel-based product, the major-
ity of samples still contained liver fluke eggs but counts
were low. Based on FECRT, which indicated a 97.9% reduc-
tion in FEC, the treatment was deemed successful against
liver fluke. The number of rumen fluke positive samples
was higher after treatment than it had been before treat-
ment (Table 1). Group A.2 was treated with a TCBZ-based
product and showed an increase in the number of samples
that were positive for liver fluke and rumen fluke as well
as an increase in liver fluke FEC after treatment, resulting
in a negative value for the FECRT (Table 1).
On farm B, located in a different region of Scotland, most
samples from group B.1 were positive for liver fluke and
rumen fluke prior to treatment, whereas group B.2 was pos-
itive for rumen fluke only (Table 1). After treatment of both
groups with a TCBZ-based product, group B.1 was  still pos-
itive for both types of fluke, whereas group B.2 was still
Author's personal copy
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Fig. 1. Immunohistochemical staining of Fasciola hepatica with MM3  monoclonal as primary antibody. The gastrodermis in the negative control shows
no  labelling of the brush border (panel A), whereas intense staining of the lamellae lining the gastrodermis is observed in the positive control (panel B).
Arrows indicate gut profiles.
Fig. 2. Immunohistochemical staining of rumen fluke with MM3  monoclonal as primary antibody. Neither negative controls (panel A), nor rumen fluke
with  MM3  MAb applied (panel B) show specific staining. Arrows indicate gut profiles.
largely negative for liver fluke and remained positive for
rumen fluke.
On farm C, located in Wales, a single post-treatment
sample was positive for rumen fluke. This sample was  neg-
ative for liver fluke based on FEC and cELISA.
Fig. 3. Rumen fluke egg (A, light colour) and liver fluke egg (B, dark colour)
obtained by the faecal sedimentation technique.
In total, 20 samples were positive for rumen fluke eggs
but negative for liver fluke eggs (2 from farm A, 17 from
farm B, 1 from farm C; Supplementary Table S1). None
of those samples were positive by cELISA, indicating that
there was  no cross-reactivity with rumen fluke.
4. Discussion
Liver fluke is increasingly common in the UK, and the
number of reported and confirmed cases of flukicide resis-
tance is growing (Fairweather, 2011; Sargison and Scott,
2011a). In practice, flukicide resistance is diagnosed based
on the FECRT. Presence of rumen fluke eggs, if mistaken
for liver fluke eggs, could lead to erroneous interpretation
of FECRT results as indicative of treatment failure. Using
standard FEC methods, co-infections with liver fluke and
rumen fluke were detected in 3 of 18 sheep farms in
our study. Liver fluke and some species of rumen fluke
(including C. daubneyi) may  occur together in ruminants
as they can use the same intermediate host snail species
and have similar life-cycles (Abrous et al., 2000; Díaz et al.,
2006). This would suggest that the increase in incidence
and geographic distribution that has been described for
liver fluke (Pritchard et al., 2005; Kenyon et al., 2009) may
also occur for rumen fluke, making accurate differentiation
Author's personal copy
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Table 1
Results of pre- and post-treatment testing of faecal samples from 2 Scottish sheep flocks for liver fluke and rumen fluke showing results for faecal egg
counts  (FEC), coproantigen ELISA (cELISA) and faecal egg count reduction testing (FECRT). The number of positive samples is shown relative to the number
of  samples tested. A negative result for the FECRT means that FEC increased after treatment.
Farm Group Outcome Pre-treatment Post-treatment
Liver fluke Rumen fluke Liver fluke Rumen fluke
A 1 Individual FEC 10/10 5/10 8/10 7/10
Individual cELISA 9/10 n/a 0/10 n/a
Average FEC 41.4 n/a 0.88 n/a
FECRT n/a n/a 97.9% n/a
2  Individual FEC 9/10 7/10 10/10 10/10
Individual cELISA 9/10 n/a 9/10 n/a
Average FEC 46.4 n/a 126.7 n/a
FECRT n/a n/a −173.1% n/a
B 1  Individual FEC 7/10 7/10 10/10 10/10
Individual cELISA 7/10 n/a 3/10 n/a
Average FEC 4.7 n/a 6.0 n/a
FECRT n/a n/a −27.7% n/a
2  Individual FEC 0/10 7/10 1/10 6/10
Individual cELISA 0/10 n/a 0/10 n/a
Average FEC 0 n/a 0.1 n/a
FECRT n/a n/a n/a n/a
of the two types of fluke increasingly important. Until
recently, reports of rumen fluke from Great Britain were
rare (Foster et al., 2008; Mason et al., 2012) but the high
within-flock prevalence of rumen fluke in home-bred ewes
in the current study implies that that rumen fluke is estab-
lished rather than imported on a number of Scottish sheep
farms. Liver fluke treatments used on those farms were
not effective against rumen fluke, as previously observed
for a range of treatments in sheep and cattle (Rolfe and
Boray, 1987, 1988; Foster et al., 2008). Thus, there is a
genuine risk that the increasing prevalence of rumen
fluke may  compromise the usefulness of standard FECRT
methods as an indicator of treatment success for liver
fluke.
Until now, it was assumed that the predominant rumen
fluke species in the British Isles was P. cervi (Willmott,
1950; De Waal, 2010). Historically, rumen fluke was  identi-
fied based on phenotypic methods. This led to designation
of apparently new species of rumen fluke from Scotland
and Ireland as P. scotiae and P. hiberniae (Willmott, 1950).
Both species names, as well as P. leydeni, were later recog-
nised as being synonyms of P. cervi, showing the potential
for inaccurate species identification based on morphology
(Odening, 1983). In the present study, rumen fluke from
cattle and sheep were identified using modern molecu-
lar methods. All specimens were identified as C. daubneyi,
previously known as P. daubneyi, whilst P. cervi was not
detected. Included among these specimens were samples
from a recently reported fatal bovine clinical case, which
were also confirmed to be C. daubneyi by ITS-2 sequenc-
ing (Millar et al., 2012; unpublished data). C. daubneyi
has also been reported from cattle, sheep and goats in
mainland Europe, e.g. from France (Abrous et al., 2000;
Silvestre et al., 2000), Italy (Rinaldi et al., 2005; Biggeri
et al., 2007) and Spain (Díaz et al., 2006). Despite pub-
lished reports of morbidity and mortality due to rumen
fluke (Foster et al., 2008; Mason et al., 2012) and anec-
dotal reports of clinically favourable responses after rumen
fluke treatment, the economic impact of C. daubneyi and
other paramphistomes is yet to be determined. Accurate
determination of the disease burden caused by rumen fluke
species will require accurate differentiation of C. daubneyi
and P. cervi and ITS-2 sequencing would be an appro-
priate method to achieve this (Rinaldi et al., 2005; this
study).
There have been various attempts to overcome the dif-
ficulties associated with FECRT as a measure of treatment
efficacy for liver fluke, including the use of compos-
ite sampling (Daniel et al., 2012) and egg hatch tests
(Fairweather et al., 2012). Another approach is the use
of the coproantigen reduction test (CRT), which was suc-
cessful in experimental challenge models and field studies
(Flanagan et al., 2011; Gordon et al., 2012b). The specificity
of the MM3  antibodies used in a commercially available
coproantigen ELISA was  previously evaluated and con-
firmed in relation to the trematodes D. dendriticum, P.
cervi and the cestode, Taenia hydatigena (Mezo et al., 2004;
Kajugu et al., 2012). Our in vitro experiments using IHC on
rumen fluke derived from cattle and sheep show that C.
daubneyi can be added to this list. Testing of faecal sam-
ples from naturally infected sheep did not yield any false
positive results for samples that were positive for rumen
fluke eggs but negative for liver fluke eggs. Thus, the CRT
would be a viable alternative to FECRT for the assessment
of liver fluke treatment outcome in flocks or herds with a
high rumen fluke burden.
5. Conclusion
The rumen fluke C. daubneyi is present on sheep and
cattle farms in Scotland. The within-farm prevalence of C.
daubneyi in home-bred animals can be high. Eggs of C. daub-
neyi are similar in appearance to those of liver fluke and
may  continue to be present after successful treatment of
liver fluke. This could result in an incorrect diagnosis of
liver fluke treatment failure based on FEC. C. daubneyi does
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not cross-react with the Bio X K 201 coproantigen ELISA,
making it a useful test for evaluation of treatment efficacy
on farms with co-infections due to rumen fluke and liver
fluke. Further study using accurate species identification
methods would be required to determine the prevalence
and impact of C. daubneyi and P. cervi in livestock in Great
Britain.
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